NZ737956B2 - Immunotherapy against several tumors including gastrointestinal and gastric cancer - Google Patents

Abstract

Disclosed is a peptide consisting the amino acid sequence of SEQ ID No. 86 YLYGQTTTYL. Disclosed is the use of a peptide consisting of the sequence according to SEQ ID No. 86 YLYGQTTTYL which is derived from TOP2A in the manufacture of a medicament for the treatment of cancer, wherein said cancer is gastric, gastrointestinal, colorectal, pancreatic, lung or renal cancer. is gastric, gastrointestinal, colorectal, pancreatic, lung or renal cancer.

Description

[Link] http://www.who.int/mediacentre/factsheets/fs297/en/ Immunotherapy against several tumors including gastrointestinal and gastric cancer The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to associated epitopes recognized by CD8+ T cells, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ients of vaccine compositions that ate umor immune ses. The present ion relates to 33 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses, particularly cytotoxic T cell (CTL) responses.

Background of the invention Gastric cancer is a disease in which maligant cells form in the lining of the stomach.

Stomach or gastric cancer can develop in any part of the stomach and may spread throughout the stomach and to other organs; particularly the esophagus, lungs and the liver. Stomach cancer is the fourth most common cancer worldwide with 930,000 cases diagnosed in 2002.

It is a disease with a high death rate (~800,000 per year) making it the second most common cause of cancer death ide after lung cancer. It is more common in men and occurs more often in Asian countries and in developing ies. (http://www.who.int/mediacentre/factsheets/fs297/en/.) It represents roughly 2% (25,500 cases) of all new cancer cases yearly in the United States, but it is more common in other countries. It is the leading cancer type in Korea, with 20.8% of ant neoplasms. In Japan gastric cancer remains the most common cancer for men.

Each year in the United States, about 13,000 men and 8,000 women are diagnosed with stomach cancer. Most are over 70 years old.

Stomach cancer is the fourth most common cancer ide, after cancers of the lung, breast, and colon and rectum. Furthermore, stomach cancer remains the second most _ 2 _ common cause of death from cancer. The American Cancer Society estimates that in 2007 there were an estimated one million new cases, nearly 70% of them in developing countries, and about 800,000 deaths (http://www.cancer.org/downloads/STT/Global_Facts_and_Figures_2007_rev2.pdf) Tremendous geographic variation exists in the incidence of this disease around the world.

Rates of the disease are highest in Asia and parts of South America and lowest in North America. The highest death rates are recorded in Chile, Japan, South America, and the former Soviet Union.

Gastric cancer is often diagnosed at an advanced stage, because screening is not performed in most of the world, except in Japan (and in a limited fashion in Korea) where early detection is often achieved. Thus, it continues to pose a major challenge for healthcare professionals. Risk factors for gastric cancer are Helicobacter pylori (H. pylori) infection, smoking, high salt intake, and other dietary factors. A few gastric cancers (1% to 3%) are associated with inherited gastric cancer predisposition syndromes. E-cadherin mutations occur in approximately 25% of es with an autosomal dominant predisposition to e type gastric cancers. This subset of gastric cancer has been termed hereditary diffuse gastric cancer. 12 It may be useful to provide genetic counseling and to er prophylactic gastrectomy in young, asymptomatic carriers of germ-line truncating The wall of the stomach is made up of 3 layers of tissue: the mucosal (innermost) layer, the muscularis (middle) layer, and the l (outermost) layer. Gastric cancer begins in the cells lining the mucosal layer and s through the outer layers as it grows. Four types of standard treatment are used. Treatment for gastric cancer may involve surgery, chemotherapy, radiation therapy or chemoradiation. y is the primary treatment for gastric cancer. The goal of surgery is to accomplish a complete resection with negative s (R0 resection). r, approximately 50% of patients with locoregional c cancer cannot undergo an R0 resection. R1 indicates microscopic al cancer (positive margins); and R2 indicates gross (macroscopic) residual cancer but not t e.

Patient outcome s on the initial stage of the cancer at diagnosis (NCCN Clinical Practice Guidelines in OncologyTM). _ 3 _ The 5-year survival rate for curative surgical resection ranges from 30-50% for patients with stage II disease and from 10-25% for patients with stage III disease. These patients have a high likelihood of local and systemic relapse. Metastasis occurs in 80-90% of individuals with stomach cancer, with a six month survival rate of 65% in those diagnosed in early stages and less than 15% of those diagnosed in late .

Thus, there s a need for new efficacious and safe treatment option for gastric cancer, te carcinoma, oral cavity carcinomas, oral squamous carcinoma (OSCC), acute myeloid leukemia (AML), H. pylori-induced MALT lymphoma, colon carcinoma/colorectal cancer, glioblastoma, non-small-cell lung cancer (NSCLC), cervical carcinoma, human breast cancer, prostate , colon cancer, pancreatic s, pancreatic ductal adenocarcinoma, ovarian cancer, cellular carcinoma, liver cancer, brain tumors of ent phenotypes, leukemias such as acute lymphoblastic leukemia (ALL), lung cancer, Ewing’s sarcoma, endometrial cancer, head and neck squamous cell carcinoma, lial cancer ofthe larynx, oesophageal carcinoma, oral carcinoma, carcinoma ofthe urinary bladder, ovarian carcinomas, renal cell carcinoma, atypical meningioma, papillary thyroid carcinoma, brain tumors, salivary duct carcinoma, cervical cancer, extranodal ell lymphomas, Non-Hodgkins Lymphoma and malignant solid tumors of the lung and breast and other tumors enhancing the eing of the patients without using chemotherapeutic agents or other agents which may lead to severe side effects.

The present invention incorporates peptides which stimulate the immune system and act as anti-tumor-agents in a non-invasive fashion.

Summary of the invention Stimulation of an immune response is dependent upon the presence of antigens recognised as n by the host immune system. The discovery of the existence of tumour associated antigens has raised the possibility of using a host's immune system to intervene in tumour growth. Various mechanisms of harnessing both the l and cellular arms of the immune system are currently being explored for cancer immunotherapy. _ 4 _ Specific elements of the cellular immune response are capable of specifically recognising and destroying tumour cells. The isolation of cytotoxic T-cells (CTLs) from tumour- infiltrating cell tions or from peripheral blood ts that such cells play an important role in natural immune es t cancer. CD8-positive T-cells (TCD8+) in particular, which recognise Class I molecules of the major histocompatibility complex (MHC)-bearing peptides of y 8 to 10 amino acid residues derived from proteins or defect ribosomal ts ) located in the cytosol, play an important role in this response. The MHC-molecules of the human are also designated as human leukocyte- antigens (HLA).

There are two classes of MHC-molecules: MHC class I molecules that can be found on most cells having a nucleus. MHC molecules are composed of an alpha heavy chain and betamicroglobulin (MHC class I receptors) or an alpha and a beta chain (MHC class II receptors), respectively. Their three-dimensional conformation results in a binding groove, which is used for non-covalent interaction with es. MHC class I present peptides that result from proteolytic cleavage of inantly endogenous proteins, DRIPs and larger peptides. MHC class II molecules can be found predominantly on professional antigen presenting cells (APCs). They primarily present peptides of exogenous or transmembrane proteins that are taken up by APCs during the course of tosis, and are subsequently processed. Complexes of peptide and MHC class I molecules are recognized by CD8- positive cytotoxic T-lymphocytes bearing the appropriate T-cell receptor (TCR), whereas complexes of peptide and MHC class II molecules are recognized by CD4-positive-helper- T cells bearing the appropriate TCR. It is well known that the TCR, the peptide and the MHC are thereby present in a stoichiometric amount of l : l : 1.

For a peptide to elicit a cellular immune response, it must bind to an MHC-molecule. This process is dependent on the allele of the MHC-molecule and specific polymorphisms of the amino acid sequence of the peptide. MHC-class-I-binding peptides are usually 8-12 amino acid residues in length and y contain two conserved residues ors") in their sequence that interact with the corresponding binding groove of the MHC-molecule. In this way each MHC allele has a ng motif" determining which peptides can bind specifically to the binding groove. _ 5 _ In the MHC class I dependent immune reaction, peptides not only have to be able to bind to n MHC class I molecules being sed by tumor cells, they also have to be recognized by T cells bearing specific T cell receptors (TCR).

The antigens that are recognized by the tumor c CTLs, that is, their epitopes, can be molecules derived from all n classes, such as enzymes, receptors, ription factors, etc. which are expressed and, as compared to unaltered cells of the same origin, up- regulated in cells of the tive tumor.

The current classification of tumor associated antigens (TAAs) comprises the following major groups: a) Cancer-testis antigens: The first TAAs ever identified that can be recognized by T cells belong to this class, which was originally called cancer-testis (CT) antigens because of the expression of its members in histologically different human tumors and, among normal tissues, only in spermatocytes/spermatogonia of testis and, occasionally, in placenta. Since the cells of testis do not express class I and II HLA molecules, these antigens cannot be recognized by T cells in normal tissues and can therefore be ered as immunologically tumor-specific. Well-known examples for CT antigens are the MAGE family members or NY-ESO-l. b) Differentiation antigens: These TAAs are shared between tumors and the normal tissue from which the tumor arose; most are found in melanomas and normal melanocytes. Many of these melanocyte lineage-related proteins are involved in the biosynthesis of melanin and are therefore not tumor specific but nevertheless are widely used for cancer immunotherapy. Examples include, but are not limited to, tyrosinase and Melan—A/MART- l for melanoma or PSA for prostate cancer. c) Overexpressed TAAs: Genes encoding widely expressed TAAs have been detected in ogically different types of tumors as well as in many normal tissues, generally with lower expression levels. It is le that many of the epitopes processed and potentially presented by normal tissues are below the threshold level for T-cell recognition, while their overexpression in tumor cells can trigger an anticancer response by breaking previously established tolerance. Prominent examples for this class of TAAs are neu, Survivin, Telomerase or WTl. _ 6 _ d) Tumor specific antigens: These unique TAAs arise from mutations of normal genes (such as B-catenin, CDK4, etc.). Some of these molecular changes are associated with neoplastic transformation and/or progression. Tumor c antigens are generally able to induce strong immune responses without bearing the risk for autoimmune reactions against normal tissues. On the other hand, these TAAs are in most cases only relevant to the exact tumor on which they were identified and are usually not shared between many individual tumors. e) TAAs g from al post-translational modifications: Such TAAs may arise from proteins which are neither ic nor overexpressed in tumors but nevertheless become tumor associated by posttranslational processes primarily active in tumors.

Examples for this class arise from altered glycosylation patterns leading to novel epitopes in tumors as for MUCl or events like n splicing during degradation which may or may not be tumor specific. f) Oncoviral proteins: These TAAs are viral proteins that may play a critical role in the oncogenic process and, because they are foreign (not of human origin), they can evoke a T- cell response. Examples of such proteins are the human papilloma type 16 virus proteins, E6 and E7, which are expressed in cervical carcinoma.

For proteins to be recognized by cytotoxic T-lymphocytes as tumor-specific or -associated antigens, and to be used in a therapy, particular prerequisites must be ed. The antigen should be expressed mainly by tumor cells and not or in comparably small s by normal healthy tissues. It is rmore ble, that the respective antigen is not only present in a type of tumor, but also in high concentrations (i.e. copy numbers ofthe respective peptide per cell). Tumor-specific and tumor-associated antigens are often derived from proteins directly involved in transformation of a normal cell to a tumor cell due to a function e.g. in cell cycle control or ssion of sis. Additionally, downstream targets ofthe proteins ly causative for a transformation may be lated und thus may be indirectly tumor-associated. Such indirect tumor-associated antigens may also be targets of a vaccination approach (Singh—Jasuja H., Emmerich N. P., Rammensee H. G., Cancer Immunol. Immunother. 2004 Mar; 453 (3): 187-95). In both cases it is essential that epitopes are present in the amino acid sequence of the antigen, since such a peptide ("immunogenic peptide") that is derived from a tumor associated n should lead to an in vitro or in vivo T-cell—response. _ 7 _ Basically, any peptide able to bind a MHC molecule may function as a T-cell epitope. A uisite for the induction of an in vitro or in vivo T-cell-response is the presence of a T cell with a corresponding TCR and the absence of immunological tolerance for this particular epitope.

Therefore, TAAs are a starting point for the development of a tumor e. The methods for fying and characterizing the TAAs are based on the use of CTL that can be isolated from patients or healthy subjects, or they are based on the generation of differential transcription profiles or differential peptide expression patterns between tumors and normal tissues.

However, the identification of genes over-expressed in tumor tissues or human tumor cell lines, or selectively expressed in such tissues or cell lines, does not provide precise information as to the use of the antigens being transcribed from these genes in an immune y. This is because only an individual subpopulation of es of these antigens are suitable for such an application since a T cell with a corresponding TCR has to be present and immunological tolerance for this particular epitope needs to be absent or minimal. It is therefore important to select only those peptides from over-expressed or ively expressed proteins that are presented in connection with MHC molecules against which a functional T cell can be found. Such a functional T cell is defined as a T cell which upon stimulation with a specific antigen can be clonally expanded and is able to execute effector functions ("effector T cell").

T-helper cells play an important role in trating the effector fianction of CTLs in anti- tumor immunity. T-helper cell epitopes that trigger a T-helper cell response of the TH1 type support effector functions of CD8-positive killer T cells, which e cytotoxic functions directed against tumor cells displaying associated peptide/MHC xes on their cell surfaces. In this way tumor-associated T-helper cell peptide es, alone or in combination with other tumor-associated peptides, can serve as active pharmaceutical ingredients of e compositions which stimulate anti-tumor immune responses.

Brief description of the drawings _ 8 _ Figure 1: Exemplary mass spectrum from CDC2-001 trating its presentation on primary tumor sample GC2464. NanoESI-LCMS was performed on a peptide pool eluted from the GC sample 2464. The mass chromatogram for m/z 597.3501 :: 0.001 Da, z = 2 shows a peptide peak at the retention time 151.63 min. B) The detected peak in the mass chromatogram at 151.63 min revealed a signal of m/z 597.3501 in the MS spectrum. C) A collisionally induced decay mass spectrum from the selected precursor m/z 597.3501 recorded in the I-LCMS experiment at the given retention time confirmed the presence of CDC2-001 in the GC2464 tumor sample. D) The fragmentation pattern of the synthetic 01 reference peptide was recorded and compared to the generated l TUMAP fragmentation pattern shown in C for sequence verification.

Figure 2: Expression profiles of mRNA of selected proteins in normal tissues and in 25 gastric cancer samples a) CDC2 (Probeset ID: 203213_at) b) ASPM (Probeset ID: 219918_s_at) Figure 3: Exemplary results of peptide-specific in Vitro immunogenicity of class I TUMAPs. CD8+ T cells were primed using artificial APCs loaded with relevant (left panel) and irrelevant peptide (right panel), respectively. After three cycles of stimulation, the detection of peptide-reactive cells was performed by double staining with relevant plus irrelevant A*2402-multimers. Shown cells are gated on live CD8+ cytes and the numbers in the plots represent percentages of multimer-positive cells. ed description of the invention As used herein and except as noted otherwise, all terms are defined as given below. The term "peptide" is used herein to designate a series of amino acid residues, connected one to the other typically by peptide bonds n the alpha-amino and carbonyl groups of the nt amino acids. The peptides are ably 9 amino acids in length, but can be as short as 8 amino acids in length, and as long as 10, 11, 12, 13 or 14 amino acids in length.

The term "oligopeptide" is used herein to designate a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and yl groups ofthe adjacent amino acids. The length of the oligopeptide is not critical to _ 9 _ the invention, as long as the correct epitope or epitopes are maintained therein. The oligopeptides are typically less than about 30 amino acid residues in length, and r than about 14 amino acids in length.

The term eptide" designates a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The length of the ptide is not critical to the invention as long as the correct epitopes are ined. In contrast to the terms peptide or oligopeptide, the term polypeptide is meant to refer to molecules containing more than about 30 amino acid A peptide, oligopeptide, protein or polynucleotide coding for such a molecule is ogenic" (and thus is an "immunogen" within the present invention), if it is capable of inducing an immune response. In the case of the present invention, immunogenicity is more specifically defined as the ability to induce a T-cell response. Thus, an "immunogen" would be a molecule that is capable of inducing an immune response, and in the case of the present invention, a molecule capable of inducing a T-cell response.

A T-cell "epitope" requires a short peptide that is bound to a class I MHC receptor, g a ternary complex (MHC class I alpha chain, betamicroglobulin, and peptide) that can be recognized by a T cell bearing a matching T-cell receptor binding to the MHC/peptide x with appropriate affinity. Peptides binding to MHC class I molecules are lly 8-14 amino acids in length, and most typically 9 amino acids in length.

In humans there, are three different genetic loci that encode MHC class I molecules (the MHC-molecules of the human are also designated human leukocyte antigens (HLA)): HLA-A, HLA-B, and HLA-C. HLA-A*Ol, HLA-A*02, and HLA-A*O24 are examples of different MHC class I alleles that can be expressed from these loci.

Table 1: Expression frequencies F of HLA*A024 and the most frequent HLA*A02402 serotypes. Frequencies are deduced from haplotype frequencies Gf within the an population adapted from Mori et al. (Mori et al. 7) employing the Hardy-Weinberg formula -Gf)2. For details refer to Chanock et al. (Chanock et al. 1211-23). _ 10 _ Expression frequencies 24 and A*2402 serotypes worldwide Allele Population Calculated phenotype from Allele ncy A*24 Philippines 65% A*24 Russia Nenets 61% A*2402 Japan 59% A*24 Malaysia 58% A*2402 Philippines 54% A*24 India 47% A*24 South Korea 40% A*24 Sri Lanka 37% A*24 China 32% A*2402 India 29% A*24 Australia West 22% A*24 USA 22% A*24 Russia Samara 20% A*24 South Amerika 20% A*24 Europa 18% As used herein, reference to a DNA sequence includes both single stranded and double stranded DNA. Thus, the specific ce, unless the context indicates otherwise, refers to the single strand DNA of such sequence, the duplex of such sequence with its complement (double stranded DNA) and the complement of such sequence. The term "coding region" refers to that portion of a gene which either naturally or normally codes for the expression product of that gene in its natural genomic enVironment, i.e., the region coding in Vivo for the native expression product of the gene.

The coding region can be from an non-mutated al"), mutated or d gene, or can even be from a DNA sequence, or gene, wholly synthesized in the laboratory using methods well known to those of skill in the art ofDNA synthesis.

The term "nucleotide sequence" refers to a heteropolymer of deoxyribonucleotides. _ 11 _ The nucleotide sequence coding for a particular peptide, oligopeptide, or polypeptide may be naturally occurring or they may be tically constructed. Generally, DNA segments encoding the peptides, polypeptides, and proteins of this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene that is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a ial or viral operon.

The term "expression product" means the ptide or protein that is the natural translation product of the gene and any nucleic acid sequence coding equivalents resulting from genetic code degeneracy and thus coding for the same amino ).

The term ent", when referring to a coding sequence, means a portion of DNA comprising less than the complete coding , whose expression product retains ially the same biological function or activity as the expression product of the complete coding region.

The term "DNA segment" refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in ntially pure form, i.e., free of contaminating endogenous als and in a quantity or concentration enabling identification, manipulation, and recovery of the segment and its component nucleotide sequences by rd biochemical methods, for example, by using a cloning vector. Such segments are provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns, which are typically present in eukaryotic genes. ces of non-translated DNA may be present downstream from the open reading frame, where the same do not interfere with manipulation or sion of the coding regions.

The term "primer" means a short nucleic acid sequence that can be paired with one strand of DNA and provides a free 3'OH end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain.

The term "promoter" means a region of DNA involved in binding of RNA polymerase to initiate transcription. _ 12 _ The term ted" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.

The polynucleotides, and recombinant or immunogenic polypeptides, disclosed in ance with the t invention may also be in "purified" form. The term "purified" does not e absolute purity; , it is intended as a relative definition, and can include preparations that are highly purified or preparations that are only partially purified, as those terms are understood by those of skill in the relevant art. For example, individual clones isolated from a cDNA y have been tionally purified to electrophoretic homogeneity. Purification of starting material or natural al to at least one order of magnitude, preferably two or three , and more preferably four or five orders of magnitude is expressly contemplated. Furthermore, a claimed polypeptide which has a purity of preferably %, or at least 99.99% or 99.9%; and even desirably 99% by weight or greater is expressly contemplated.

The nucleic acids and polypeptide expression products disclosed according to the present invention, as well as expression vectors containing such nucleic acids and/or such polypeptides, may be in "enriched form". As used herein, the term "enriched" means that the concentration of the material is at least about 2, 5, 10, 100, or 1000 times its natural concentration (for example), advantageously 0.01 %, by weight, preferably at least about 0.1% by weight. Enriched preparations of about 0.5%, l%, 5%, 10%, and 20% by weight are also contemplated. The sequences, constructs, vectors, clones, and other als comprising the present invention can advantageously be in enriched or isolated form.

The term "active fragment" means a nt that tes an immune response (i.e., has immunogenic activity) when administered, alone or optionally with a suitable adjuvant, to an animal, such as a , for example, a rabbit or a mouse, and also including a _ 13 _ human, such immune response taking the form of stimulating a T-cell response within the recipient animal, such as a human. Alternatively, the "active fragment" may also be used to induce a T-cell response in Vitro.

As used herein, the terms "portion", "segment" and "fragment," when used in relation to polypeptides, refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger ce. For example, if a polypeptide were ted to treatment with any of the common ptidases, such as n or chymotrypsin, the oligopeptides resulting from such treatment would represent portions, segments or fragments of the starting polypeptide. This means that any such fragment will necessarily contain as part of its amino acid ce a segment, fragment or portion, that is substantially identical, if not exactly identical, to a sequence of SEQ ID NO: 1 to 33, which correspond to the lly occurring, or "parent" ns of the SEQ ID NO: 1 to 33. When used in relation to polynucleotides, these terms refer to the products produced by treatment of said polynucleotides with any of the common endonucleases.

In accordance with the present invention, the term "percent identity" or "percent identical", when referring to a sequence, means that a sequence is compared to a claimed or described ce after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence"). The Percent Identity is then determined ing to the following a: Percent Identity = 100 [I -(C/R)] wherein C is the number of ences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence, wherein (i) each base or amino acid in the Reference Sequence that does not have a ponding aligned base or amino acid in the Compared Sequence and (ii) each gap in the Reference Sequence and (iii) each d base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference; and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid. _ 14 _ If an alignment exists between the Compared Sequence and the Reference Sequence for which the percent identity as calculated above is about equal to or greater than a specified minimum Percent Identity then the Compared Sequence has the specified minimum t identity to the nce ce even though alignments may exist in which the herein above calculated Percent Identity is less than the ed Percent Identity.

The original peptides disclosed herein can be modified by the substitution of one or more residues at different, possibly selective, sites within the peptide chain, if not otherwise stated. Such substitutions may be of a conservative nature, for example, where one amino acid is replaced by an amino acid of similar structure and characteristics, such as where a hydrophobic amino acid is replaced by r hydrophobic amino acid. Even more vative would be replacement of amino acids of the same or similar size and chemical nature, such as where leucine is replaced by isoleucine. In studies of sequence variations in families of naturally occurring homologous proteins, certain amino acid substitutions are more often tolerated than , and these are often show correlation with similarities in size, charge, polarity, and hydrophobicity between the original amino acid and its replacement, and such is the basis for defining "conservative substitutions." Conservative substitutions are herein defined as exchanges within one of the following five groups: Group l-small aliphatic, nonpolar or slightly polar residues (Ala, Ser, Thr, Pro, Gly); Group 2-polar, negatively charged residues and their amides (Asp, Asn, Glu, Gln); Group 3-polar, positively charged residues (His, Arg, Lys); Group e, aliphatic, ar residues (Met, Leu, Ile, Val, Cys); and Group 5-large, aromatic residues (Phe, Tyr, Trp).

Less vative substitutions might involve the replacement of one amino acid by another that has similar characteristics but is somewhat different in size, such as replacement of an alanine by an isoleucine residue. Highly non-conservative ements might involve substituting an acidic amino acid for one that is polar, or even for one that is basic in ter. Such "radical" substitutions cannot, however, be dismissed as potentially ineffective since al effects are not totally predictable and l substitutions might 2011/053863 _ 15 _ well give rise to ipitous effects not otherwise predictable from simple chemical principles.

Of course, such substitutions may involve structures other than the common L-amino acids.

Thus, D-amino acids might be substituted for the L-amino acids commonly found in the antigenic peptides of the invention and yet still be encompassed by the disclosure . In addition, amino acids possessing non-standard R groups (i.e., R groups other than those found in the common 20 amino acids of natural proteins) may also be used for substitution purposes to produce immunogens and immunogenic ptides according to the t invention.

If substitutions at more than one position are found to result in a peptide with ntially equivalent or greater antigenic activity as defined below, then combinations of those substitutions will be tested to determine if the combined substitutions result in additive or synergistic effects on the antigenicity of the peptide. At most, no more than 4 positions within the peptide would simultaneously be substituted.

The term l se" means the specific proliferation and activation of effector ons induced by a peptide in vitro or in vivo. For MHC class I restricted CTLs, effector functions may be lysis of peptide-pulsed, peptide-precursor pulsed or naturally e-presenting target cells, secretion of cytokines, preferably Interferon-gamma, TNF- alpha, or IL-2 induced by peptide, secretion of effector molecules, preferably granzymes or perforins induced by peptide, or degranulation.

Preferably, when the CTLs specific for a peptide of SEQ IDs NO: 1 to 33 are tested against the substituted peptides, the peptide concentration at which the substituted peptides achieve half the maximal increase in lysis relative to background is no more than about 1 mM, preferably no more than about 1 uM, more preferably no more than about 1 nM, and still more preferably no more than about 100 pM, and most preferably no more than about 10 pM. It is also preferred that the substituted peptide be recognized by CTLs from more than one individual, at least two, and more preferably three individuals. _ l6 _ Thus, the epitopes of the present invention may be identical to naturally occurring tumor- associated or tumor-specific epitopes or may include epitopes that differ by no more than 4 residues from the reference peptide, as long as they have substantially cal antigenic Immunotherapeutic approaches for treatment ation of an immune response is dependent upon the presence of antigens ized as foreign by the host immune system. The ery of the existence of tumor associated antigens has now raised the possibility of using a host's immune system to intervene in tumor . Various mechanisms of harnessing both the humoral and cellular arms ofthe immune system are currently explored for cancer immunotherapy.

Specific ts of the cellular immune response are capable of ically recognizing and destroying tumor cells. The isolation of cytotoxic T-cells (CTL) from tumor-infiltrating cell populations or from peripheral blood ts that such cells play an important role in natural immune defenses against cancer. CD8-positive T-cells in particular, which recognize class I les of the major histocompatibility complex (MHC)-bearing es of usually 8 to 12 residues derived from proteins or defect ribosomal products (DRIPS) located in the cytosols, play an important role in this se. The MHC- molecules of the human are also designated as human leukocyte-antigens (HLA).

MHC class I molecules can be found on most cells having a nucleus which present peptides that result from proteolytic cleavage of mainly endogenous, cytosolic or nuclear proteins, DRIPS, and larger peptides. However, peptides derived from endosomal compartments or exogenous sources are also ntly found on MHC class I molecules. This non-classical way of class I tation is referred to as cross-presentation in literature.

For proteins to be recognized by cytotoxic T-lymphocytes as tumor-specific or -associated antigens, and to be used in a therapy, particular prerequisites must be fillfilled. The antigen should be expressed mainly by tumor cells and not by normal healthy tissues or in comparably small amounts. It is fiarthermore desirable, that the respective antigen is not only present in a type of tumor, but also in high concentrations (i.e. copy numbers of the respective peptide per cell). Tumor-specific and tumor-associated antigens are often _ 17 _ derived from proteins directly involved in transformation of a normal cell to a tumor cell due to a function e.g. in cell cycle control or apoptosis. Additionally, also downstream targets of the ns directly causative for a transformation may be upregulated und thus be ctly tumor-associated. Such indirectly associated antigens may also be targets of a vaccination approach. ial is in both cases the presence of es in the amino acid ce of the n, since such peptide ("immunogenic peptide") that is derived from a tumor associated antigen should lead to an in vitro or in vivo T-cell- I'GSpOIlSG.

Basically, any peptide able to bind a MHC molecule may function as a T-cell epitope. A prerequisite for the induction of an in vitro or in vivo T-cell-response is the presence of a T cell with a ponding TCR and the absence of immunological tolerance for this particular epitope.

Therefore, TAAs are a starting point for the development of a tumor vaccine. The methods for identifying and characterizing the TAAs are based on the use of CTL that can be isolated from patients or healthy subjects, or they are based on the generation of differential transcription profiles or differential peptide expression patterns between tumors and normal tissues (Lemmel et al. 450-54;Weinschenk et al. 5818-27).

However, the identification of genes over-expressed in tumor tissues or human tumor cell lines, or selectively expressed in such tissues or cell lines, does not provide precise information as to the use of the antigens being transcribed from these genes in an immune therapy. This is because only an individual ulation of epitopes of these antigens are suitable for such an application since a T cell with a corresponding TCR has to be present and immunological tolerance for this particular epitope needs to be absent or minimal. It is therefore ant to select only those peptides from over-expressed or selectively expressed proteins that are ted in connection with MHC molecules against which a functional T cell can be found. Such a functional T cell is defined as a T cell that upon stimulation with a specific antigen can be clonally expanded and is able to execute effector ons ("effector T cell").

WO 13819 _ 18 _ T-helper cells play an important role in orchestrating the or function of CTLs in anti- tumor immunity. T-helper cell epitopes that trigger a T-helper cell se of the THl type support or functions of CD8-positive killer T cells, which e cytotoxic fianctions directed t tumor cells displaying tumor-associated peptide/MHC complexes on their cell surfaces. In this way, associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, can serve as active pharmaceutical ingredients of vaccine compositions that stimulate umor immune responses.

Since both types of response, CD8 and CD4 dependent, contribute jointly and synergistically to the anti-tumor effect, the identification and characterization of tumor- associated antigens recognized by either CD8-positive CTLs (MHC class 1 molecule) or by CD4-positive CTLs (MHC class II molecule) is important in the development of tumor vaccines. It is therefore an object of the present invention, to provide compositions of peptides that contain peptides binding to MHC complexes of either class.

Considering the severe side-effects and expense associated with treating cancer better prognosis and stic methods are desperately needed. Therefore, there is a need to identify other factors representing biomarkers for cancer in general and gastric cancer in ular. Furthermore, there is a need to identify factors that can be used in the treatment of cancer in general and gastric cancer in particular.

Furthermore there is no established eutic design for gastric cancer patients with biochemical relapse after radical prostatectomy, usually caused by al tumor left in situ in the presence of locally advanced tumor growth. New therapeutic approaches that confer lower morbidity with comparable therapeutic efficacy relative to the currently available therapeutic approaches would be desirable.

The present invention provides es that are useful in ng gastric cancer and other tumors that overexpress the peptides of the invention. These peptides were shown by mass spectrometry to be naturally presented by HLA molecules on primary human gastric cancer samples (see example 1, and figure 1).

WO 13819 _ 19 _ The source gene from which the peptides are derived were shown to be highly overexpressed in gastric cancer, renal cell oma, colon cancer, non-small cell lung carcinoma, adenocarcinoma, prostate cancer, benign neoplasm and malignant melanoma ed with normal tissues (see example 2, and figure 2) demonstrating a high degree of tumor ation of the peptide, i.e. these peptides are strongly presented on tumor tissue but not on normal tissues.

HLA-bound peptides can be recognized by the immune system, specifically by T lymphocytes/T cells. T cells can destroy the cells presenting the recognized HLA/peptide complex, e. g. gastric cancer cells presenting the derived peptides.

All es, that were compatible with the validation platform —see example 3-, of the present invention have been shown to be capable of stimulating T cell responses (see Example 3 and Figure 3). Thus, the peptides are useful for generating an immune response in a patient by which tumor cells can be destroyed. An immune response in a patient can be induced by direct administration of the bed peptides or suitable precursor substances (e. g. elongated es, proteins, or nucleic acids encoding these peptides) to the patient, ideally in combination with an agent enhancing the immunogenicity (i.e. an adjuvant). The immune response originating from such a eutic vaccination can be expected to be highly specific against tumor cells because the target peptides of the t invention are not presented on normal tissues in comparable copy numbers, preventing the risk of red autoimmune reactions against normal cells in the patient.

The pharmaceutical compositions comprise the peptides either in the free form or in the form of a pharmaceutically acceptable salt. As used herein, "a ceutically acceptable salt" refers to a derivative of the disclosed peptides wherein the peptide is modified by making acid or base salts of the agent. For example, acid salts are prepared from the free base (typically wherein the neutral form of the drug has a neutral —NH2 group) involving reaction with a suitable acid. Suitable acids for ing acid salts include both c acids, e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, c acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methane sulfonic acid, ethane sulfonic acid, p- toluenesulfonic acid, salicylic acid, and the like, as well as inorganic acids, e.g., _ 20 _ hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid phosphoric acid and the like.

Conversely, preparation of basic salts of acid moieties which may be present on a peptide are prepared using a pharmaceutically acceptable base such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, trimethylamine or the like.

In an especially preferred embodiment, the pharmaceutical compositions comprise the peptides as salts of acetic acid (acetates) or hloric acid (chlorides).

In addition to being useful for treating cancer, the peptides of the present invention are also useful as diagnostics. Since the peptides were generated from gastric cancer cells and since it was determined that these peptides are not present in normal tissues, these peptides can be used to diagnose the ce of a cancer.

The presence of claimed peptides on tissue biopsies can assist a pathologist in diagnosis of cancer. Detection of certain es by means of antibodies, mass spectrometry or other methods known in the art can tell the ogist that the tissue is malignant or inflamed or generally diseased. Presence of groups of peptides can enable classification or subclassification of diseased tissues.

The detection of peptides on diseased tissue specimen can enable the decision about the benefit of therapies ing the immune system, especially if T-lymphocytes are known or expected to be involved in the mechanism of action. Loss of MHC expression is a well described mechanism by which infected of malignant cells escape surveillance.

Thus, presence of peptides shows that this mechanism is not exploited by the ed cells.

The peptides might be used to analyze lymphocyte ses t those peptides such as T cell responses or dy responses against the peptide or the e complexed to MHC molecules. These lymphocyte responses can be used as prognostic s for decision on fiarther therapy steps. These responses can also be used as surrogate markers in immunotherapy approaches aiming to induce lymphocyte responses by different means, e.g. vaccination of protein, nucleic acids, autologous materials, adoptive transfer of _ 21 _ lymphocytes. In gene therapy settings, lymphocyte responses against peptides can be considered in the assessment of side effects. Monitoring of cyte responses might also be a valuable tool for follow-up examinations of transplantation therapies, e. g. for the ion of graft versus host and host versus graft es.

The peptides can be used to generate and develop specific antibodies against MHC/peptide complexes. These can be used for therapy, targeting toxins or ctive substances to the diseased tissue. Another use ofthese antibodies can be targeting radionuclides to the diseased tissue for imaging purposes such as PET. This use can help to detect small metastases or to determine the size and precise localization of diseased tissues.

In on, they can be used to verify a pathologist’s diagnosis of a cancer based on a biopsied sample.

Table 2 shows the peptides according to the present invention, their respective SEQ ID NO:, and the source ns from which these peptides may arise. All peptides bind the HLA A*024 alleles.

Table 2: es of the present invention Source SEQ ID NO: Peptide Code Sequence Protein(s) 14 ABM 17 W Further interesting HLA A*024 peptides of the invention SEQ ID Source NO: Peptide Code ce Protein(s) CCDC88A- QYIDKLNEL CCDC88A CCNB1-003 MYMTVSIIDRF CCNBI CCND2-001 RYLPQCSYF CCND2 CCNE2-001 IYAPKLQEF CCNE2 IYPDASLLI CEACAM l CEACAMS CEA-O l 0 CEACAM6 CLCN3-OOl VYLLNSTTL CLCN3 DNA]C 1 0-00 1 HNL DNA]C l 0 DNA]C 1 0-002 FYF IFSKIVSLF EIFZS3, YYYVGFAYL EIF3L, __CN2001_S_YLELVKSL_YNVTSVLF_CN2 LOC642502 SDHC-001 SDHC -——_ -—-— TSPAN8-001 VYKETCISF TSPAN8 In another embodiment of the invention HLA A*02 binding peptides against gastric cancer are disclosed. For people which are A*02 and/or A*24 positive, mixtures of the disclosed _ 24 _ peptides can be used for the treatment of gastric cancer. Preferred are mixtures of 2 to 20 peptides and mixtures of2, 3, 4, 5, 6, 7, 8, 9,10,11,12,13,14,15,16,17,18,19 and 20 peptides.

SEQ ID Source NO: Peptide Code ce Protein(s) 64 LMNBl-OOI LMNBI VLEDLEVTV COPG, COPG2, COPG-OOl TSGA13 COL6A3-002 FLLDGSANV COL6A3 COL6A3-003 NLLDLDYEL COL6A3 COL6A3-004 EGV COL6A3 PSMC2-001 ALDEGDIAL PSMC2 UBEZS-001 GRLLL UBE2S ILSPTVVSI KIF1 1 KLLTEVHAA ADAMS ALVQDLAKA CCNBI ILQDRLNQV CDC6 TLDPRSFLL F2R TLDDLLLYI OLFM4 TSWLL THYl SLAEVNTQL CEP250 ALDGFVMVL HIFlA GVDDAFYTL KRAS YVDPVITSI MET 66666666 _——— CEACAM6- VLYGPDVPTI CEACAM6 OOI SIFGEDALANV COPBl HMMR—OOI EEI HMMR TPX2-001 KILEDVVGV TPX2 95 KIFDEILVNA TOP2A, TOP-001 TOP2B Cell division cycle 2 protein (CDC2) The serine/threonine kinase CDC2, also known as Cdkl n-dependent kinase 1), plays a key role in cell cycle control. It is known as the main regulator of the G2-to-M transition.

At the end of interphase, it binds to A-type s. After breakdown of the nuclear envelope, A-type cyclins are replaced by cyclin B, which forms the mitosis promoting factor (MPF) with Cdc2. MPF is ial for driving cells through mitosis.

The fianction of Cdc2 in mitosis is non-redundant and cannot be compensated by the activity of other Cdks, such as Cdk2, 4 and 6. By contrast, Cdc2 was reported to function in other phases of the cell cycle such as the Gl-S tion as well, and it is able to substitute for the "interphase Cdks". Thus, Cdc2 was proposed to be the only essential cell cycle Cdk.

Overexpression of Cdc2 was found in several cancers, often correlating with poor prognosis,. Among them are prostate carcinoma, oral cavity carcinomas, oral squamous carcinoma (OSCC), acute myeloid leukemia (AML) (Qian et al.), H. pylori-induced MALT lymphoma (Banerjee et al. 217-25) and colon carcinoma (Yasui et al. 36-41). In gastric carcinoma, overexpression and/or enhanced ty has been reported and could play a causative role. Inhibitors of Cdc2 and other Cdks have been considered as drug candidates for cancer therapy (Shapiro 1770-83). _ 26 _ Abnormal spindle-like microcephaly associated protein (ASPM) Abnormal spindle-like microcephaly ated (ASPM) is the human ogue of the hila abnormal spindle (asp). It is ed in the regulation of neurogenesis, and mutation causes autosomal recessive y microcephaly. ASPM is localized in the spindle poles during mitosis. ASPM overexpression was suggested as marker and potential therapeutic target in glioblastoma. siRNA-mediated knockdown inhibits tumor cell proliferation and neural stem cell proliferation. ASPM overexpression may also predict ed invasive/metastatic potential, early tumor recurrence and poor prognosis in hepatocellular carcinoma. ASPM was upregulated in immortalized cells and non-small-cell lung cancer tissues (Jung, Choi, and Kim 703-13).

Matrix metalloproteases 3 (MMP3) MMP3, also called progelatinase or stromelysin l, is an endopeptidase that cleaves extracellular matrix (ECM) components such as fibronectin, laminin, elastin, the proteoglycan core protein and nonhelical regions of collagens. MMPs are important in several physiological processes ing ECM rearrangement, such as cell migration during embryogenesis, tissue remodeling, vascularization, involution of the lactating breast and wound healing. MMP3 also plays a role in platelet aggregation. Pathological conditions ing enhanced expression and secretion of MMP3 include autoimmune inflammatory conditions and cancer.

MMP3 is over-expressed in some tumors, and plays a role in epithelial-mesenchymal transition (EMT). It might also contribute to early steps in cancerogenesis, triggering epigenetic changes that result in the generation of a malignant phenotype (Lochter et al. 180-93). Polymorphisms in the MMP3 promoter that are associated with expression levels were shown to impact risk and prognosis for some s like esophageal adenocarcinoma (Bradbury et al. 793-98) and oral squamous cell carcinoma ktaris et al. 4095-100) (Liu et al. 430-35). H.pylori—positive c cancer patients with ed MMP3- and MMP7 serum levels showed higher lymph node invasion and shorter survival. In a cohort of 74 gastric cancer patients, MMP3 was expressed in 27% of the cases, (Murray et al. 791- 97). c—Met _ 27 _ c-Met mediates the potentially oncogenic activities of the hepatocytic growth factor (HGF)/scatter , including promotion of cell growth, motility, survival, ellular matrix dissolution, and angiogenesis. Binding of HGF activates downstream signalling events including the Ras, phosphatidylinositol 3’-kinase, phospholipase Cy, and mitogen— activated protein kinase-related pathways (Dong et al. 5911-18;Furge et al. 10722- 27;Furge, Zhang, and Vande Woude 5582-89;Montesano et al. 355-65;Naldini et al. 501- 04;Ponzetto et al. 4600-08). c-Met is expressed predominantly in epithelial cells.

Oncogenic activation of c-Met (also in non-epithelial malignant tissues) can result from amplification/over-expression, activating mutations, acquisition of HGF/c-Met autocrine loops or constitutive phosphorylation (Di Renzo et al. l47-54;Ferracini et al. 739- 49;Fischer et al. 733-39;Koochekpour et al. 5391-98;Li et al. 8125-35;Maulik et al. 41- 59;Qian et al. 589-96;Ramirez et al. 635-44;Tuck et al. 225-32) (Nakaigawa et al. 3699- 705). Constitutive activation of c-Met in er-expressing transgenic mice promotes broad tumorigenesis (Takayama et al. 701-06;Wang et al. 4). Silencing MET results in inhibition of tumor growth and metastasis (Corso et al. 684-93). cation of MET has been associated with human c cancer progression (Lin et al. 5680-89).(Yokozaki, Yasui, and Tahara 49-95).

Ubiquitin carboxyl-terminal ase L5 (UCHLS) UCHLS, also known as Ubiquitin inal hydrolase (UCH37) or INOSOR, is a proteasome-associated deubiquitinase. It disassembles protein-attached poly-ubiquitin chains from the distal end by cleaving the isopeptide bond between the inal Cys76 and Lys48 (Nishio et al. 855-60). In the nucleus, UCHLS is associated with the Ino80 chromatin-remodeling complex. Upon binding of a proteasome, it becomes activated and may bute to the regulation of transcription or DNA repair that has been suggested to be mediated by In080 and the proteasome.

Ubiquitin specific proteases like UCHLS are involved in several processes such as control of cell cycle progression, differentiation, DNA ation and repair, ription, protein quality control, immune response and sis. UCHLS might contribute to malignant transformation. Its activity has been shown to be upregulated in human cervical carcinoma tissue as compared to adjacent normal tissue. It is able to deubiquitinate and thereby stabilize the TGF-beta receptor and its ream mediators, the Smads, thereby _ 28 _ enhancing TGF-beta signaling. Enhanced TGF-beta signaling can act as a tumor er in late stages of cancer progression, although it has a dual function and can also be a tumor suppressor in early stages and before initiation (Bierie and Moses 29-40;Horton et al. 138- ks et al. 8080-84;Wicks et al. 761-63).

Macrophage-stimulating protein receptor (MSTlR) The MSTlR (alias RON) receptor is a member of the Met family of cell surface receptor tyrosine kinases and is primarily expressed on lial cells and macrophages. MSTlR can induce cell ion, invasion, proliferation and survival in response to its ligand.

Oncogenic properties have been shown in vitro as well as in animal models in vivo, and it is often deregulated in human cancers (Dussault and Bellon, 2009). Clinical s have shown that MSTlR over-expression is ated with poor diagnosis and metastasis.

MSTlR expression is significant in gastric carcinoma tissue and corresponding paraneoplastic tissue, but is not observed in normal c mucosa (Zhou et al. 236-40).

Knockdown of MSTlR in prostate cancer cells results in d endothelial cell chemotaxis in and in reduced tumor growth and decreased microvessel density after orthotopic lantation into the prostate in vivo. siRNA-mediated knockdown ofMSTlR in a highly tumorigenic colon cancer cell line led to reduced proliferation as compared with control cells.

Kinesin-like protein (KIFZC) KIFZC is a ubule depolymerase regulating proper kinetochore-microtubule attachment during spindle formation. It is important for anaphase chromosome segregation and may be required to coordinate the onset of sister centromere separation. Disturbed microtubule attachment at kinetochores leads to chromosome mis-segregation and aneuploidy, which is observed in most solid tumors (Maney et al. 67-131;Moore and Wordeman 537-46). KIFZC is over-expressed in breast cancer cells (Shimo et al. 62-70), colon cancer, colorectal cancer and gastric cancer (Nakamura et al. ). A gastric cancer cell line (AZ521) that stably expressed KIFZC showed a increased proliferation and migration compared to ransfected cells. Elevated expression of KIFZC in gastric cancer may be associated with lymphatic invasion, lymph node metastasis, and poor prognosis. Treatment of breast cancer cells with small interfering RNA against KIFZC inhibited their growth. _ 29 _ Structural maintenance of chromosomes ns 4 (SMC4) SMC proteins are chromosomal ATPases that play roles in higher-order chromosome zation and dynamics. SMC4 is a core ent of the condensin complex that plays a role in chromatin condensation and has also been associated with nucleolar segregation, DNA repair, and maintenance of the chromatin scaffold. The SMC4 gene was found to be expressed highly in normal prostate and salivary gland, very weakly in colon, pancreas, and intestine, and not at all in other tissues.RNA expression was observed at high levels in many cancer cell lines and cancer specimens, including breast, te colon and pancreatic cancer (Egland et al. 4).

Ephrin type-A receptor 2 (EPAH2) Eph receptors are a unique family ofreceptor tyrosine kinases (RTK) that play critical roles in embryonic patterning, neuronal targeting, and vascular development during normal embryogenesis. Stimulation of EphA2 by its ligand (ephrin-Al) results in EphA2 autophosphorylation, the stimulation es oncogenic transformation. Eph receptors and their ligands, the ephrins, are frequently overexpressed in a wide variety of cancers. EphA2 is frequently overexpressed and fianctionally altered in aggressive tumor cells, and is thought to promote tumor growth by enhancing cell- extracellular matrix on, anchorage-independent growth and angiogenesis. Overexpression ofEphA2 and EphrinA-l was shown in gastric carcinoma, correlating with the depth of tumor invasion, tumor-node- metastasis (TNM) stages, lymph node metastasis and poor prognosis (Yuan et al. 2410-17).

ATAD2 ATAD2 (also known as ANCCA) is a new member of the AAA+ ATPase family proteins.

It enhances the transcriptional activity of androgen receptor (AR) and estrogen or (ER), leading to transcription of genes including IGFlR, IRS-2, SGKl and surviving (AR) and cyclin D1, c-myc and E2Fl (ER), tively. It also enhances the transcriptional activity of c-Myc.

ATAD2 sion is high in several human tumors, such as breast cancer, prostate cancer and arcoma. Expression has been associated with poor prognosis.

AVL9 _ 30 _ Surprisingly this protein was found as source protein, and only poor and very limited data is available about the AVL9 n and the fianction of the corresponding gene. en alpha-l(XII) chain protein (CollZAl) Collagen alpha-1(XII) chain is a protein that in humans is encoded by the COLlZAl gene.

This gene encodes the alpha chain of type XII en, a member of the FACIT (fibril- associated collagens with interrupted triple helices) collagen family. Type XII collagen is a homotrimer found in association with type I collagen, an association that is thought to modify the interactions between collagen I s and the nding matrix. Alternatively spliced ript variants encoding different isoforms have been identified.

Collagen alpha-3(VI) chain protein (COL6A3) COL6A3 encodes the alpha-3 chain, one of the three alpha chains of type VI collagen. The protein domains have been shown to bind ellular matrix proteins, an ction that explains the importance of this collagen in organizing matrix components. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. The ce of collagen VI correlated with tumor grade, an ovarian cancer prognostic factor (Sherman-Baust et al. 377-86). COL6A3 is overexpressed in colorectal tumour (Smith et al. 4), salivary gland carcinoma (Leivo et al. 104-13) and differentially expressed in gastric cancer (Yang et al. 1033-40). COL6A3 was identified as one of seven genes with tumor-specific splice variants. The validated tumor-specific splicing alterations were highly consistent, enabling clear separation of normal and cancer samples and in some cases even of different tumor stages (Thorsen et al. 1214—24).

Fanconi anemia, mentation group I (FANCI) The FANCI protein localizes to chromatin in response to DNA damage and is involved in DNA repair (Smogorzewska et al. 289-301). Mutations in the FANCI gene cause Fanconi anemia, a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal ge, and defective DNA repair. Alternative splicing of FANCI results in two transcript variants encoding different isoforms. _ 31 _ Heat shock protein 90kDa beta member 1 (HSP90B1) HSP90 (also known as e-regulated protein 94, Grp94), member 1 is a human chaperone protein. It participates in ER—associated processes: translation, protein quality control and ER—associated degradation (ERAD), ER stress sensing and calcium binding / retention of calcium in the ER (Christianson et al. 272-82;Fu and Lee 741-44). HSP90 contains the KDEL sequence typical for ER—retained proteins, but it also s on the surface of tumor cells (Altmeyer et al. 340-49), as well as ellularly. HSPs are known to be released from necrotic (but not apoptotic) cells and from cells stressed by various stimuli such as heat shock and ive stress, and can occur in circulation (Basu et al. lS39-46;Tsan and Gao 274-79). Extracellularly, HSP90 modulates (mainly stimulates) immune responses and is involved in antigen presentation. On the cell surface, it may serve as receptor for pathogen entry and / or signaling (Cabanes et al. 2827-38). In case of tumor-specific cell e sion or release it may induce umor immunity (Zheng et al. 6731-35). HSP90-based vaccines have been shown to immunize against cancer and infectious diseases in both prophylactic and therapeutic protocols (reviewed in (Bolhassani and Rafati 9;Castelli et al. 227-33;Murshid, Gong, and Calderwood 1019-30)).

However, HSP90 can also be considered as target for tumor therapy as 1) it correlates with tumor progression and leads to resistance towards apoptosis, also upon irradiation or chemotherapy ent, and 2) it is overexpressed in many tumors ing GC, osteosarcoma (Guo et al. 62-67), breast carcinoma (Hodorova et al. 31-35). Overexpression of HSP90 is associated with aggressive behavior and poor prognosis in GC (Wang, Wang, and Ying 35-4l;Zheng et al. 1042-49). Downregulation of HSP90 in GC leads to apoptosis of cancer cells (Sheu, Liu, and Lan elO96).

Muc 6 MUC6 is expressed in mucous cells. Its primary function is thought to be the protection of vulnerable epithelial surfaces from damaging effects of constant exposure to a wide range of endogenous caustic or proteolytic agents (Toribara et al., 1997). MUC6 may also play a role in epithelial organogenesis (Reid and Harris, 1999). MUC6 expression is found in normal gastric mucosa. It is over-expressed in some cancers like intestinal adenoma and carcinoma, pulmonary carcinoma (Hamamoto et al. 891-96), colorectal polyps an et al. 210-18), and breast carcinoma (Pereira et al. 210-13), whereas it is not sed in the respective normal s. The high sion rate of MUC6 in mucinous carcinoma _ 32 _ suggests was suggested to act as a r to cancerous extension resulting in their less aggressive biological behaviour (Matsukita et al. 26-36). MUC6 expression was lower in gastric carcinomas than in adenomas or normal mucosa and ely correlated with tumor size, depth of invasion, lymphatic and venous invasion, lymph node metastasis and UICC g. Down-regulation of MUC6 may contribute to malignant transformation of gastric epithelial cells and ie the molecular bases of growth, invasion, metastasis and differentiation of c carcinoma (Zheng et al. 817-23). There is also evidence that Helicobacter pylori infection, one of the major causes of c carcinoma, is associated with reduced MUC6 expression (Kang et al. Wang and Fang 425-31).

Kinetochore protein Nuf2 NUF2 (CDCA-l) gene encodes a protein that is highly similar to yeast Nuf2, a ent of a conserved protein complex associated with the centromere. Yeast Nuf2 disappears from the centromere during c prophase when centromeres lose their connection to the spindle pole body, and plays a regulatory role in chromosome segregation. It was shown that survivin and hNuf2 csiRNAs temporally knockdown their mRNAs causing multinucleation and cell death by mitotic arrest, respectively (Nguyen et al. 394-403). Nuf2 and Hecl are required for organization of stable microtubule plus-end binding sites in the outer plate that are needed for the sustained poleward forces required for biorientation at kinetochores (DeLuca et al. ).

Nuf2 protein was found to be over-expressed in NSCLC, associated with poor prognosis (Hayama et al. 10339-48), and in cervical cancer (Martin et al. 333-59). In surgically resected gastric cancer tissues (diffuse type, 6; inal type, 4), 2 ts ofNUF2 were upregulated. The alternative splicing variants detected in this study were suggested be potentially usefill as diagnostic markers and/or novel targets for ncer therapy a et al. 57-68). siRNA-mediated own against NUF2 has been found to inhibit cell proliferation and induction of apoptosis in NSCLC, ovarian cancer, cervical cancer, gastric cancer, colorectal cancer and glioma (Kaneko et al. 1235-40).

Lipid phosphate phosphohydrolase 2 (PPAPZC) Phosphatidic acid phosphatases (PAPs) convert phosphatidic acid to diacylglycerol, and function in de novo synthesis of glycerolipids as well as in receptor-activated signal _ 33 _ transduction mediated by phospholipase D. Three alternatively spliced transcript variants encoding distinct isoforms have been reported. PPAP2C is up-regulated in transformed y human adult mesenchymal stem cells (MSCs), and numerous human cancers. It might be required for increased cell proliferation. Overexpression of PPAP2C, but not a catalytically inactive mutant, caused premature S-phase entry, anied by premature cyclin A accumulation. Knockdown decreases cell proliferation by delaying entry into S phase (Flanagan et al. 249-60). 40S ribosomal protein S11 is a protein (RPSl l) Ribosomes consist of a small 40S subunit and a large 60S t. er these subunits are composed of 4 RNA species and approximately 80 structurally ct proteins. The RPSll gene encodes a ribosomal protein that is a component of the 40S subunit. RPSll was among six genes found in a screen for fecal RNA-based markers for colorectal cancer diagnosis. It was specifically found in cancer-patient d fecal cytes (Yajima et al. 1029—37).

E3 ubiquitin-protein ligase Seven in absentia g 2 (SIAH2) SIAH2 is a E3 ubiquitin ligase. Among its substrates are beta-catenin, TRAF2, and DCC (deleted in colorectal cancer) hah et al. 5756-65;Hu and Fearon 724-32;Nakayama, Qi, and Ronai 443-51). SIAH2 also leads to degradation ofthe nuclear protein repp86, resulting in abrogation of the mitotic arrest d by overexpression of this protein (Szczepanowski et al. 485-90). SIAH2 has tumor- as well as metastasis-promoting properties via at least two pathways, reviewed in (Nakayama, Qi, and Ronai 443-51): First, it leads to tination and degradation of proteins in the a response pathway, which leads to enhanced transcriptional activity of hypoxia-inducible factors (HIFs) (Nakayama, Qi, and Ronai 443-51)(Calzado et al. 85-91). Second, it suppresses Sprouty2, a ic inhibitor of Ras/ERK signaling. SIAH2 activity is correlated with pancreatic tumor development likely through its positive effect on Ras signaling(Nakayama, Qi, and Ronai 443-5 1).

Although the role of SIAH2 in cancer is partly controversial, some reports showing association of low levels of SIAH2 with poorer prognosis or therapy response (Confalonieri et al. 2959-68) n et al. 263-71), others show a tumorigenic function (Frasor et al. 13153-57). SIAH2 inhibition has been considered as anti-cancer treatment, as it has been _ 34 _ shown to inhibit growth of xenografts in melanoma mouse models (Qi et al. 16713-18;Shah et al. 799-808), and of human lung cancer cell lines engrafted into nude mice (Ahmed et al. 1606-29).

Sodium— and chloride-dependent taurine orter (SLC6A6) SLC6A6 is a sodium- and de-dependent taurine transporter (TauT) (Han et al., 2006).

Taurine transporter knockout (taut-/-) mice suffer from chronic liver disease due to taurine deficiency, which may involve mitochondrial dysfunction ulat et al., 2006). sion of SLC6A6 is sed by the p53 tumour suppressor gene and is transactivated by proto-oncogenes such as WTl, c-Jun, and c-Myb. Over-expression of SLC6A6 protects renal cells from cisplatin-induced nephrotoxicity (Han et al., 2006; Han and Chesney, 2009). SLC6A6 mRNA expression was upregulated by tumor necrosis factor alpha (TNF-alpha) in human intestinal epithelial Caco-2 cells (Mochizuki et al., 2005).

Ubiquinol—cytochrome c ase binding protein (UQCRB) The protein encoded by the UQCRB-gene is part of the ubiquinol—cytochrome c oxidoreductase complex. It binds ubiquinone and participates in the transfer of electrons. ons in this gene are associated with mitochondrial complex III deficiency. A pseudogene has been described on the X chromosome.

The UQCRB-gene may be a potential oncogen or a tumour suppressor gene in pancreatic ductal arcinoma (Harada et al. 13-24). It was found to be overexpressed in hepatocellular carcinoma (Jia et al. 1133-39) Human Epidermal growth factor Receptor 3 ) ERBB3 encodes a member of the epidermal growth factor receptor (EGFR) family of receptor ne kinases. It is activated by neuregulins, by other ERBB and nonERBB receptors as well as by other kinases, and by novel mechanisms. ream it interacts prominently with the phosphoinositol 3-kinase/AKT survival/mitogenic pathway, but also with GRB, SHC, SRC, ABL, rasGAP, SYK and the transcription regulator EBPl (Sithanandam and Anderson 413-48). ERBB3 overexpression has been found in many cancers including gastric cancer, where it may play a key causative role and negatively _ 35 _ impacts prognosis (Kobayashi et al. 1294-301) (Slesak et al. 2727-32). (Zhang et al. 2112- 18) found that over-expression of ERBB3 was more frequent in the diffuse type (26.2%) of gastric cancer than in the intestinal type . In both types, overexpression was associated with poor sis. Approaches for targeting of ERBB3 in cancer therapy include RNA aptamers to the extracellular domain (Chen et al. 9226-31), blockade of its gene sion by synthetic transcription factors (Lund et al. 9082-91), small-molecule inhibitors like the Vitamin E isomer y-tocotrienol (Samant and Sylvester 563-74), miRNA (Scott et al. 1479-86) and siRNA (Sithanandam et al. 9).

Prominin 1 (Proml) Function: Prominin-1, also called CD133, was identified as a molecule specific for CD34+ poetic progenitor cells (Yin et al., 1997) and shown to be a marker for normal stem cells and cancer stem cells (CSCs) of various tissues. It is located mainly in plasma membrane protrusions, and might be involved in the organization of membrane topology or in maintaining the lipid composition of the plasma membrane. It was suggested that a splice isoform of prominin-l called AC133-2 and lacking a small exon of 27 amino acids may represent an even better stem cell marker k et al., 2008; Bidlingmaier et al., 2008).

Only a small tage of tumor cells is usually positive for prominin-1, as expected for a CSC marker. ing on the tumor type, the number of ve cells per tumor mass reaches from 1 to 15 % and is mostly around 2 %.

Prominin-1 has been ated with tumor formation, angiogenesis and chemoresistance (Zhu et al., 2009a) (Bruno et al., 2006; Hilbe et al., 2004) (Bertolini et al., 2009). However, prominin-l positive cells might be accessible by the immune system, as they can be killed by NK cells (Castriconi et al., 2007; Pietra et al., 2009) and cytotoxic T cells (Brown et al., 2009).

While for many cancer entities it has been shown that prominin-1 positive cells are fianctionally CSCs, and expression was frequently associated with poor prognosis, there are still controversies. Some reports state that it is neither necessary nor sufficient for identifying CSCs (Cheng et al., 2009; Wu and Wu, 2009). Possibly a combination of prominin-l with other molecules such as CD44, or even multiple combinations such as prom1(+), ), CD44(+), CD38(-), CD24(-) serve as better CSC markers (Zhu et al., 2009b; Fulda and Pervaiz, 2010) _ 36 _ In dlffilSG GC, PROMl expression was suggested based on an in silico analysis (Katoh and Katoh, 2007) and overexpression in GC compared to normal stomach tissue at the n level was reported by (Smith et al., 2008). However, (Boegl and Prinz, 2009) reported that prominin-l expression was reduced in GC, especially in later stages, and claimed that prominin-l expression rather correlates with angiogenesis — which is also reduced in later stages — than with tumor growth. A study using GC cell lines (Takaishi et al., 2009) claims that CD44, but not prominin-l is a CSC marker in GC.

Matrix oproteinase ll (MMPl 1) Like other MMPs, MMPll is an endopeptidase with functions in processes requiring tissue remodeling, such as development, wound healing and scar formation. It might also negatively regulate fat homeostasis by ng adipocyte differentiation. In contrast to other MMPs, it is not able to cleave typical extracellular matrix molecules — except collagen VI. r, other substrates have been identified such as alpha 2-macroglobulin, certain serine protease inhibitors (serpins) including alpha 1 anti-trypsin, insulin-like growth factor-binding protein-l and the laminin receptor. In cancer, MMPl l is mostly expressed in stromal cells surrounding tumor tissue. This has been shown for numerous tumor entities. It was stated that MMPll is overexpressed in the stroma of most ve human carcinomas, but rarely in sarcomas and other nonepithelial tumors. In most but not all cases, MMPll is expressed in stroma cells directly adjacent to the tumor, whereas the tumor cells themselves, normal tissues and stroma cells distant from the tumor are negative.

Higher levels of MMPll are ated with a malignant phenotype / higher invasiveness and bad prognosis. However, in papillary thyroid carcinomas, MMPll expression was ely linked to aggressive characteristics. MMPll was found in tumor tissue as well as in serum of gastric cancer patients, and sion correlated with asis (Yang et al.).

Moreover, (Deng et al. 274-81) showed that MMPll is highly expressed in tumor cell lines and y tumor of gastric cancer — in contrast to other cancer types not exclusively in the stroma — and that it s to enhance tumor cell proliferation.

Nuclear transcription factor Y subunit beta (NFYB) NFYB, also called CBF-B or CBF-A is, besides NFYA and NFYC, a part of the trimeric basal transcription factor NF-Y (also CCAAT-binding factor or CBF) that binds to CCAAT motifs — or the reverse motifs, ATTGG, called Y-box — in the promoters _ 37 _ and enhancers of numerous genes. Among the NF-Y target genes are MHC class 11 genes, the PDGF beta-receptor, several heat shock proteins, the mismatch repair gene hMLHl, and topoisomerase II alpha.

NFYB is not a classical oncogene, however its on might contribute to tumorigenesis.

First, many cell-cycle genes such as cyclin A, cyclin B1, Aurora A and cdkl are targets of NF-Y. Cells are arrested at G2 / M phase without functional NFYB. (Park et al.) show that upregulation of cyclin B2 and other cell-cycle related genes in colorectal adenocarcinoma are due to NF-Y activity. Second, NF-Y ty counteracts apoptosis. Cells g NF-Y undergo apoptosis due to p53 activation and reduced transcription of anti-apoptotic genes containing CCAAT-boxes in their promoters, such as Bcl-2 (Benatti et al. 1415-28). Third, its tumorigenic properties are enhanced in combination with other transcription factors. For example, mutated p53 binds to NF-Y and p300 ns, increasing the expression ofNF- Y-induced cell cycle genes.

ABLl The protein tyrosine kinase c-Abl shuttles n the nuclear and cytoplasmic compartments. Nuclear c-Abl is involved in cell growth inhibition and apoptosis, while asmic c-Abl may play a role in actin dynamics, morphogenesis and signaling induced by extracellular stimuli like growth factors and integrin s. Cytoplasmic c-Abl was reported to promote mitogenesis. ty of c-Abl n is negatively regulated by its SH3 domain, and deletion of the SH3 domain turns ABLl into an oncogene. In chronic myeloic leukemia (CML), the gene is activated by translocation within the BCR (breakpoint cluster region) gene on chromosome 22. This resulting fusion protein BCR-ABL s to the cytosol and allows the cells to proliferate without being regulated by cytokines (Zhao et al.). c-Abl activity is also upregulated in solid , as it was shown for breast carcinomas and NSCLC.

Overexpression is not sufficient and constitutive kinase activity required protein phosphorylation. In breast cancer cells, c-Abl phosphorylation is induced by plasma membrane tyrosine kinases, including SFK, EGFR family members and the IGF-l receptor.

ABL fusion proteins have not been detected in solid tumors (Lin and Arlinghaus, 2008).

ABL was shown to be espressed in gastric carcinoma and ated microvessels, suggesting a possible role in angiogenesis. Notably, ri cytotoxin—associated gene A (CagA) leads to activation of c-Abl, which, consequently phosphorylates EGFR and, thus, _ 38 _ blocks EGFR endocytosis (Bauer, Bartfeld, and Meyer ). Several tyrosine kinase inhibitors are more or less c for Abl. Imatinib (Gleevec) is used as a first line therapy for CML and has also been approved for patients with advanced intestinal stromal tumors (GIST), as it also targets KIT (Pytel et al. 66-76) (Croom and Perry, 2003). Other tors used for cancer therapy are Dasatinib and Nilotinib (Pytel et al. 66-76) (Deremer, Ustun, and Natarajan 1956-75).

Polo-like kinase 4 (Plk4) Polo kinase family members (Plkl-4) are important during cell division, regulating several steps during mitosis. Plk4 is an organizer of centriole formation and duplication (Rodrigues-Martins et al. 1046-50). While Plkl is a clear oncogene, Plk4’s function in cancer is ambiguous. gulation as well as pression of Plk4 has been associated with cancer in humans, mice and flies (Cunha-Ferreira et al. 43-49). For instance, in colorectal cancer, Plk4 was found overexpressed, but a small group of patients showed strong Plk4 downregulation (Macmillan et al. 729-40). This can be explained by the fact that both pression and deficiency of Plk4 lead to aberrant centriole formation, resulting in abnormal centrosome numbers and structures that are frequently detected in tumor cells and contribute to c aberrations that cause chromosome missegregation and aneuploidy (Peel et al. 834-43). (Kuriyama et al. 2014-23).

(Korzeniewski et al. 6668-75).

IQ motif containing GTPase activating protein 3 (IQGAP3) IQGAPs participate in cellular signaling pathways as well as cytoskeletal architecture and cell adhesion. They possess a domain with sequence similarity to RasGAPs and, correspondingly, bind to small GTPases. However (and despite their name), none of them has GTPase-activating activity. For IQGAPl and IQGAP2 it has been shown that they even stabilize the GTP-bound state of Racl and Cdc42, and IQGAP3 was suggested to ize activated Ras (Nojima et al. 97l-78;White, Brown, and Sacks 1817-24). Via their IQ- domain they bind to calcium/calmodulin, and via a calponin homology domain to actin filaments (White, Brown, and Sacks 1817-24). (Wang et al. 567-77) report that IQGAP3 is expressed in brain, where it ates wit actin nts as well as Racl and Cdc42. It accumulates at the distal region of axons and promotes Racl/Ccd42-dependent axon _ 39 _ outgrowth. The IQGAPs have been ated in cancer. IQGAPl is ered to be an oncogene. It enhances several cancer-related pathways like MAP kinase, beta-catenin and ediated signaling and is overexpressed in many tumors.IQGAP2 rather seems to function as tumor suppressor and was found reduced in gastric cancers with poor prognosis (White, Brown, and Sacks 1817-24). Little information is available about IQGAP3.

(Skawran et al. 505-16) found it to be among the genes significantly upregulated in hepatocellular carcinoma. Two studies report that IQGAP3 is specifically expressed in proliferating (Ki67+) cells in mouse small intestine, colon and liver (Nojima et al. 971-78) (Kunimoto et al. 62 l -3 l).

Coiled-coil domain containing 88a (CCDC88A) CCDC88A is an actin-binding Akt substrate that plays a role in actin organization and Akt- dependent cell motility in fibroblasts. The CCDC88A/Akt pathway is also essential in ediated postneonatal enesis.

CCDC88A is also highly expressed in a variety of human malignant tissues, including breast, colon, lung, and uterine al carcinomas. It plays an important role in tumor progression with aberrant activation of the Akt signaling pathway.

Cyclin Bl (CCNBl) CCNBl is induced during G2/M phase of mitosis and forms the mitosis-promoting factor (MPF) together with -dependent kinase 1 (Cdkl)/Cdc2. Overexpression is found in a y of cancers and is often associated with poor prognosis, e.g. in breast cancer (Aaltonen et al., 2009; Agarwal et al., 2009; Suzuki et al., 2007), medulloblastoma (de et al., 2008), NSCLC (Cooper et al., 2009), cervical cancer (Zhao et al., 2006), and others. It was one ofthe genes included in an ll-gene signature that was found to predict short interval to e recurrence in patients with 12 distinct types of cancer (Glinsky, 2006).

No specific information on gastric cancer was found.

Cyclin D2 (CCND2) CCND2 binds and activates, like other D-type cyclins (D1 and D3), -dependent kinase 4 (Cdk4) or Cdk6. This is required for Gl/S tion. CCND2 was found to be overexpressed in many tumors, including testicular and ovarian tumors (Sicinski et al., 1996), hematological malignancies (Hoglund et al., 1996; Gesk et al., 2006), and gastric _ 40 _ cancer, where it may be caused by H.pylori infection, and associated with poor prognosis (Yu et al., 2003). (Yu et al., 2001) (Oshimo et al., 2003) (Takano et al., 1999) o et al., 2000).

Cyclin E2 (CCNE2) CCNE2 binds and tes, like the other E-type cyclin CCNEl, Cdk2. This activity peaks at Gl/S phase transition. Under healthy conditions, CCNE2 is not detectable in quiescent cells and can only be found in actively dividing tissues (Payton and Coats, 2002). It is often aberrantly expressed in cancer, e.g. in breast cancer, ated to bad prognosis (Desmedt et al., 2006; Ghayad et al., 2009; Payton et al., 2002; Sieuwerts et al., 2006), and in atic prostate cancer (Wu et al., 2009).

Carcinoembryogenic antigen-related cell on molecules 1, 5 and 6 (CEACAM l, 5, and 6) CEACAMs are membrane-anchored roteins that mediate cell-cell interactions and activate integrin signaling pathways (Chan and Stanners, 2007). They may also serve as receptors for pathogens such as E.coli (Berger et al., 2004) (Hauck et al., 2006) and be involved in immune regulation (Shao et al., 2006).

CEACAMS and CEACAM6 have pro-cancerogenic fianctions. They inhibit anoikis (Ordonez et al., 2000), promote metastasis (Marshall, 2003; Ordonez et al., 2000), and disrupt cell polarization and tissue architecture (Chan and Stanners, 2007). The role of CEACAMl in cancer is ambiguous. It may be a tumor suppressor in early , and contribute to metastasis formation, tumor immune escape and angiogenesis in later phases (Hokari et al., 2007; Liu et al., 2007; Moh and Shen, 2009). Its functional role depends on the isoform, as l occurs in ll splice variants, whose ratio determines the signaling outcome (Gray-Owen and rg, 2006; Leung et al., 2006; Neumaier et al., 1993; Nittka et al., 2008). The ratio of the splice variants may be altered in cancer (Gaur et al., 2008).

CEACAMS or CEACAM6 or both are overexpressed in as many as 70% of all human tumors, often associated with poor prognosis (Chan and Stanners, 2007; sky, 1991).

Serum CEACAMS is an established clinical marker for colon and rectal carcinoma, high levels indicating poor sis or recurrence (Chevinsky, 1991; Goldstein and Mitchell, 2005). It was also suggested as a marker for other entities including gastric cancer, however _ 41 _ with limited prognostic power (Victorzon et al., 1995). CEACAMl can be up- or gulated in cancer, depending on the entitiy (Kinugasa et al., 1998) (Dango et al., 2008) (Simeone et al., 2007). (Han et al., 2008) found abundant levels of S and CEACAM6 in nine gastric cancer cell lines, while CEACAMl was undetectable. By contrast, an analysis of primary tumor samples from 222 patients showed either cytoplasmic or membranous staining for CEACAMl. The membrane-bound form was related to enhanced angiogenesis (Zhou et al., 2009). Also the study by (Kinugasa et al., 1998) showed an upregulation in gastric adenocarcinomas.

In some tumors, CEACAMl is gulated in tumor cells, which leads to upregulation of VEGF, and VEGF or hypoxic conditions may induce CEACAMl in the adjacent endothelium. Accordingly, a onal antibody against CEACAMl blocked VEGF- induced endothelial tube formation (Oliveira-Ferrer et al., 2004; Tilki et al., 2006; Ergun et al., 2000).

Especially CEACAMS has been tested as target for anti-cancer drugs, amongst others by vaccination ches. These studies showed that CEACAMS can be a target of cellular immune ons en et al., 2007; Marshall, 2003). An overview about CEACAMS T cell epitopes is provided in (Sarobe et al., 2004).

Chloride channel 3 (CLCN3) CLCN3 is a Cl- channel that may be volume-gated and contribute to the regulatory volume se (RVD) that occurs as on to an increase in cell volume in case of conditions like cell g or hypoosmosis (Lemonnier et al., 2004; Sardini et al., 2003). However, this point is controversially sed (Wang et al., 2004) and the volume-reducing channel activated during apoptosis is different from CLCN3 (Okada et al., 2006).

CLCN3 expression changes during cell cycle, peaking in S phase (Wang et al., 2004).

CLCN3 currents may be important in cancer-relevant processes in entities where CLCN3 is upregulated, such as glioma: Tumor cells need to handle proliferative volume increases, encounter hypoosmotic conditions, e. g. in peritumoral edema (Ernest et al., 2005; Olsen et al., 2003; Sontheimer, 2008).

Moreover, it was reported that CLCN3 enhances etoposide resistance by increasing ication of the late endocytic compartment (Weylandt et al., 2007). siRNA-mediated knockdown of CLCN3 reduced the migration of nasopharyngeal carcinoma cells in vitro (Mao et al., 2008). _ 42 _ DNAJClO 0 is a member of a supramolecular ER—associated degradation (ERAD) complex that recognizes and unfolds misfolded proteins for their efficient retrotranslocation (Ushioda et al., 2008). The protein was shown to be elevated in hepatocellular carcinoma (Cunnea et al., 2007). Knockdown of DNA]C10 by siRNA in neuroectodermal tumour cells increased the apoptotic response to the chemotherapeutic drug fenretinide (Corazzari et al., 2007). It was shown that ERdjS decreases lastoma cell al by down- regulating the ed protein se (UPR) (Thomas and Spyrou, 2009).

Eukaryotic translation initiation factor 2, subunit 3 gamma (EIF2S3) EIF2S3 is the largest subunit of a protein complex (EIF2) ting the initial methionyl- tRNA to the 40S ribosomal subunit (Clemens, 1997). The action of kinases that downregulate EIF ty, such as RNA-dependent protein kinase (PKR), may be proapoptotic and tumor-suppressing (Mounir et al., 2009). In gastric cancer, higher levels of phosphorylated and unphosphorylated EIF2 were ed, and a redistribution to the nucleus was observed. This deregulation points towards an implication of eIF2alpha in gastrointestinal cancer (Lobo et al., 2000). otic translation initiation factor 3 subunit L (EIF3L) EIF3L is one of 10-13 subunits of EIF3, which is associated with the small ribosomal subunit. EIF3 plays a role in prevention of ure binding ofthe large ribosomal subunit. EIF3L is among the five subunits that have been reported to not be essential for EIF3 formation (Masutani et al., 2007). A screen with an antisense-library suggested that downregulating EIF3L enhances the anti-tumorigenic activity of 5-fluorouracil in hepatocellular carcinoma cells (Doh, 2008).

Epiplakinl (EPPKl) EPPKl is a plakin family gene with largely unknown functions. The plakin genes are known to on in interconnecting cytoskeletal filaments and anchoring them at plasma membrane-associated ve junction (Yoshida et al., 2008).

G-protein coupled receptor 39 (GPR39) _ 43 _ GPR39 is a Gq protein-coupled receptor that is thought to be involved in gastrointestinal and metabolic function (Yamamoto et al., 2009). Its signalling activates cAMP and serum response elements (Holst et al., 2004). The endogenous ligand for GPR39 is probably zinc (Chen and Zhao, 2007). GPR39 is a novel inhibitor of cell death, which might represent a therapeutic target with implications for processes involving apoptosis and endoplasmic reticulum stress like cancer (Dittmer et al., 2008). GPR39 was found to be up-regulated in rrays of both human fetal kidney HFK and blastema-enriched stem-like wilms' tumor xenografts (Metsuyanim et al., 2009), and in a hippocampal cell line resistant against diverse stimulators of cell death (Dittmer et al., 2008).

ERBB2/HER2/NEU ERBB2 is a member of the EGFR family of receptor ne kinases. Its ligand is not known, but it is the preferred heterodimerization r for other members of the HER family (Olayioye, 2001). In carcinomas, HER2 acts as an oncogene, mainly because high- level amplification of the gene induces protein overexpression in the cellular membrane and subsequent acquisition of advantageous properties for a malignant cell (Slamon et al., 1989). Over-expression is observed in a certain percentage of many cancers, including gastric . Mostly, it is ated with bad prognosis (Song et al., 2010) ura et al., 1991) (Uchino et al., 1993) ani et al., 1993).

ERBB2 is the target of the monoclonal antibody zumab (marketed as Herceptin), which has been suggested as treatment option for patients with HER2-positive advanced gastric cancer, in combination with herapy Junco et al., 2009; Van Cutsem et al., 2009). Another monoclonal antibody, Pertuzumab, which inhibits zation of HER2 and HER3 receptors, is in advanced clinical trials (Kristjansdottir and Dizon, 2010).

The selective overeXpression of HER2 and HER3 in the two histologic types of gastric cancer (intestinal type and diffuse type) is strongly associated with a poor prognosis (Zhang et al., 2009).

Beta-4 Integrin (ITGB4) Integrins mediate cell on as well as outside-in and inside-out signal transduction. The integrin beta-4 t heterodimerizes with the alpha-6 subunit. The resulting integrin promotes the formation of hemidesmosomes between the intracellular keratin cytoskeleton and the basement membrane (Giancotti, 2007). Integrin beta-4 has a dual fianction in _ 44 _ cancer, as it can mediate stable adhesion on the one hand, and pro-invasive signalling (including Ras/Erk and PI3K signalling) and angiogenesis on the other hand otti, 2007; Raymond et al., 2007). It is overexpressed in many tumors as well as in enic endothelial cells, often correlating with progression and asis. High levels have been in gastric cancer, particularly in stroma-invading cells (Giancotti, 2007; Tani et al., 1996).

However, it was downregulated in undifferentiated-type gastric carcinoma as the tumor invaded deeper, possibly du to the gradual epithelial-mesenchymal transition, as beta-4 integrin is an epithelial integrin (Yanchenko et al., 2009).

Lipocalin (LCN2) LCN2 or neutrophil gelatinase-associated lipocalin (NGAL) is an iron regulatory protein that exists as a r, homodimer, or as a disulfide-linked heterodimer with MMP9 (Coles et al., 1999; en et al., 1993). Expression is increased in several cancers, in some cases associated with progression. Mechanistically, it may stabilize MMP9 and alter E-cadherin-mediated cell-cell adhesion, thereby increasing invasion. Complexes of MMP-9 and LCN2 were d with worse survival in gastric cancer (Kubben et al., 2007) (Hu et al., 2009). Although a clear pro-tumoral effect has been observed in various tumors in humans, some studies have demonstrated that LCN2 can inhibit the pro-neoplastic factor HIF-lalpha, FA-Kinase phosphorylation and also VEGF synthesis, thus suggesting that, in alternative conditions, LCN2 also, paradoxically, has an anti-tumoral and anti-metastatic effect in neoplasias of, for example, the colon, ovary and pancreas. nano et al., 2009; Tong et al., 2008). LCN2 may be useful for inhibiting tumor angiogenesis, in addition to suppressing tumor metastasis, in cancers which show ras activation (Venkatesha et al., 2006) Succinate dehydrogenase complex, subunit C (SDHC) SDHC is one of four nuclear-encoded subunits of succinate dehydrogenase hondrial x 11), which transfers electrons from succinate to none, yielding filmarate and nol. Succinate dehydrogenase deficiency may cause GISTs (McWhinney et al., 2007). Familial gastrointestinal l tumors may be caused by mutations in the subunit genes SDHB, SDHC, and SDHD, and abdominal paragangliomas associated with gastrointestinal tumors may be caused uniquely by SDHC mutations (Pasini et al., 2008).

Mutant SDHC protein in transgenic mice generates ive stress and can contribute to _ 45 _ r DNA damage, mutagenesis, and ultimately, tumorigenesis (Ishii et al., 2005). ate dehydrogenase is considered a tumor suppressor (Baysal, 2003; Gottlieb and Tomlinson, 2005). Decreased levels of this enzyme complex may result in tumorigenesis (Eng et al., 2003). nding kinase (PBK) PBK is a MEK3/6-related MAPKK which activates p38 MAP kinase, e.g. downstream of growth factor receptors (Abe et al., 2000; Ayllon and O'connor, 2007). JNK may be a secondary target (Oh et al., 2007). As in adults PBK is sed in testis (see below), a function in spermatogenesis has been ed (Abe et al., 2000; Zhao et al., 2001). Apart from that, it contributes to proliferation and apoptosis resistance in tumor cells: It is phosphorylated and activated during mitosis, which is necessary for spindle ion and nesis (Gaudet et al., 2000; Matsumoto et al., 2004; Park et al., 2009) (Abe et al., 2007). Other -promoting and anti-apoptotic fianctions include downregulation of p53 and histone phosphorylation (Park et al., 2006; Zykova et al., 2006) (Nandi et al., 2007).

PBK has been classified as cancer-testis antigen (Abe et al., 2000; Park et al., 2006) and was found to be overexpressed in many cancers.

Polymerase (DNA-directed), delta 3, accessory subunit ) The DNA polymerase delta complex is involved in DNA replication and repair. It consists of the proliferating cell nuclear antigen (PCNA), the multisubunit replication factor C, and the 4 subunit polymerase complex: POLDl, POLD2, POLD3, and POLD4 (Liu and Warbrick, 2006). POLD3 plays a l role in the efficient recycling of PCNA during dissociation-association cycles of pol delta during elongation phase of DNA replication (Masuda et al., 2007).

Proteasome (Prosome, macropain) 26S subunit, non-ATPase, l4 (PSMDl4) PSMD14 is a component of the 26S proteasome. It belongs to the 198 complex (198 cap; PA700), which is responsible for substrate deubiquitination during proteasomal degradation (Spataro et al., 1997). PSMD14 overexpression in ian cells affects cell proliferation and the response to cytotoxic drugs like vinblastine, cisplatin and doxorubicin (Spataro et al., 2002). siRNA suppression of PSMD14 in HeLa cells resulted in a reduction in cell viability and an increase in polyubiquitinated protein levels (Gallery et al., 2007). _ 46 _ Down-regulation of PSMDl4 by siRNA had a considerable impact on cell viability causing cell arrest in the G0-Gl phase, ultimately leading to senescence (Byrne et al., 2010).

Proteasome (Prosome, macropain) 26S subunit, ATPase, 2 (PSMC2) PSMC2 is part of the 26S proteasome system. It is a member ofthe triple-A family of ATPases, which have a chaperone-like activity. This subunit has been shown to interact with l of the basal transcription factors so, in addition to participation in proteasome functions, this subunit may participate in the regulation of transcription. It was shown that the 26S proteasome system in skeletal muscle can be activated by TNF-alpha (Tan et al., 2006). In HBX transgenic mice, which bear the Hepatitis B regulatory gene HBX in their germline, and develop HCC, PSMC2 and other some subunits are up-regulated in tumor tissues (Cui et al., 2006). The mRNA levels for the ATPase subunit PSMC2 of the 198 complex increased in cancer cachexia (Combaret et al., 1999). n ne kinase 2 (PTK2) PTK2 is a non-receptor tyrosine kinase which modulates integrin signalling and may e tumor growth, progression and metastastis ((Giaginis et al., 2009); (Hauck et al., 2002); (Zhao and Guan, 2009)). PTK2 was suggested to be a marker for carcinogenesis and the progression of cancer (Su et al., 2002; Theocharis et al., 2009; Jan et al., 2009)..Overexpression and/or increased activity occurs in a wide variety of human cancers including gastric cancer. PTK2 also transduces signals ream of the gastrin receptor, which contributes to eration of gastric cancer cells (Li et al., 2008b). 8% of gastric carcinomas have been shown to carry the n-Barr virus (EBV). EBV-infected human gastric cancer cell line sublines presented increased PTK2 phosphorylation (Kassis et al., 2002). The level of PTK2 tyrosine phosphorylation in gastric epithelial cells is reduced by the cagA-positive Helicobacter pylori product.

Tetraspanin l (TSPAN l) and tetraspanin 8 (TSPAN8) TSPANl and TSPAN8 belong to the family of tetraspanins which are characterized by four transmembrane-domains and an intracellular N— and C-terminus and which have roles in a variety of ses including cellular adhesion, motility, activation and tumor invasion.

They often form large molecular xes with other proteins such as integrins at the cell surface (Tarrant et al., 2003; Serru et al., 2000). The fianctions ofTSPAN l are yet unknown _ 47 _ and may include a role in secretion (Scholz et al., 2009). TSPANl is overexpressed in several cancers, often ating with stage, progression and worse clinical outcome. y, it was reported to be overexpressed in 56.98% of 86 cases of gastric carcinoma, and overexpression correlated positively with clinical stage, infiltration and lymph node status and negatively with survival rates and differentiation grade of the tumor (Chen et al., 2008). TSPAN8 has been reported as a metastasis-associated gene in many types of tumors (PMID: 16467180). In gastrointestinal cancer, TSPAN8 expression is associated with poor prognosis (PMID: 16849554).

Zinc finger protein 598 (ZNF598) ZNF598 is a zinc finger protein with yet unknown fianction.

A disintegrin and metalloproteinase 10 (ADAM10) ADAM10 plays a role in angiogenesis, development and tumorigenesis. It is overexpressed in gastric carcinoma. ive ADAM inhibitors against ADAM-10 are undergoing al trials for the treatment of . (PMID: 19408347) Matrix metalloproteinase 12 (MMP12) MMP12 is a zinc endopeptidase which degrades elastin and many other matrix- and non- -proteins and is involved in macrophage migration and inhibition of angiogenesis (Chakraborti et al., 2003; Chandler et al., 1996; Sang, 1998). It also plays a role in pathological processes oftissue destruction like asthma, emphysema and chronic obstructive pulmonary disease , rheumatoid arthritis and tumor growth (Cataldo et al., 2003; Wallace et al., 2008). MMP12 inhibitors are discussed as agents for treatment of these conditions (Churg et al., 2007; Norman, 2009). MMP12 is frequently over-expressed in cancer, where it may have ous functions. While it may be involved in matrix dissolution and, thus, metastasis, it can also inhibit tumor growth through production of angiostatin, which negatively impacts angiogenesis. Enhanced MMP12 expression was ed for GC, and shown to be favorable: It negatively correlated with essel density, VEGF, tumor differentiation grade, vascular invasion, lymph node asis and recurrence. Patients with MMP12 xpression demonstrated a significantly better survival rate (Cheng et al., 2010; Zhang et al., 2007b; Zhang et al., 2007a) W0 2011/113819 _ 48 _ Ribonucleotide reductase M2 (RRM2) RRM2 is one of two subunits of ribonucleotide reductase, which generates ibonucleotides from ribonucleotides. Overexpression of RRM2 has been observed in tumors including c cancer and enhances the metastatic potential (PMID: 18941749) (PMID: 19250552) siRNA knockdown of RRM2 slowed tumor growth in various species (mouse, rat, monkey) (PMID: 17929316; PMID: 17404105).

Transmembrane protease, serine 4 (TMPRSS4) TMPRSS4 is a type II transmembrane serine se found at the cell surface that is highly expressed in several cancer tissues, including pancreatic, colon and gastric cancer. The ical functions of TMPRSS4 in cancer are not yet known. TMPRSS4 has four splice variants (Scott et al., 2001; Sawasaki et al., 2004). Expression in ovarian carcinoma ated with stage aki et al., 2004). TMPRSS4 is highly elevated in lung cancer tissues, and siRNA knockdown of TMPRSS4 by small interfering RNA treatment in lung and colon cancer cell lines was associated with reduction of cell invasion and cell-matrix on as well as modulation of cell proliferation (Jung et al., 2008).

Deiodinase, Iodothyronine, type II (D102) D102 converts the prohormone thyroxine (T4) to bioactive 3,3 ’,5-triiodothyronine (T3). It is highly expressed in the thyroid, and expression and/or activity were found deregulated in cancers of the thyroid (de Souza Meyer et al., 2005) (Amaldi et al., 2005). However, it was also found in other tissues, such as normal lung and lung cancer (Wawrzynska et al., 2003), and in brain tumors (Murakami et al., 2000).

Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) IGF2BP3 is primarily present in the nucleolus, where it binds IGF2 mRNA and represses its translation. It plays a role in embryogenesis and is gulated in adult tissues. In tumor cells it can be upregulated and is, thus, considered an oncofetal protein (Liao et al. 2005). In many cancers including gastric cancer it was found to be overexpressed, associated with poor prognosis (Jeng et al. Jiang et al. 2006). Peptides derived from 3 were tested in cancer vaccination studies (Kono et al. 2009).

Lamin B 1 (LMNB 1) _ 49 _ Lamin B1 is a protein of the nuclear lamina matrix and is involved in nuclear ity, tin structure and gene expression. In early stages of apoptosis, lamin is degraded (Neamati et al. 1995) (Sato et al. 2008b; Sato et al. 2008a; Sato et al. 2009). LMNBl is expressed to some extent in essentially all normal somatic cells, and inary studies indicate that it may be reduced during the pathogenesis of some cancers including gastric cancer (Moss et al. 1999). In other cancers, such as hepatocellular carcinoma, LMNBl was found upregulated and correlated positively with tumor stage, size and number of nodules(Lim et al. 2002).

Wingless-type MMTV integration site family, member 5A WNTSA is a secreted signaling protein implicated in developmental processes and oncogenesis. Canonical WNTSA signaling through Frizzled and LRPS/LRP6 receptors leads to nance of stem/progenitor cells, while non-canonical WNTSA signaling through Frizzled and ROR2/PTK/RYK receptors ls tissue polarity, cell adhesion or nt, e. g. at the tumor-stromal interface, leading to invasion (Katoh and Katoh, 2007). It may be a tumor suppressor in some s, but is upregulated in others including gastric cancer, where it contributes to progression and metastasis and leads to poor prognosis (Li et al., 2010) oto et al., 2009) (Kurayoshi et al., 2006).

Fibroblast activating protein, alpha (FAP) FAP is an integral membrane gelatinase. Its putative serine protease activity may play a role in the control of fibroblast growth or epithelial-mesenchymal interactions during development, tissue repair and epithelial carcinogenesis (Scanlan et al. 1994). FAP has a potential role in cancer growth, asis and angiogenesis through cell adhesion and migration processes, as well as rapid degradation of ECM components. It is present on tumor cells invading the ECM, in reactive -associated fibroblasts, and in endothelial cells involved in angiogenesis, but not in inactive cells of the same type. ig et al. 2005; Kennedy et al. 2009; Rettig et al. 1993; Rettig et al. 1994; Scanlan et al. 1994; Zhang et al. 2010). FAP expression has been found in gastric cancer cells and associated stromal fibroblasts (Zhi et al. 2010) (Chen et al. 2006)(Mori et al. 2004; Okada et al. 2003). In a mouse model, pressing cells where shown to be a nonredundant, immune- suppressive component of the tumor microenvironment (Kraman et al. 2010). In mouse models of tumor vaccination, FAP was successfully used as target for CD8+ and CD4+ T- _ 50 _ cell responses (Loeffler et al. 2006; Wen et al. 2010)(Lee et al. 2005) (Fassnacht et al. 2005).

Coatomer protein complex, subunit gamma (COPG); coatomer protein complex, subunit gamma 2 (COPG2); Coatomer protein complex, subunit beta 1 (COPBl) COPG, COPG2 and COPBl are subunits of the er complex, also called coat protein complex 1 (COPI) that is associated with non-clathrin coated vesicles. COPI-coated vesicles mediate retrograde transport from the Golgi back to the ER and intra-Golgi transport (Watson et al., 2004). They may also be involved in anterograde transport (Nickel et al., 1998). The retrograde trafficking tes, amongst others, pendent nuclear transport of EGFR, which binds to COPG (Wang et al., 2010). COPG was found to be pressed in lung cancer cells and lung cancer-assocated ascular endothelial cells (Park et al., 2008).

The sequence of the ubiquitously expressed COPG2 is 80% identical to GOPG (Blagitko et al., 1999). COPG2 can form a COP I-like complex in place of GOPG, which is probably onally redundant (Futatsumori et al., 2000).

Knockdown of COPBl in a cystic fibrosis transmembrane conductance regulator (CFTR) expressing cell line suggested that the er complex is involved in CRTR trafficking to the plasma membrane (Denning et al., 1992) (Bannykh et al., 2000).

Ubiquitin-conjugating enzyme E2S (UBE2S) UBE2S is an auxiliary factor of the anaphase-promoting complex (APC), an E3 ubuiqitin ligase that regulates mitotic exit and G1 by targeting cell cycle regulators. UBE2S elongates ubiquitin chains after the substrates are pre-ubiquitinated by other ents (Wu et al., 2010). UBE2S also targets the VHL protein for proteasomal degradation, thereby stabilizing HIF-lalpha (Lim et al., 2008), and possibly supporting proliferation, epithelial-mesenchymal transition, and metastasis (Chen et al., 2009) (Jung et al., 2006).

UBE2S is overexpressed in several cancer entities.

Kinesin family member 1 l (KIFl l) _ 51 _ KlFll is required for the assembly of a bipolar mitotic spindle. It has been found upregulated in several cancers, often correlating with clinicopathological ters (Liu et al., 2010) (Peyre et al., 2010). Small molecule inhibitors of KlFll like S-Trityl-L- cysteine (STLC), developed as potential ancer drugs, arrest cells in mitosis and promote apoptosis of cancer cells (Tsui et al., 2009) hire et al., 2010) (Ding et al., 2010). In the clinic, KlFll inhibitors have shown only modest activity (Kaan et al., 2010; Tunquist et al., 2010; Wiltshire et al., 2010; Zhang and Xu, 2008).

A disintegrin and metalloprotease domain 8 (ADAM8) ADAM8 was initially considered to be an immune-specific ADAM, but was found also in other cell types, often under conditions involving inflammation and ECM remodelling, including cancers and respiratory diseases like asthma (Koller et al. 2009). Many ADAM species, ing ADAM8, are sed in human malignant tumors, where they are involved in the regulation of growth factor activities and integrin functions, leading to promotion of cell growth and invasion, although the precise mechanisms of these are not clear at the present time (Mochizuki and Okada 2007). In mouse gastric tumors, ADAM8 and other ADAMs were increased, probably due to enhanced EGFR signaling (Oshima et al. 2011).

Cell division cycle 6 homolog evisiae) (CDC6) CDC6 is ial for the initiation of DNA ation. It localizes in the nucleus during G1, but ocates to the cytoplasm at the start of S phase. CDC6 also regulates replication-checkpoint activation through interaction wih ATR da et al. 2010). CDC6 deregulation may cause the inactivation of the lNK4/ARF locus encoding three important tumor suppressor genes: 4a and p151NK4b, both activators of the retinoblastoma pathway, and ARF, an activator of p53 (Gonzalez et al. 2006). siRNA knockdown of CDC6 could prevent proliferation and promote apoptosis (Lau et al. 2006). CDC6 is lated in cancers including gastric cancer (Nakamura et al. 2007) (Tsukamoto et al. 2008).

F2R coagulation factor II (thrombin) receptor (F2R) F2R, also called proteinase activated receptor (PARl) is a G-protein coupled receptor.

Signals by PARl, PAR2, and PAR4 can regulate calcium release or mitogen-activated protein kinase activation and lead to platelet aggregation, vascular relaxation, cell _ 52 _ proliferation, cytokine release, and inflammation (Oikonomopoulou et al. 2010). F2R is thought to be ed in endothelial and tumor cell proliferation and angiogenesis, and is overexpressed in invasive and metastatic tumors of many types. The expression levels directly correlate with the degree of invasiveness of the cancer (Garcia-Lopez et al. 2010) (Lurje et al. 2010). In gastric carcinoma cells, F2R activation can trigger an array of responses that promote tumor cell growth and invasion, e.g. overexpression ofNF-kappaB, EGFR, and Tenascin—C (TN-C) (Fujimoto et al. 2010). Accordingly, F2R expression in gastric cancer was found to be ated with the depth of wall on, peritoneal dissemination, and poor prognosis oto et al. 2008). A mouse monoclonal anti-human PARl antibody (ATAP-2), that recognizes an e (SFLLRNPN) within the N—terminus of the thrombin receptor, was described as well as the PARl agonist peptide TFLLRNPNDK (Hollenberg and Compton 2002; Mari et al. 1996; Xu et al. 1995) omedin 4 (OLFM4) OLFM4, whose fianction is largely unknown, is overexpressed in inflamed colonic lium and a number of human tumor types, especially those of the digestive system da et al., 2007). OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells (van der Flier et al., 2009). OLFM4 inhibits the apoptosis-promoting protein GRIM-19 (Zhang et al., 2004) (Huang et al., 2010), regulates cell cycle and promotes S phase transition in proliferation of cancer cells. In addition, OLFM4 is associated with cancer adhesion and metastasis (Yu et al., 2011b). Forced overexpression of OLFM4 in murine prostate tumor cells led to more rapid tumor formation in a syngeneic host (Zhang et al., 2004). OLFM4 was found to be overexpressed in GC (Aung et al., 2006). Inhibition of OLFM4 expression could induce apoptosis in the ce of cytotoxic agent in c cancer cells (Kim et al., 2010). Also serum OLFM4 concentration in presurgical GC patients was enhanced as compared to healthy donors (Oue et al., 2009). OLFM4 was identified as a novel target gene for retinoic acids (RAs) and the demethylation agent 5-aza-2'-deoxycytidine. These two agents have proven to be effective in ng certain myeloid leukemia patients (Liu et al., 2010).

Thy-1 cell surface antigen (THYl) Thy-1 (CD90) is a GPI-anchored glycoprotein found on many cell types including T cells, neurons, endothelial cells and fibroblasts. Thy-1 is involved in processes including _ 53 _ adhesion, nerve ration, tumor growth, tumor suppression, migration, cell death, and activation ofT cells. (Rege and Hagood 2006b; Rege and Hagood 2006a) (Jurisic et al. 2010). Thy-1 appears to be a marker of adult but not embryonic angiogenesis (Lee et al. 1998). Moreover, it was considered as a marker for s kind of stem cells (mesenchymal stem cells, hepatic stem cells ("oval cells") (Masson et al. 2006), keratinocyte stem cells (Nakamura et al. 2006) and hematopoietic stem cells (Yamazaki et al. 2009)). Thy-1 is upregulated in several cancers including gastric cancer and GISTs, for which it was proposed to be a marker (Yang and Chung 2008; Zhang et al. 2010) (Oikonomou et al. 2007).

Centrosomal protein 250 kDa 0) Cep250 plays a role in the cohesion of ubule-organizing s (Mayor et al., 2000). It is also named centrosomal Nek2-associated protein or C-Napl, as it lizes with and is a substrate of the serine/threonine kinase Nek2. Nek2 kinase and its substrates regulate the e between centrosomes (Bahmanyar et al., 2008). At the onset of mitosis, when centrosomes separate for bipolar spindle formation, C-Napl is phosphorylated and, subsequently, iates from centrosomes. In vitro experiments showed that overexpression of Cep250 impaired microtubule organization at the centrosome (Mayor et al., 2002).

Hypoxia ble factor 1, alpha subunit (basic loop-helix transcription factor) (HIFlA) HIFlA is the oxygen-sensitive subunit of the hypoxia-inducible factor (HIF), a transcription factor active under hypoxic conditions that are frequently found in tumors. It es transcription of over 60 genes involved in survival, glucose metabolism, invasion, metastasis and angiogenesis (e. g. VEGF). HIFl is overexpressed in many cancers, often associated with poor prognosis, and is considered an interesting target for pharmacological manipulation (Griffiths et al. 2005; Quintero et al. 2004; Stoeltzing et al. 2004) (Zhong et al. 1999).

In gastric cancer, HIFlA contributes to angiogenesis (Nam et al. 2011), correlates with tumor size, lower differentiation, tumor stage shorter survival (Qiu et al. 201 1) and metastasis (Wang et al. 2010) (Han et al. 2006; Kim et al. 2009; Oh et al. 2008; Ru et al. 2007). It is also thought to lead to resistance to chemotherapeutic drugs such as S-FU via _ 54 _ inhibition of drug-induced apoptosis and decrease of intracellular drug accumulation (Nakamura et al. 2009) (Liu et al. 2008). The HIF-lalpha-inhibitor 2-methoxy-estradiol significantly reduced metastatic properties of gastric cancer cells (Rohwer et al. 2009). as2 Kirsten rat sarcoma viral oncogene homolog (KRAS) KRAS is a member of the small GTPase superfamily and a protooncogene involved in early steps ofmany signal transduction ys, such as MAPK— and AKT-mediated pathways, that are ially oncogenic. Single amino acid substitutions lead to activating mutations, resulting in a transforming protein that plays a key role in various malignancies including gastric cancer la et al., 1991). Oncogenic mutations of KRAS are infrequent in c cancer. In a subset of gastric cancers, the KRAS locus was ed, resulting in pression of KRAS protein. Thus, gene amplification likely forms the molecular basis of overactivation of KRAS in gastric cancer (Mita et al., 2009). Mutant KRAS alleles contribute to hypoxia-driven VEGF induction (Kikuchi et al., 2009; Zeng et al., 2010).

Mutated KRAS can also be detected in serum or plasma of cancer patients and was, thus, suggested as an easily accessible tumor marker (Sorenson, 2000). The e KRAS-001 is derived from only one of two splice variants - 976 (188 amino acids) and not from the splice variant - NP_203524 (189 amino acids). The splice variants differ in their last exon, on which KRAS-001 is d.

Non-SMC condensinI complex, subunit G (NCAPG) NCAPG is part of the condensin 1 complex, which is composed of structural maintenance of chromosomes (SMC) and non-SMC proteins, and regulates chromosome condensation and segregation during mitosis (Seipold et al., 2009). NCAPG overexpression was found in us tumors including nasopharyngeal carcinoma (Li et al., 2010), hepatocellular carcinoma (Satow et al., 2010) and melanoma (Ryu et al., 2007). Among normal tissues, NCAPG showed highest expression in the testis. It was suggested to be a possible proliferation marker and a potential prognostic indicator in cancer (Jager et al., 2000).

Topoisomerase (DNA) 11 alpha (TOP2A) and topoisomerase (DNA) 11 beta (TOP2B) TOP2A and TOP2B encode highly homologous isoforms of a DNA topoisomerase, which controls and alters topologic states of DNA during transcription and is involved in chromosome condensation, chromatid separation, replication and transcription. _ 55 _ Topoisomerase is a target for several anticancer drugs, such as anthracyclins, and a variety of mutations have been associated with drug ance (Kellner et al., 2002) (Jarvinen and Liu, 2006). TOP2A (not TOP2B) is essential for cell proliferation. It is located adjacent to the HER2 oncogene and is ed in a great majority of HER2-amplified breast tumors, but also in such without HER2 amplification (Jarvinen and Liu, 2003), and in many other tumor entities. Also in a subset of gastric cancers, TOP2A was found amplified and overexpressed, frequently together with HER2 (Varis et al., 2002) (Liang et al., 2008).

Laminin, gamma 2 (LAMC2) Laminins are the major non-collagenous constituents of basement membranes. They are involved in cell on, differentiation, migration, ing, and metastasis. The gamma 2 chain er with alpha 3 and beta 3 chains constitute laminin 5. LAMC2 promotes invasive growth of human cancer cells in vivo. It is highly expressed by human cancers at the invasion front, and expression correlates with poor prognosis (Tsubota et al., 2010). A MMPgenerated cleavage product of laminin 5 is able to activate EGFR signaling and promote cell motility (Schenk et al., 2003). In gastric oma, LAMC2 may be induced by members of the EGFR family or by WntSa, and invasive ty was shown to depend on LAMC2 (Tsubota et al., 2010) (Yamamoto et al., 2009).

Aryl hydrocarbon receptor (AHR) AHR binds planar aromatic hydrocarbons such as TCDD (2,3,7,8-tetrachlorodibenzo-p- dioxin), and es transcription of genes including xenobiotic-metabolizing enzymes such as cytochrome P450 enzymes. It also plays a role in cell cycle ssion (Barhoover et al. 2010). AhR is thought to be partly associated with the tumor promoting activity of dioxin, as it has pro-proliferative and anti-apoptotic functions, and may lead to deregulation of cell-cell contact, erentiation and ed motility (Watabe et al. 2010) (Dietrich and Kaina 2010) (Marlowe et al. 2008). AHR expression can be down-regulated by TGF- beta (Dohr and Abel 1997; Wolff et al. 2001) and induced by Wnt or beta-catenin signaling (Chesire et al. 2004). AHR overexpression was found in many s including gastric cancer, where it correlated with the frequent CYP1A1 sion (Ma et al. 2006). AHR expression and nuclear translocation were higher in gastric cancer than in normal tissues, and expression increased gradually during cancerogenesis (Peng et al. 2009a). AhR pathway activation enhances gastric cancer cell invasiveness likely through a c-Jun— _ 56 _ dependent induction of MMP-9 (Peng et al. 2009b). In a mouse model, expression of a constitutively active mutant ofthe aryl hydrocarbon receptor (CA-AhR) results in development of stomach tumours, correlating with increased mortality (Andersson et al. 2002; Kuznetsov et al. 2005). The function of AhR in cancer s to be ambiguous, as some s also point towards a tumor-suppressing activity (Gluschnaider et al. 2010)(Fan et al. 2010).

Hyaluronan-mediated motility or (RHAMM) (HMMR) HMMR can occur on the cell surface where it binds hyaluronic acid (HA) and interacts with the HA or CD44. This interaction plays a role in processes like cell motility, wound healing and invasion (Gares and Pilarski, 2000). Intracellularly, HMMR associates with the cytoskeleton, microtubules, centrosomes and the c spindle and plays a role in control of mitotic spindle integrity. HMMR is overexpressed in several cancer s (Sohr and Engeland, 2008). HA was suggested to protect cancer cells against immune attack. Serum HA is often increased in metastatic ts (Delpech et al., 1997). HMMR was identified as promising tumor-associated antigen and possible prognostic factor in AML and CLL. Peptides derived from HMMR have been used in anti-leukemia vaccines. 01 was tested for in vitro immunogenicity as well, but not used for vaccination (Tzankov et al., 2011) (Greiner et al., 2010; Schmitt et al., 2008; Tabarkiewicz and Giannopoulos, 2010) (Greiner et al., 2005). HMMR overexpression was also found in several other cancers, often ated with bad prognosis. HMMR was also overexpressed in gastric cancer, often together with CD44, and was suggested to facilitate invasion and metastasis (Li et al., 1999) (Li et al., 2000a) (Li et al., 2000b).

TPX2, microtubule-associated, homolog (Xenopus laevis) (TPX2) TPRX2 is a proliferation-associated protein expressed in S-, G(2)- and M-phases of the cell cycle and regarded as a proliferation marker (Cordes et al., 2010).

It is required for normal microtubule tion, e. g. for assembly of mitotic es.

TPX2 recruits and activates Aurora A (Bird and Hyman, 2008; Moss et al., 2009). orylation of TPX2 with Polo-like kinase 1 increases its ability to activate Aurora A (Eckerdt et al., 2009). TPX2 is pressed in many tumor types and frequently co- overexpressed with Aurora-A (Asteriti et al., 2010). Examples where TPX2 overexpression was found (frequently associated with bad prognosis or later stage) are meningioma (Stuart _ 57 _ et al., 2010), lung cancer (Kadara et al., 2009) (Lin et al., 2006; Ma et al., 2006) (Manda et al., 1999) and hepatocellular carcinoma (Shigeishi et al., 2009b) (Satow et al., 2010) (Wang et al., 2003).

The present invention therefore relates to a peptide comprising a sequence that is selected from the group of SEQ ID NO: 1 to SEQ ID NO: 95 or a variant thereofwhich is at least 80% homolog to SEQ ID NO: 1 to SEQ ID NO: 95 or a variant thereof that induces T cells cross-reacting with said peptide, wherein said peptide is not a fiJll-length polypeptide.

The present invention r relates to a peptide comprising a sequence that is selected from the group of SEQ ID NO: 1 to SEQ ID NO: 95 or a variant fwhich is at least 80% homolog to SEQ ID No: 1 to SEQ ID No. 95, wherein said peptide or variant has an l length of between 8 and 100, preferably between 8 and 30, and most preferred between 8 and 14 amino acids.

The t ion further relates to the peptides previously described, having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or -II.

The t invention further s to the peptides previously described wherein the e consists or consists essentially of an amino acid sequence according to SEQ ID No. 1to SEQ ID No. 95.

The present invention further relates to the peptides previously described, wherein the peptide is modified and/or includes non-peptide bonds.

The present invention further relates to the peptides usly described, wherein the peptide is a fiasion protein, in particular sing N—terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii).

The present invention further relates to a nucleic acid, encoding the peptides previously described, provided, that the e is not the fill human protein. _ 58 _ The present invention further relates to the nucleic acid previously described which is DNA, cDNA, PNA, CNA, RNA or combinations thereof.

The present invention further relates to an expression vector e of expressing a nucleic acid previously described.

The present invention further s to a e as described before, a nucleic acid as described before or an expression vector as described before for use in medicine.

The present invention further relates to a host cell sing a nucleic acid as bed before or an expression vector as described before.

The present invention fiarther relates to the host cell described that is an antigen presenting cell.

The t ion further relates to the host cell described wherein the antigen ting cell is a dendritic cell.

The present invention further relates to a method of producing a peptide described, the method comprising culturing the host cell described and isolating the peptide from the host cell or its culture medium.

The present invention fiarther relates to an in vitro method for producing activated cytotoxic T cytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I or II MHC molecules expressed on the surface of a suitable antigen- presenting cell for a period of time sufficient to activate said CTL in an antigen ic manner, wherein said antigen is any peptide described.

The present invention further relates to the method as described, wherein the antigen is loaded onto class I or II MHC molecules expressed on the surface of a suitable antigen- presenting cell by ting a sufficient amount of the antigen with an antigen-presenting cell. _ 59 _ The present invention further relates to the method as described, wherein the antigen- presenting cell comprises an expression vector capable of expressing said peptide containing SEQ ID NO 1 to SEQ ID NO 33 or said variant amino acid sequence.

The present invention further relates to activated cytotoxic T lymphocytes (CTL), produced by the method described, which selectively recognise a cell which ntly expresses a polypeptide comprising an amino acid sequence described.

The present ion further relates to a method of killing target cells in a patient which target cells aberrantly express a polypeptide comprising any amino acid ce described, the method comprising administering to the patient an effective number of xic T lymphocytes (CTL) as defined.

The present invention further relates to the use of any peptide described, a nucleic acid as described, an expression vector as described, a cell as bed, or an ted cytotoxic T lymphocyte as described as a medicament or in the manufacture of a medicament.

The present invention further relates to a use as described, wherein the medicament is a vaccine.

The t invention further relates to a use as bed, wherein the medicament is active against cancer.

The present invention further relates to a use as described, wherein said cancer cells are gastric cancer cells, gastrointestinal, colorectal, pancreatic, lung or renal.

The present invention fiarther relates to particular marker proteins that can be used in the prognosis of gastric cancer.

Further, the present invention relates to the use of these novel s for cancer ent.

As provided herein, the proteins encoded by ABLl, ADAMlO, AHR, CCND2, CDC6, CDKI, CEACAMI, CEACAMS, CEACAM6, CEACAM6, COL6A3, EIFZS3, _ 60 _ LOC255308, EPHA2, ERBBZ, ERBB3, F2R, FAP, HMMR, HSP90Bl, IGFZBP3, ITGB4, KIFZC, KRAS, LAMCZ, LCN2, MET, MMPl 1, MMP12, MMP3, MSTlR, NUF2, OLFM4, PROMl, RRMZ, THYl, TMPRSS4, TOP2A and , TSPANl, WNTSA, HIFlA, PTK2 were described to be overexpressed in gastric cancer ed with normal gastric and other vital tissues (e. g. liver kidney, heart) in literature.

The proteins encoded by ABLl, ADAMlO, ADAM8, AHR, ASPM, ATAD2, CCDC88A, CCNBl, CCNDZ, CCNE2, CDC6, CDKl, CEACAMl, CEACAMS, CEACAM6, CEACAM6, CLCN3, COL6A3, EPHA2, ERBBZ, ERBB3, F2R, FAP, HIFlA, HMMR, HSP90Bl, IGF2BP3, IQGAP3, ITGB4, KIFl l, KIFZC, KRAS, LAMC2, LCN2, MET, MMPl l, MMP3, MSTlR, MUC6, NCAPG, NFYB, NUF2, OLFM4, PBK, PLK4, PPAP2C, PROMl, PTK2, RRMZ, SIAH2, THYl, TOP2A, TPX2, TSPANl, , UBE2S, UCHLS, and WNTSA were shown to have an important role in tumorgenesis as they are involved in ant transformation, cell growth, proliferation, angiogenesis or invasion into normal tissue. Also for the proteins encoded by DNAJClO, EIFZS3, EIF3L, POLD3, PSMC2, PSMDl4, and TMPRSS4, there is some ce for cancer-relevant fianctions.

The proteins encoded by PROMl, WNTSA, SMC4, PPAPZC, GPR3 8, OLFM4 and THYl have been shown to be highly expressed and/or functionally important in stem cells and/or cancer stem cells. PROMl has been discussed as marker for gastric cancer stem cells, although data are controversial. Cancer stem cells are a tumor cell subpopulation with selfrenewing potential required for sustained tumor . These cells reside in lized and highly organized structures, so called cancer stem cell niches that are required for the maintenance ofthe self-renewing potential of cancer stem cells.

Overexpression of the proteins AHR, ASPM, ATAD2, CCNBl, CCNDZ, CCNE2, CDKl (CDC2), CEACAMl, CEACAMS, CEACAM6, CEACAM6, , EPHA2, ERBBZ, ERBB3, F2R, FAP,HIF1A, HMMR,HSP9OB1, IGF2BP3, ITGB4, KIF11,KIF2C,KRAS, LAMC2, LCN2, LMNBl, MET, MMPl l, MMP3, MSTlR, MUC6, NCAPG, NUF2, OLFM4, PBK, PPAPZC, PROMl, PTK2, TMPRSS4, TPX2, TSPANl, and WNTSA in tumors has been shown to be associated with advanced e stages and poor prognosis for the patients. _ 61 _ Therefore, the present invention es s of identifying an animal, preferably a human, which is likely to have gastric cancer. In one embodiment the likelihood determined is between 80% to 100%. One such method comprises determining the level of at least one of the proteins MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB and MUC6 in a tumor sample from the animal subject. In one embodiment, the sample is obtained by radical y. In another embodiment, the sample is obtained by needle biopsy.

When the level of MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6 determined is 20 % or more up-regulated in cells relative to that determined in benign lial cells of the same specimen, the animal subject is identified as being likely to have gastric cancer.

The more different proteins of the group comprising MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB and MUC6 are ulated the higher the possibility of the animal subject is identified as being likely to have gastric cancer.

In one embodiment the determination of the level of MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6 is performed in situ. In another ment the determination of the level of MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6 is performed in vitro. In still another embodiment, the ination of the level of MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6 is performed in vivo. In a preferred embodiment, the determination of the level of MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6 is performed by Laser Capture Microscopy coupled with a Western blot.

In a particular embodiment, the determination of the level of MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6 is performed with an antibody specific for MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6. In another such ment the determination of the level of MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6 is performed by PCR with a primer specific for an mRNA encoding MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB or MUC6. In still 2011/053863 _ 62 _ another ment the determination of the level of MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB or MUC6 is performed with a nucleotide probe specific for an mRNA encoding MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB or MUC6. In one such embodiment, the determination of the level of MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6 is performed by a Northern blot. In another ment, the determination of the level of MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6 is performed by a ribonuclease protection assay. In other embodiments, immunological tests such as enzyme-linked immunosorbent assays (ELISA), radioimmunoassays (RIA), and Western blots may be used to detect MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB and MUC6 polypeptides in a body fluid sample (such as blood, serum, sputum, urine, or peritoneal fluid). Biopsies, tissue samples, and cell samples (such as ovaries, lymph nodes, n surface epithelial cell scrapings, lung biopsies, liver biopsies, and any fluid sample containing cells (such as peritoneal fluid, sputum, and pleural effusions) may be tested by disaggregating and/or solubilizing the tissue or cell sample and subjecting it to an assay for polypeptide detection, such as ELISA, RIA, or Western blotting. Such cell or tissue samples may also be ed by nucleic acid-based methods, e.g., reverse transcription-polymerase chain reaction (RT- PCR) amplification, Northern hybridization, or slot- or dot-blotting. To visualize the distribution of tumor cells within a tissue sample, diagnostic tests that preserve the tissue structure of a sample, e.g., immunohistological staining, in situ RNA hybridization, or in situ RT-PCR may be employed to detect gastric cancer marker polypeptide or mRNA, respectively. For in vivo localization of tumor masses, imaging tests such as ic resonance imaging (MRI) may be employed by introducing into the subject an antibody that specifically binds a MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6 ptide cularly a cell surface-localized polypeptide), wherein the antibody is conjugated or otherwise coupled to a paramagnetic tracer (or other appropriate detectable moiety, depending upon the imaging method used); alternatively, localization of an unlabeled tumor marker-specific antibody may be detected using a secondary dy coupled to a detectable moiety.

In addition, the present invention fiarther provides chimeric/fusion proteins/peptides comprising the MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6 _ 63 _ polypeptides, and fragments f, ing fianctional, proteolytic and antigenic fragments.

The filSlOIl partner or ns of a hybrid molecule suitably provide epitopes that stimulate CD4+ T-cells. CD4+ stimulating epitopes are well known in the art and include those identified in tetanus toxoid. In a further preferred embodiment the peptide is a fusion protein, in particular comprising N—terminal amino acids of the HLA-DR antigen- associated invariant chain (Ii). In one embodiment the peptide of the invention is a truncated human protein or a fusion protein of a protein fragment and r polypeptide portion provided that the human portion includes one or more inventive amino acid SGQUGIICGS. dies to the MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6 polypeptides, to the chimeric/fusion proteins comprising the MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6 polypeptides, as well as to the fragments of the MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6 polypeptides, including proteolytic, and antigenic fragments, and to the chimeric/fusion proteins/peptides comprising these fragments are also part of the present invention. In addition, s of using such antibodies for the prognosis of cancer, and c cancer in particular, are also part of the present invention.

The antibodies of the present invention can be polyclonal antibodies, monoclonal antibodies and/or chimeric antibodies. Immortal cell lines that produce a monoclonal antibody ofthe present invention are also part of the present invention.

One of ordinary skill in the art will understand that in some instances, higher expression of MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6 as a tumor marker gene will indicate a worse prognosis for a subject haVing gastric . For e, relatively higher levels MSTlR, UCHLS, SMC4, NFYB, , AVL9, UQCRB or MUC6 expression may indicate a relative large primary tumor, a higher tumor burden (e.g., more metastases), or a relatively more malignant tumor phenotype.

The more different proteins of the group comprising MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB and MUC6 are overexpressed the worse the prognosis is. _ 64 _ The diagnostic and prognostic methods of the invention involve using known methods, e.g., antibody-based methods to detect MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB and MUC6 polypeptides and nucleic acid hybridization- and/or amplificationbased methods to detect MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB, and MUC6 mRNA.

In addition, since rapid tumor cell ction often results in autoantibody generation, the gastric cancer tumor markers of the invention may be used in serological assays (e.g., an ELISA test of a subject's serum) to detect autoantibodies against MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6 in a subject. MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB, and MUC6 polypeptide-specific autoantibody levels that are at least about 3-fold higher (and preferably at least 5-fold or 7-fold higher, most preferably at least lO-fold or 20-fold higher) than in a control sample are indicative of gastric cancer.

Cell-surface localized, intracellular, and secreted MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB and MUC6 polypeptides may all be employed for analysis of biopsies, e.g., tissue or cell samples (including cells obtained from liquid samples such as peritoneal cavity fluid) to identify a tissue or cell biopsy as containing gastric cancer cells.

A biopsy may be analyzed as an intact tissue or as a cell sample, or the tissue or cell sample may be disaggregated and/or lized as necessary for the particular type of diagnostic test to be used. For example, es or s may be subjected to Whole- tissue or Whole-cell analysis of MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB and MUC6 ptide or mRNA levels in situ, e.g., using histochemistry, in situ mRNA hybridization, or in situ RT-PCR. The skilled artisan will know how to process s or cells for is of polypeptide or mRNA levels using immunological methods such as ELISA, immunoblotting, or equivalent methods, or analysis of mRNA levels by nucleic acid-based ical methods such as RT-PCR, Northern hybridization, or slot- or dot-blotting.

Kits for Measuring Expression Levels of MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB, and MUC6. _ 65 _ The present invention provides kits for detecting an increased expression level of MSTlR, UCHLS, SMC4, NFYB, , AVL9, UQCRB and MUC6 as a c cancer marker gene in a subject. A kit for detecting gastric cancer marker polypeptide preferably contains an dy that specifically binds a chosen c cancer marker polypeptide. A kit for detecting gastric cancer marker mRNA preferably contains one or more nucleic acids (e. g., one or more oligonucleotide primers or probes, DNA probes, RNA probes, or tes for generating RNA probes) that specifically hybridize with MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB, and MUC6 mRNA.

Particularly, the antibody-based kit can be used to detect the presence of, and/or measure the level of, a MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB and MUC6 ptide that is specifically bound by the antibody or an reactive fragment thereof The kit can e an dy reactive with the antigen and a reagent for detecting a reaction of the antibody with the antigen. Such a kit can be an ELISA kit and can contain a control (e.g., a specified amount of a particular c cancer marker polypeptide), primary and secondary antibodies when appropriate, and any other necessary reagents such as detectable moieties, enzyme substrates and color reagents as bed above. The diagnostic kit can, alternatively, be an immunoblot kit generally comprising the ents and reagents described herein.

A nucleic acid-based kit can be used to detect and/or measure the expression level of MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB and MUC6 by detecting and/or measuring the amount of MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB and MUC6 mRNA in a , such as a tissue or cell biopsy. For example, an RT-PCR kit for detection of ed expression of MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB and MUC6 preferably contains oligonucleotide primers sufficient to perform reverse transcription of gastric cancer marker mRNA to cDNA and PCR amplification of gastric cancer marker cDNA, and will preferably also contain control PCR template molecules and primers to perform appropriate negative and positive controls, and internal controls for quantization. One of ordinary skill in the art will understand how to select the appropriate primers to perform the reverse transcription and PCR reactions, and the appropriate control reactions to be performed. Such guidance is found, for example, in F. Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New _ 66 _ York, N.Y., 1997. Numerous variations ofRT-PCR are known in the art. Targeted Delivery of immunotoxins to MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB and MUC6 can be employed as therapeutic targets for the treatment or prevention of gastric cancer. For example, an dy le that specifically binds a cell surface-localized MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB and MUC6 polypeptide can be ated to a radioisotope or other toxic compound. Antibody conjugates are stered to the subject so that the binding of the antibody to its cognate gastric cancer polypeptide results in the targeted delivery of the therapeutic compound to gastric cancer cells, thereby treating an n cancer.

The therapeutic moiety can be a toxin, radioisotope, drug, al, or a protein (see, e.g., Bera et al. "Pharmacokinetics and antitumor actiVity of a bivalent disulfide-stabilized FV immunotoxin with improved n g to erbB2" Cancer Res. 59:4018-4022 (1999)).

For example, the antibody can be linked or conjugated to a bacterial toxin (e.g., ria toxin, pseudomonas exotoxin A, cholera toxin) or plant toxin (e. g., ricin toxin) for targeted delivery of the toxin to a cell expressing MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB and MUC6 This immunotoxin can be delivered to a cell and upon binding the cell surface-localized gastric cancer marker polypeptide, the toxin conjugated to the gastric cancer marker-specific antibody Will be delivered to the cell.

In addition, for any MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB and MUC6 polypeptide for Which there is a specific ligand (e.g., a ligand that binds a cell surface-localized protein), the ligand can be used in place of an antibody to target a toxic compound to a gastric cancer cell, as bed above.

The term "antibodies" is used herein in a broad sense and includes both polyclonal and monoclonal antibodies. In addition to intact immunoglobulin molecules, also ed in the term "antibodies" are fragments or polymers of those immunoglobulin les and humanized versions of immunoglobulin molecules, so long as they exhibit any of the desired properties (e.g., specific binding of an gastric cancer marker polypeptide, delivery of a toxin to an gastric cancer cell expressing an gastric cancer marker gene at an increased level, and/or inhibiting the actiVity of an gastric cancer marker polypeptide) described herein. _ 67 _ Whenever possible, the antibodies of the invention may be purchased from commercial s. The antibodies of the invention may also be generated using well-known methods.

The skilled artisan will understand that either full length gastric cancer marker ptides or fragments thereofmay be used to generate the antibodies of the invention. A polypeptide to be used for generating an antibody of the ion may be partially or fully purified from a natural source, or may be produced using recombinant DNA ques. For example, a cDNA encoding a MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB or MUC6 ptide, or a fragment thereof, can be expressed in prokaryotic cells (e.g., bacteria) or eukaryotic cells (e.g., yeast, insect, or mammalian , after which the recombinant protein can be purified and used to generate a monoclonal or onal antibody preparation that specifically bind the gastric cancer marker ptide used to generate the antibody.

One of skill in the art will know that the generation of two or more different sets of onal or polyclonal antibodies maximizes the likelihood of obtaining an antibody with the specificity and affinity required for its intended use (e.g., ELISA, immunohistochemistry, in vivo imaging, immunotoxin therapy). The antibodies are tested for their desired activity by known methods, in ance with the purpose for which the antibodies are to be used (e.g., ELISA, immunohistochemistiy, immunotherapy, etc.; for fiarther guidance on the generation and testing of antibodies, see, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1988). For example, the antibodies may be tested in ELISA assays, Western blots, immunohistochemical ng of formalin-fixed gastric cancers or frozen tissue sections. After their initial in vitro characterization, antibodies intended for therapeutic or in vivo diagnostic use are tested according to known clinical testing methods.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e.; the individual antibodies comprising the population are identical except for possible naturally ing mutations that may be present in minor amounts. The monoclonal antibodies herein specifically include "chimeric" dies in which a portion of the heavy and/or light chain is identical with or gous to corresponding sequences in antibodies derived from a particular _ 68 _ species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is cal with or homologous to corresponding sequences in antibodies derived from another s or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired antagonistic activity (US.

Pat. No.4,816,567).

Monoclonal antibodies of the invention may be prepared using hybridoma methods. In a oma method, a mouse or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro.

The monoclonal antibodies may also be made by recombinant DNA s, such as those described in U.S. Pat. No.4,816,567. DNA ng the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using ucleotide probes that are e of binding specifically to genes encoding the heavy and light chains of murine antibodies).

In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art. For instance, digestion can be performed using papain. Examples of papain digestion are described in WO 94/29348 published Dec. 22, 1994 and US. Pat. No.4,342,566. Papain digestion of antibodies lly produces two identical n g fragments, called Fab fragments, each with a single antigen g site, and a residual Fe fragment. Pepsin treatment yields a fragment that has two antigen combining sites and is still capable of cross-linking antigen.

The antibody fragments, whether attached to other sequences or not, can also include insertions, deletions, substitutions, or other ed modifications of particular regions or specific amino acids residues, provided the activity of the fragment is not significantly altered or impaired compared to the nonmodified antibody or antibody fragment. These modifications can provide for some additional property, such as to remove/add amino acids e of disulfide bonding, to increase its bio-longevity, to alter its secretory _ 69 _ characteristics, etc. In any case, the antibody fragment must possess a bioactive property, such as binding activity, regulation of binding at the binding domain, etc. Functional or active regions of the antibody may be identified by nesis of a specific region of the protein, followed by expression and g of the expressed polypeptide. Such methods are readily nt to a skilled practitioner in the art and can include site-specific mutagenesis of the nucleic acid encoding the antibody fragment.

The antibodies of the ion may further comprise humanized dies or human dies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab' or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human globulins ient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and ty. In some instances, Fv framework (FR) residues of the human globulin are replaced by corresponding non-human es. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the zed antibody will comprise substantially all of at least one, and typically two, le domains, in which all or substantially all ofthe CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an globulin constant region (Fc), typically that of a human immunoglobulin.

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain.

Humanization can be essentially performed by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (US. Pat. No.4,816,567), n substantially less than an intact human variable domain has been substituted by the corresponding sequence from 2011/053863 _ 70 _ a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Transgenic animals (e.g., mice) that are capable, upon immunization, of ing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production can be employed. For example, it has been described that the homozygous deletion of the antibody heavy chain joining region gene in chimeric and germ-line mutant mice s in complete tion of endogenous antibody production. Transfer of the human germ-line globulin gene array in such germ-line mutant mice will result in the production of human dies upon antigen challenge. Human antibodies can also be produced in phage display libraries.

Antibodies of the invention are preferably administered to a subject in a ceutically acceptable carrier. Typically, an appropriate amount of a pharmaceutically-acceptable salt is used in the formulation to render the formulation isotonic. Examples ofthe pharmaceutically-acceptable carrier include saline, Ringer's on and dextrose solution.

The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5. Further carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. It will be apparent to those s d in the art that certain rs may be more preferable depending upon, for instance, the route of administration and concentration of antibody being administered.

The antibodies can be administered to the subject, patient, or cell by injection (e.g., intravenous, eritoneal, subcutaneous, intramuscular), or by other methods such as infusion that ensure its delivery to the bloodstream in an effective form. The dies may also be administered by intratumoral or peritumoral routes, to exert local as well as ic therapeutic effects. Local or intravenous injection is preferred.

Effective dosages and schedules for administering the antibodies may be determined empirically, and making such determinations is within the skill in the art. Those skilled in _ 71 _ the art will understand that the dosage of antibodies that must be administered will vary depending on, for example, the subject that will receive the antibody, the route of administration, the particular type of antibody used and other drugs being administered. A l daily dosage of the dy used alone might range from about 1 (ug/kg to up to 100 mg/kg of body weight or more per day, depending on the factors mentioned above.

Following administration of an antibody for treating gastric cancer, the efficacy of the therapeutic antibody can be assessed in s ways well known to the skilled practitioner.

For instance, the size, number, and/or distribution of gastric cancer in a subject receiVing treatment may be monitored using standard tumor imaging techniques. A eutically- administered antibody that arrests tumor growth, results in tumor shrinkage, and/or prevents the development ofnew tumors, compared to the disease course that would occurs in the absence of antibody administration, is an efficacious antibody for treatment of gastric Because the proteins ABLl, ADAMlO, AHR, CCND2, CDC6, CDKl, l, CEACAMS, CEACAM6, CEACAM6, COL6A3, , LOC255308, EPHA2, ERBBZ, ERBB3, F2R, FAP, HMMR, HSP90Bl, IGF2BP3, ITGB4, KIFZC, KRAS, LAMC2, LCN2, MET, MMPl l, MMPlZ, MMP3, MSTlR, NUF2, OLFM4, PROMl, RRMZ, THYl, TMPRSS4, TOP2A and PTK2 have been shown to be , TSPANl, WNTSA, HIFlA, highly expressed in at least a subset of c cancer s as compared to normal tissues, inhibition of their expression or actiVity may be integrated into any eutic strategy for treating or preventing gastric cancer.

The principle of antisense therapy is based on the hypothesis that sequence-specific suppression of gene expression (Via transcription or translation) may be achieved by intra- cellular hybridization between genomic DNA or mRNA and a mentary antisense species. The formation of such a hybrid nucleic acid duplex interferes with transcription of the target tumor antigen-encoding genomic DNA, or processing/transport/translation and/or stability of the target tumor antigen mRNA. nse nucleic acids can be delivered by a variety of approaches. For example, nse oligonucleotides or anti-sense RNA can be directly administered (e.g., by intravenous injection) to a subject in a form that allows uptake into tumor cells. Alternatively, Viral or _ 72 _ plasmid vectors that encode antisense RNA (or RNA fragments) can be introduced into cells in vivo. Antisense effects can also be induced by sense sequences; however, the extent of phenotypic changes is highly le. Phenotypic changes induced by effective antisense therapy are assessed according to changes in, e.g., target mRNA levels, target protein levels, and/or target protein activity levels.

In a specific example, inhibition of gastric tumor marker fianction by antisense gene therapy may be lished by direct administration of antisense gastric tumor marker RNA to a subject. The antisense tumor marker RNA may be produced and isolated by any standard technique, but is most readily produced by in vitro transcription using an antisense tumor marker cDNA under the control of a high efficiency promoter (e. g., the T7 promoter).

Administration of anti-sense tumor marker RNA to cells can be carried out by any of the methods for direct c acid administration described below.

An alternative strategy for inhibiting MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB or MUC6 function using gene therapy involves intracellular sion of an anti- MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB or MUC6 antibody or a portion of an anti- MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB or MUC6 antibody. For example, the gene (or gene nt) encoding a monoclonal antibody that specifically binds to a MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB or MUC6 polypeptide and inhibits its biological ty is placed under the transcriptional control of a specific (e.g., tissue- or tumor-specific) gene regulatory ce, within a nucleic acid expression vector. The vector is then stered to the subject such that it is taken up by gastric cancer cells or other cells, which then secrete the anti- MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB or MUC6 antibody and thereby block biological activity of the MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB and MUC6 polypeptide. ably, the MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB and MUC6 polypeptides are present at the extracellular surface of gastric cancer cells.

In the methods bed above, which e the administration and uptake of exogenous DNA into the cells of a subject (i.e., gene transduction or transfection), the nucleic acids of the t invention can be in the form of naked DNA or the nucleic acids can be in a _ 73 _ vector for delivering the nucleic acids to the cells for inhibition of gastric tumor marker protein expression. The vector can be a commercially available preparation, such as an irus vector (Quantum Biotechnologies, Inc. (Laval, Quebec, Canada). Delivery of the nucleic acid or vector to cells can be via a y of mechanisms. As one example, delivery can be via a liposome, using commercially available liposome preparations such as CTIN, LIPOFECTAMINE (GIBCO- 25 BRL, Inc., Gaithersburg, Md.), SUPERFECT (Qiagen, Inc. Hilden, y) and TRANSFECTAM ga Biotec, Inc., Madison, Wis), as well as other liposomes developed according to procedures standard in the art. In on, the nucleic acid or vector of this invention can be delivered in vivo by electroporation, the technology for which is available from onics, Inc.

(San Diego, Calif.) as well as by means of a SONOPORATION e (ImaRx Pharmaceutical Corp., , Arizona).

As one example, vector delivery can be Via a Viral system, such as a retroviral vector system that can package a recombinant retroviral genome. The recombinant retrovirus can then be used to infect and thereby deliver to the infected cells antisense c acid that inhibits expression of MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB or MUC6. The exact method of introducing the altered nucleic acid into mammalian cells is, of course, not limited to the use of retroviral vectors. Other techniques are widely available for this procedure including the use of iral vectors, adeno-associated viral (AAV) vectors, lentiviral s, pseudotyped retroviral vectors. Physical transduction techniques can also be used, such as liposome delivery and receptor-mediated and other endocytosis mechanisms. This invention can be used in conjunction with any of these or other commonly used gene transfer methods.

The antibodies may also be used for in vivo diagnostic assays. lly, the antibody is labeled with a radionucleotide (such as 111In, 99Tc, 14C, 131I, 3H, 32 35 S) P or so that the tumor can be localized using immunoscintiography. In one embodiment, antibodies or fragments thereof bind to the extracellular domains of two or more MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB, and MUC6 targets and the affinity value (Kd) is less than lxlOuM.

WO 13819 _ 74 _ Antibodies for diagnostic use may be labeled with probes suitable for detection by various imaging s. Methods for detection of probes include, but are not limited to, fluorescence, light, confocal and electron microscopy; magnetic resonance imaging and spectroscopy; fluoroscopy, computed aphy and positron emission tomography.

Suitable probes include, but are not limited to, fluorescein, rhodamine, eosin and other fluorophores, radioisotopes, gold, gadolinium and other lanthanides, paramagnetic iron, fluorine-18 and other positron-emitting radionuclides. Additionally, probes may be bi— or multi-functional and be detectable by more than one of the methods listed. These antibodies may be directly or indirectly labeled with said probes. Attachment of probes to the antibodies includes covalent attachment of the probe, incorporation of the probe into the antibody, and the covalent attachment of a chelating compound for binding of probe, amongst others well recognized in the art. For immunohistochemistry, the disease tissue sample may be fresh or frozen or may be embedded in in and fixed with a preservative such as formalin. The fixed or embedded section ns the sample are contacted with a labeled primary antibody and secondary antibody, wherein the dy is used to detect the MSTlR, UCHLS, SMC4, NFYB, PPAPZC, AVL9, UQCRB and MUC6 proteins express in situ.

The t invention thus provides a peptide comprising a sequence that is selected from the group of SEQ ID NO: 1 to SEQ ID NO: 95 or a variant thereof which is 85%, preferably 90% and more preferred 96%, homologous to SEQ ID NO: 1 to SEQ ID NO: 950r a variant thereof that will induce T cells cross-reacting with said e.

The es of the invention have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I.

In the present invention, the term "homologous" refers to the degree of identity between sequences of two amino acid ces, i.e. peptide or polypeptide ces. The aforementioned "homology" is determined by comparing two sequences aligned under optimal conditions over the sequences to be compared. The sequences to be compared herein may have an addition or on (for e, gap and the like) in the optimum alignment of the two sequences. Such a sequence homology can be calculated by creating an ent using, for example, the ClustalW algorithm. Commonly available sequence _ 75 _ is software, more specifically, Vector NTI, GENETYX or analysis tools provided by public databases.

A person skilled in the art will be able to assess, r T cells induced by a variant of a specific peptide will be able to cross-react with the peptide itself (Fong et al. 8809-14); (Appay et al. 1805-14;Colombetti et al. 2730-38;Zaremba et al. 4570-77).

By a "variant" of the given amino acid sequence the inventors mean that the side chains of, for example, one or two of the amino acid residues are altered (for e by replacing them with the side chain of another lly occurring amino acid residue or some other side chain) such that the peptide is still able to bind to an HLA molecule in substantially the same way as a peptide consisting of the given amino acid ce in SEQ ID NO: 1 to 33.

For example, a peptide may be modified so that it at least maintains, if not improves, the ability to interact with and bind to the binding groove of a suitable MHC molecule, such as HLA-A*02 or -DR, and in that way it at least maintains, if not improves, the ability to bind to the TCR of activated CTL.

These CTL can uently cross-react with cells and kill cells that express a polypeptide which contains the natural amino acid sequence of the cognate peptide as defined in the aspects of the invention. As can be derived from the scientific literature (Rammensee, Bachmann, and Stevanovic) and databases (Rammensee et al. 213-19), certain ons of HLA binding peptides are typically anchor residues forming a core ce fitting to the binding motif of the HLA receptor, which is defined by polar, electrophysical, hydrophobic and spatial properties of the polypeptide chains constituting the binding groove. Thus one skilled in the art would be able to modify the amino acid sequences set forth in SEQ ID NO: 1 to 95, by maintaining the known anchor residues, and would be able to determine whether such variants maintain the ability to bind MHC class I or II molecules. The variants of the present invention retain the ability to bind to the TCR of activated CTL, which can uently cross-react with- and kill cells that express a ptide containing the natural amino acid sequence of the cognate peptide as defined in the aspects ofthe invention. _ 76 _ Those amino acid residues that do not substantially contribute to interactions with the T- cell receptor can be modified by replacement with another amino acid whose incorporation does not substantially affect T-cell vity and does not eliminate binding to the relevant MHC. Thus, apart from the proviso given, the peptide of the invention may be any peptide (by which term the inventors include oligopeptide or polypeptide), which includes the amino acid sequences or a n or variant thereof as given.

Table 3: Variants and motif of the peptides according to SEQ ID NO: 1 to 33 ——-llllllnnnl ——llnllnllll __-Illlllllll ———lllllnlnnl ——lllnllllll __-IIIIIIIIII ———lllllnlnnl ——lllnllllll lllllll ———lllllnmnl ——lllnllnlll __-IIIIIIIIII ———lllllnlnnl ——llllnnllll __-IIIIIIIIII ———lllllnlnnl ——lllnllnlll __-llllllllll ———lllllnmnl llllll __-IIIIIIIIII ———lllllnlnnl ——llllllnnll __-IIIIIIIIII __-llllllllll ———lllllnmnl ——lllnlnllll __-Illlllllll ———lllllnlnnl _—IIIIIIIIII __-IIIIIIIIII ———lllllnnnnl llnlll __-llllllllll ———lllllnmnl ——llllnlllll __-IIIIIIIIII __1’05"" IIIIIIIIII 2011/053863 _ 79 _ _—Illlllllll—_-IIIIIIIIII ———lllllnmnl ——llllllnlll __-IIIIIIIIII ———lllllnlnnl ——llllllnlll __-IIIIIIIIII ———lllllnlnnl _—IIIIIIIIII __-llllllllll ———lllllnmnl _—Illllllflll __-IIIIIIIIII __-IIIIIIIIII __-Illlllllll ———lllllnlnnl——lllllllnll __-llllllllll ———lllllnmnl _—Illlllllll __-IIIIIIIIII ———lllllnlnnl ——nllllllnll __-IIIIIIIIII ———lllllnnnnl llnlll __-llllllllll ———lllllnmnl ——lllnlnllll __-Illlllllll ———lllllnlnnl ——lllnllllll __-llllllllll ———lllllnmnl ——llnnllmll __-IIIIIIIIII llnlnnl _—IIIIIIIIII __-IIIIIIIIII ———lllllnlnnl _—IIIIIIIIII __-llllllllll _ 82 _ __-llllllllll ——-llllllnnnl ——llnlllllll lllllll ———lllllnlnnl ——lllnllllll __-llllllllll ———lllllnmnl ——llnlllllll __-IIIIIIIIII ———lllllnlnnl ——llnlllllll __-IIIIIIIIII ———lllllnlnnl _—IIIIIIIIII __-llllllllll ———lllllnlnnl ——llllllnlll __-IIIIIIIIII ———lllllnlnnl ——lllllllnll __-llllllllll ———lllllnmnl ——llnllnllll lllllll ——-lllllnlnnl ——lllnllllll __-IIIIIIIIII 2011/053863 _ 84 _ ——-llllllnnnl——lllnllllll __-IIIIIIIIII ——-lllllnlnnl ——lllnllnlll __-IIIIIIIIII ——-lllllnlnnl ——llllnnllll __-llllllllll ———lllllnmnl ——lllnllnlll __-Illlllllll __1’05"" IIIIIIIIII _ 85 _ llllll—_-IIIIIIIIII ———lllllnmnl ——llllllmll __-Illlllllll ——-lllllnlnnl ——lllnlnllll __-IIIIIIIIII ——-lllllnlnnl _—IIIIIIIIII __-llllllllll ——-lllllnnnnl ——llllllnlll __-Illlllllll __-Illlllllll __-llllllllll _ 86 _ __-llllllllll __-IIIIIIIIII ——-llllllnnnl ——llllnlllll __-llllllllll ———lllllnmnl llllll __-Illlllllll ——-lllllnlnnl ——llllllnlll __-IIIIIIIIII ——-lllllnlnnl ——llllllnlll __-llllllllll ———lllllnmnl _—Illlllllll __-8IIIIIIIIFII ——-lllllnlnnl _—Illllllflll __-llllllllll ———lllllnmnl _—Illllllflll __-Illlllllll ——-lllllnlnnl _—IIIIIIIIII IIIIIII ——-lllllnlnnl ——nllllllnll __-llllllllll _ 88 _ __-llllllllll ——-llllllnnnl ——llllllnlll IIIIIII ——-lllllnnnnl ——lllnlnllll __-llllllllll ———lllllnmnl _—Illflllllll __-Illlllllll ——-lllllnlnnl ——llnnllnnll __-IIIIIIIIII ——-lllllnlnnl _—IIIIIIIIII __-llllllllll 2011/053863 ——-lllllnlnnl _—IIIIIIIIII __-IIIIIIIIII ——-lllllnlnnl ——llnlllllll __-llllllllll ———lllllnmnl ——lllnllllll __-Illlllllll ——-lllllnlnnl ——llnlllllll __-IIIIIIIIII _ 90 _ ——-llllllnnnl ——llnlllllll __-IIIIIIIIII ——-lllllnlnnl _—IIIIIIIIII __-IIIIIIIIII ——-lllllnlnnl ——llllllnlll __-llllllllll ———lllllnnnnl ——lllllllnll __-Illlllllll Longer peptides may also be suitable. It is also possible, that MHC class I epitopes, although y n 8-11 amino acids long, are generated by peptide processing from longer peptides or proteins that include the actual e. It is preferred that the residues WO 13819 _ 91 _ that flank the actual epitope are residues that do not substantially affect proteolytic cleavage necessary to expose the actual epitope during processing. ingly, the present invention also provides peptides and variants of MHC class I epitopes wherein the peptide or variant has an overall length of between 8 and 100, ably between 8 and 30, and most preferred between 8 and 14, namely 8, 9, 10, ll, 12, l3, 14 amino acids.

Of course, the peptide or variant according to the present invention will have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class I. Binding of a peptide or a t to a MHC complex may be tested by methods known in the art.

In a ularly preferred embodiment of the invention the peptide consists or consists essentially of an amino acid sequence according to SEQ ID NO: 1 to SEQ ID NO: 95.

"Consisting essentially of" shall mean that a peptide according to the present invention, in on to the sequence according to any of SEQ ID NO: 1 to SEQ ID NO: 95 or a variant thereof contains additional N— and/or C-terminally located stretches of amino acids that are not necessarily forming part of the peptide that ons as an epitope for MHC molecules epitope.

Nevertheless, these hes can be important to provide an efficient introduction of the peptide according to the present invention into the cells. In one embodiment of the present invention, the peptide is a fusion protein which comprises, for example, the 80 N—terminal amino acids of the HLA-DR antigen-associated invariant chain (p33, in the following "Ii") as derived from the NCBI, GenBank Accession number .

In addition, the peptide or variant may be modified further to improve ity and/or binding to MHC molecules in order to elicit a stronger immune response. Methods for such an optimization of a peptide sequence are well known in the art and e, for example, the uction of reverse peptide bonds or non-peptide bonds. _ 92 _ In a reverse peptide bond amino acid residues are not joined by peptide (-CO-NH-) linkages but the peptide bond is reversed. Such retro-inverso peptidomimetics may be made using methods known in the art, for example such as those described in Meziere et al (1997) J.

Immunol. 159, 3230-3237, incorporated herein by reference. This ch involves making peptides containing changes involving the backbone, and not the orientation of side chains. Meziere et al (1997) show that for MHC binding and T helper cell responses, these pseudopeptides are . Retro-inverse peptides, which contain NH-CO bonds d of CO-NH peptide bonds, are much more resistant to proteolysis.

A non-peptide bond is, for example, -CH2-NH, -CH2S-, -CH2CH2-, -CH=CH-, -COCH2-, - CH(OH)CH2-, and -CH2SO-. United States Patent 4,897,445 provides a method for the solid phase synthesis of non-peptide bonds NH) in polypeptide chains which involves polypeptides sized by standard ures and the non-peptide bond sized by reacting an amino aldehyde and an amino acid in the presence of NaCNBHg.

Peptides sing the sequences described above may be synthesized with additional chemical groups present at their amino and/or carboxy termini, to enhance the stability, bioavailability, and/or affinity of the es. For example, hydrophobic groups such as carbobenzoxyl, dansyl, or t-butyloxycarbonyl groups may be added to the peptides' amino termini. Likewise, an acetyl group or a 9-fluorenylmethoxy-carbonyl group may be placed at the peptides' amino termini. Additionally, the hydrophobic group, t-butyloxycarbonyl, or an amido group may be added to the peptides' carboxy termini.

Further, the peptides of the invention may be synthesized to alter their steric configuration.

For example, the D-isomer of one or more of the amino acid es of the peptide may be used, rather than the usual L-isomer. Still fiarther, at least one of the amino acid residues of the peptides of the invention may be substituted by one of the well known non-naturally occurring amino acid residues. Alterations such as these may serve to increase the stability, bioavailability and/or binding action of the peptides of the invention.

Similarly, a peptide or variant of the ion may be modified chemically by reacting specific amino acids either before or after synthesis of the peptide. Examples for such _ 93 _ modifications are well known in the art and are summarized e. g. in R. Lundblad, Chemical Reagents for Protein Modification, 3rd ed. CRC Press, 2005, which is incorporated herein by reference. al modification of amino acids includes but is not limited to, modification by acylation, amidination, pyridoxylation of lysine, reductive alkylation, trinitrobenzylation of amino groups with trinitrobenzene sulphonic acid (TNBS), amide modification of carboxyl groups and sulphydryl modification by performic acid oxidation of ne to cysteic acid, formation of mercurial derivatives, formation of mixed disulphides with other thiol compounds, reaction with maleimide, carboxymethylation with iodoacetic acid or iodoacetamide and carbamoylation with cyanate at ne pH, although without limitation thereto. In this regard, the skilled person is referred to Chapter 15 of Current Protocols In Protein Science, Eds. Coligan et al. (John Wiley and Sons NY 1995-2000) for more extensive methodology relating to al modification of proteins.

Briefly, cation of e.g. arginyl residues in proteins is often based on the reaction of l dicarbonyl compounds such as phenylglyoxal, tanedione, and 1,2- cyclohexanedione to form an adduct. Another example is the reaction of methylglyoxal with ne residues. Cysteine can be modified without concomitant modification of other nucleophilic sites such as lysine and histidine. As a result, a large number of reagents are available for the modification of cysteine. The websites of companies such as Sigma- h (http://www.sigma-aldrich.com) provide information on specific reagents.

Selective reduction of disulfide bonds in proteins is also . lde bonds can be formed and oxidized during the heat treatment ofbiopharmaceuticals.

Woodward’s Reagent K may be used to modify specific glutamic acid residues. N—(3- (dimethylamino)propyl)-N’-ethylcarbodiimide can be used to form intra-molecular crosslinks between a lysine residue and a glutamic acid residue.

For example, diethylpyrocarbonate is a reagent for the cation of histidyl residues in proteins. Histidine can also be modified using 4-hydroxynonenal. 2011/053863 _ 94 _ The reaction of lysine residues and other (x-amino groups is, for e, useful in binding of peptides to surfaces or the cross-linking of proteins/peptides. Lysine is the site of attachment of poly(ethylene)glycol and the major site of modification in the glycosylation of proteins. nine residues in proteins can be modified with e.g. iodoacetamide, bromoethylamine, and chloramine T.

Tetranitromethane and N—acetylimidazole can be used for the modification of tyrosyl residues. Cross-linking via the formation of dityrosine can be accomplished with hydrogen peroxide/copper ions.

Recent studies on the modification of tryptophan have used N—bromosuccinimide, 2- hydroxy-S-nitrobenzyl e or 3-bromomethyl(2-nitrophenylmercapto)-3H-indole (BPNS-skatole).

Successful modification of therapeutic proteins and es with PEG is often associated with an extension of circulatory ife while cross-linking of proteins with glutaraldehyde, polyethyleneglycol diacrylate and formaldehyde is used for the preparation of hydrogels. Chemical modification of allergens for therapy is often achieved by carbamylation with potassium cyanate.

A peptide or variant, wherein the peptide is modified or includes non-peptide bonds is a red ment of the invention. Generally, peptides and variants (at least those containing peptide linkages between amino acid residues) may be synthesized by the Fmocpolyamide mode of solid-phase peptide synthesis as disclosed by Lu et al (1981) and references therein. Temporary N—amino group tion is afforded by the 9- fluorenylmethyloxycarbonyl (Fmoc) group. Repetitive cleavage of this highly base-labile protecting group is done using 20% piperidine in N, N—dimethylformamide. Side-chain fianctionalities may be protected as their butyl ethers (in the case of serine threonine and tyrosine), butyl esters (in the case of glutamic acid and aspartic acid), butyloxycarbonyl derivative (in the case of lysine and histidine), trityl derivative (in the case of cysteine) and 4-methoxy-2,3,6-trimethylbenzenesulphonyl derivative (in the case of arginine). Where _ 95 _ glutamine or gine are C-terminal residues, use is made of the 4,4'- dimethoxybenzhydryl group for protection of the side chain amido fianctionalities. The phase support is based on a polydimethyl-acrylamide polymer constituted from the three rs dimethylacrylamide (backbone-monomer), bisacryloylethylene diamine (cross linker) and acryloylsarcosine methyl ester (fianctionalizing agent). The peptide-to- resin cleavable linked agent used is the acid-labile 4-hydroxymethyl-phenoxyacetic acid derivative. All amino acid derivatives are added as their preformed symmetrical anhydride tives with the exception of asparagine and glutamine, which are added using a reversed N, clohexyl-carbodiimide/lhydroxybenzotriazole mediated coupling procedure. All coupling and deprotection reactions are monitored using rin, robenzene sulphonic acid or isotin test procedures. Upon completion of synthesis, peptides are cleaved from the resin support with concomitant removal of side-chain protecting groups by treatment with 95% trifluoroacetic acid ning a 50 % scavenger mix. Scavengers commonly used include ethandithiol, , anisole and water, the exact choice depending on the constituent amino acids of the e being synthesized. Also a combination of solid phase and solution phase methodologies for the synthesis of peptides is possible (see, for example (Bruckdorfer, Marder, and cio 29-43) and the references as cited therein).

Trifluoroacetic acid is removed by evaporation in vacuo, with subsequent trituration with diethyl ether affording the crude peptide. Any gers present are removed by a simple extraction procedure which on lyophilisation of the aqueous phase affords the crude peptide free of scavengers. Reagents for peptide synthesis are lly available from e.g.

Calbiochem—Novabiochem (UK) Ltd, Nottingham NG7 2QJ, UK.

Purification may be performed by any one, or a combination of, techniques such as re- crystallization, size exclusion chromatography, ion-exchange chromatography, hydrophobic interaction chromatography and (usually) reverse-phase high performance liquid chromatography using e. g. acetonitril/water nt separation.

Analysis of peptides may be carried out using thin layer chromatography, electrophoresis, in particular capillary electrophoresis, solid phase extraction (CSPE), reverse-phase high performance liquid chromatography, amino-acid analysis after acid hydrolysis and by fast _ 96 _ atom bombardment (FAB) mass spectrometric analysis, as well as MALDI and TOF mass spectrometric analysis.

A further aspect of the invention es a nucleic acid (for example a polynucleotide) encoding a peptide or peptide variant of the invention. The polynucleotide may be, for example, DNA, cDNA, PNA, CNA, RNA or combinations thereof, either single- and/or double-stranded, or native or stabilized forms of polynucleotides, such as, for example, polynucleotides with a phosphorothioate backbone and it may or may not contain introns so long as it codes for the peptide. Of course, only peptides that contain lly occurring amino acid es joined by lly occurring peptide bonds are encodable by a polynucleotide. A still fiarther aspect of the invention provides an expression vector capable of expressing a polypeptide according to the invention.

A variety of methods have been developed to link polynucleotides, especially DNA, to vectors for example via complementary cohesive termini. For ce, complementary homopolymer tracts can be added to the DNA segment to be inserted to the vector DNA.

The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymeric tails to form recombinant DNA les.

Synthetic linkers containing one or more restriction sites provide an alternative method of joining the DNA segment to vectors. tic linkers containing a variety of restriction endonuclease sites are commercially available from a number of sources including International Biotechnologies Inc, New Haven, CN, USA.

A desirable method of modifying the DNA encoding the polypeptide of the invention s the polymerase chain reaction as sed by (Saiki et al. 487-91)). This method may be used for introducing the DNA into a suitable vector, for example by engineering in suitable restriction sites, or it may be used to modify the DNA in other useful ways as is known in the art. If viral vectors are used, pox- or adenovirus vectors are preferred.

The DNA (or in the case of retroviral vectors, RNA) may then be expressed in a suitable host to produce a polypeptide sing the e or variant of the invention. Thus, the DNA encoding the peptide or variant of the invention may be used in accordance with _ 97 _ known techniques, appropriately modified in view of the ngs contained herein, to construct an expression vector, which is then used to orm an appropriate host cell for the expression and production of the polypeptide of the invention. Such techniques include those disclosed in US Patent Nos. 4,440,859, 901, 4,582,800, 4,677,063, 4,678,751, 4,704,362, 4,710,463, 4,757,006, 4,766,075, and 4,810,648.

The DNA (or in the case of retroviral s, RNA) ng the polypeptide constituting the nd of the invention may be joined to a wide variety of other DNA sequences for uction into an appropriate host. The companion DNA will depend upon the nature of the host, the manner of the introduction of the DNA into the host, and whether episomal maintenance or integration is desired.

Generally, the DNA is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression. If necessary, the DNA may be linked to the appropriate transcriptional and translational regulatory control nucleotide sequences recognized by the desired host, although such controls are generally available in the expression vector. The vector is then uced into the host through standard techniques.

Generally, not all ofthe hosts will be transformed by the vector. Therefore, it will be necessary to select for transformed host cells. One selection technique involves incorporating into the expression vector a DNA sequence, with any necessary control elements, that codes for a selectable trait in the transformed cell, such as antibiotic resistance.

Alternatively, the gene for such selectable trait can be on another vector, which is used to co-transform the desired host cell.

Host cells that have been transformed by the inant DNA of the invention are then cultured for a sufficient time and under riate conditions known to those skilled in the art in view of the teachings disclosed herein to permit the expression of the polypeptide, which can then be red.

Many expression systems are known, including bacteria (for example E. coli and Bacillus subtilis), yeasts (for example Saccharomyces siae), filamentous fiangi (for example _ 98 _ Aspergz'llus spec), plant cells, animal cells and insect cells. Preferably, the system can be ian cells such as CHO cells available from the ATCC Cell Biology tion.

A typical mammalian cell vector plasmid for constitutive expression comprises the CMV or SV40 promoter with a suitable poly A tail and a resistance marker, such as neomycin. One example is pSVL available from Pharmacia, Piscataway, NJ, USA. An example of an inducible mammalian expression vector is pMSG, also available from Pharmacia. Useful yeast plasmid vectors are pRS403-406 and pRS4l3-4l6 and are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast Integrating plasmids (YIps) and incorporate the yeast selectable markers HIS3, TRPl, LEU2 and URA3. Plasmids pRS4l3-4l6 are Yeast Centromere plasmids (chs). CMV promoter-based vectors (for example from Sigma- Aldrich) provide transient or stable expression, cytoplasmic expression or secretion, and N- terminal or C-terminal tagging in various ations of FLAG, 3xFLAG, c-myc or MAT. These fusion proteins allow for detection, purification and analysis of inant protein. agged filSlOIlS provide flexibility in detection.

The strong human cytomegalovirus (CMV) promoter regulatory region drives constitutive n expression levels as high as 1 mg/L in COS cells. For less potent cell lines, n levels are typically ~0.l mg/L. The presence of the SV40 replication origin will result in high levels of DNA replication in SV40 replication permissive COS cells. CMV vectors, for example, can contain the pMBl (derivative of pBR322) origin for replication in ial cells, the b-lactamase gene for ampicillin ance selection in ia, hGH polyA, and the fl origin. Vectors containing the preprotrypsin leader (PPT) sequence can direct the secretion of FLAG fusion proteins into the culture medium for purification using ANTI-FLAG antibodies, resins, and plates. Other vectors and expression systems are well known in the art for use with a variety of host cells.

The present invention also s to a host cell transformed with a polynucleotide vector construct of the present invention. The host cell can be either prokaryotic or eukaryotic.

Bacterial cells may be red prokaryotic host cells in some circumstances and typically are a strain of E. coli such as, for example, the E. coli strains DHS available from Bethesda Research Laboratories Inc., Bethesda, MD, USA, and RRl available from the American _ 99 _ Type Culture Collection (ATCC) of Rockville, MD, USA (No ATCC 31343). red eukaryotic host cells e yeast, insect and mammalian cells, preferably vertebrate cells such as those from a mouse, rat, monkey or human fibroblastic and colon cell lines. Yeast host cells include YPH499, YPH500 and YPH501, which are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Preferred mammalian host cells include Chinese hamster ovary (CHO) cells available from the ATCC as CCL61, NIH Swiss mouse embryo cells NIH/3T3 available from the ATCC as CRL 1658, monkey kidney-derived COS-1 cells available from the ATCC as CRL 1650 and 293 cells which are human embryonic kidney cells. Preferred insect cells are Sf9 cells which can be transfected with baculovirus expression vectors. An overview regarding the choice of suitable host cells for expression can be found in, for example, the textbook of Paulina Balbas and Argelia e "Methods in Molecular Biology Recombinant Gene Expression, Reviews and Protocols," Part One, Second Edition, ISBN 978588299, and other literature known to the person of skill.

Transformation of appropriate cell hosts with a DNA construct of the present invention is accomplished by well known s that typically depend on the type of vector used.

With regard to transformation of yotic host cells, see, for example, Cohen et al (1972) Proc. Natl. Acad. Sci. USA 69, 2110, and Sambrook et al (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

Transformation of yeast cells is described in Sherman et al (1986) Methods In Yeast Genetics, A Laboratory Manual, Cold Spring , NY. The method of Beggs (1978) Nature 275,104-109 is also . With regard to vertebrate cells, reagents useful in transfecting such cells, for e calcium ate and DEAE-dextran or liposome formulations, are available from Stratagene Cloning Systems, or Life Technologies Inc., Gaithersburg, MD 20877, USA. Electroporation is also useful for transforming and/or transfecting cells and is well known in the art for transforming yeast cell, bacterial cells, insect cells and vertebrate cells.

Successfully transformed cells, i.e. cells that contain a DNA uct ofthe present invention, can be identified by well known ques such as PCR. Alternatively, the presence of the protein in the supernatant can be detected using antibodies.

It will be appreciated that certain host cells of the invention are useful in the ation of the peptides of the invention, for e bacterial, yeast and insect cells. However, other host cells may be useful in n therapeutic s. For example, antigen-presenting cells, such as dendritic cells, may usefully be used to express the peptides of the invention such that they may be loaded into appropriate MHC les. Thus, the current invention provides a host cell comprising a nucleic acid or an expression vector according to the invention.

In a preferred ment the host cell is an antigen presenting cell, in ular a dendritic cell or antigen presenting cell. APCs loaded with a recombinant fusion protein containing tic acid phosphatase (PAP) are currently under igation for the treatment of prostate cancer (Sipuleucel—T) (Rini et al. 67-74;Small et al. 3089-94).

A further aspect of the invention provides a method of producing a peptide or its variant, the method comprising culturing a host cell and ing the peptide from the host cell or its culture medium.

In another embodiment the peptide, the nucleic acid or the expression vector of the invention are used in medicine. For example, the peptide or its variant may be prepared for intravenous (iv) injection, sub-cutaneous (s.c.) injection, intradermal (i.d.) injection, intraperitoneal (i.p.) injection, intramuscular (i.m.) injection. Preferred methods of peptide injection include s.c., i.d., i.p., i.m., and iv. Preferred methods of DNA injection include i.d., i.m., s.c., i.p. and iv. Doses of e.g. between 50 ug and 1.5 mg, preferably 125 ug to 500 ug, of peptide or DNA may be given and will depend on the respective peptide or DNA. Dosages of this range were successfully used in previous trials (Brunsvig et al. 1553- ehler et al.).

Another aspect of the present invention includes an in vitro method for producing activated T cells, the method comprising contacting in vitro T cells with antigen loaded human MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate the T cell in an antigen specific manner, wherein the antigen is a peptide according to the invention. ably a sufficient amount of the antigen is used with an antigen-presenting cell.

Preferably the mammalian cell lacks or has a reduced level or function of the TAP peptide transporter. Suitable cells that lack the TAP peptide transporter include T2, RMA-S and Drosophila cells. TAP is the transporter associated with antigen sing.

The human peptide loading deficient cell line T2 is available from the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, USA under gue No CRL 1992; the Drosophila cell line Schneider line 2 is available from the ATCC under Catalogue No CRL 19863; the mouse RMA-S cell line is described in Karre et al 1985.

Preferably, the host cell before transfection ses substantially no MHC class I molecules. It is also preferred that the stimulator cell expresses a molecule ant for providing a co-stimulatory signal for T-cells such as any of B7.1, B7.2, ICAM-1 and LFA 3. The c acid sequences of numerous MHC class I molecules and of the ulator molecules are publicly available from the GenBank and EMBL databases.

In case of a MHC class I epitope being used as an antigen, the T cells are CD8-positive CTLs.

If an antigen-presenting cell is transfected to express such an epitope, preferably the cell comprises an expression vector capable of expressing a peptide containing SEQ ID NO: 1 to SEQ ID NO: 95 or a variant amino acid sequence thereof A number of other methods may be used for generating CTL in vitro. For example, the methods described in Peoples et al (1995) and Kawakami et al (1992) use autologous tumor-infiltrating lymphocytes in the generation of CTL. Plebanski et al (1995) makes use of autologous peripheral blood cytes (PLBs) in the preparation of CTL. Jochmus et al (1997) describes the production of autologous CTL by pulsing tic cells with peptide or polypeptide, or Via infection with recombinant Virus. Hill et al (1995) and Jerome et al (1993) make use of B cells in the production of gous CTL. In addition, hages pulsed with peptide or polypeptide, or infected with inant virus, may be used in the preparation of autologous CTL. S. Walter et al. 2003 describe the in vitro priming ofT cells by using artificial antigen presenting cells (aAPCs), which is also a suitable way for generating T cells against the peptide of choice. In this study, aAPCs were generated by the coupling of preformed MHC:peptide xes to the surface of polystyrene particles (microbeads) by biotin:streptavidin biochemistry. This system permits the exact control of the MHC density on aAPCs, which allows to selectively elicit high- or idity antigen-specific T cell ses with high efficiency from blood samples.

Apart from MHC:peptide complexes, aAPCs should carry other proteins with co- stimulatory activity like anti-CD28 antibodies coupled to their e. Furthermore such aAPC-based systems often require the addition of riate soluble factors, e. g. cytokines like interleukin-l2.

Allogeneic cells may also be used in the preparation of T cells and a method is described in detail in WO 97/26328, incorporated herein by reference. For example, in addition to Drosophila cells and T2 cells, other cells may be used to t antigens such as CHO cells, baculovirus-infected insect cells, bacteria, yeast, vaccinia-infected target cells. In addition plant viruses may be used (see, for example, Porta et al (1994)) which describes the development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides.

The activated T cells that are directed against the es of the invention are useful in therapy. Thus, a further aspect of the invention provides activated T cells obtainable by the foregoing methods ofthe ion.

Activated T cells, which are produced by the above method, will selectively recognize a cell that aberrantly expresses a polypeptide that ses an amino acid sequence of SEQ ID NO: 1 to 95.

Preferably, the T cell recognizes the cell by interacting h its TCR with the HLA/peptide-complex (for example, binding). The T cells are useful in a method of g target cells in a patient whose target cells aberrantly express a polypeptide comprising an amino acid ce of the invention wherein the patient is administered an effective number of the activated T cells. The T cells that are administered to the patient may be derived from the patient and activated as described above (i.e. they are autologous T cells).

Alternatively, the T cells are not from the patient but are from another individual. Of , it is preferred if the dual is a healthy individual. By "healthy individual" the ors mean that the individual is generally in good health, preferably has a ent immune system and, more preferably, is not suffering from any e which can be readily tested for, and detected.

In vivo, the target cells for the CD8-positive T cells according to the present invention can be cells of the tumor (which sometimes express MHC class 1) and/or stromal cells surrounding the tumor (tumor cells) (which sometimes also express MHC class I; (Dengjel et al. 4163-70)).

The T cells of the present invention may be used as active ingredients of a eutic composition. Thus, the invention also provides a method of killing target cells in a patient whose target cells aberrantly express a polypeptide comprising an amino acid sequence of the invention, the method comprising administering to the patient an effective number of T cells as defined above.

By "aberrantly expressed" the inventors also mean that the polypeptide is over-expressed compared to normal levels of expression or that the gene is silent in the tissue from which the tumor is derived but in the tumor it is expressed. By "over-expressed" the inventors mean that the polypeptide is present at a level at least ld of that present in normal tissue; preferably at least 2-fold, and more preferably at least 5-fold or lO-fold the level present in normal tissue.

T cells may be obtained by methods known in the art, e.g. those described above.

Protocols for this so-called adoptive er of T cells are well known in the art and can be found, e.g. in (Dudley et al. 850-54;Dudley et al. 2346-57;Rosenberg et al. 889- 97;Rosenberg et al. l676-80;Yee et al. 16168-73); ed in (Gattinoni et al. 383-93) and (Morgan et al.).

Any molecule ofthe invention, i.e. the peptide, nucleic acid, expression vector, cell, activated CTL, T-cell receptor or the nucleic acid ng it is useful for the treatment of — 104 — disorders, characterized by cells escaping an immune se. Therefore any molecule of the t invention may be used as medicament or in the manufacture of a medicament.

The molecule may be used by itself or combined with other le(s) of the invention or (a) known molecule(s).

Preferably, the medicament of the present invention is a vaccine. It may be administered directly into the t, into the affected organ or systemically i.d., i.m., s.c., i.p. and iv, or applied ex vivo to cells derived from the t or a human cell line which are subsequently administered to the patient, or used in vitro to select a subpopulation of immune cells d from the patient, which are then inistered to the patient. If the nucleic acid is administered to cells in vitro, it may be useful for the cells to be transfected so as to co-express immune-stimulating cytokines, such as interleukin-2. The peptide may be substantially pure, or combined with an immune-stimulating adjuvant (see below) or used in combination with immune-stimulatory cytokines, or be stered with a suitable delivery system, for example liposomes. The peptide may also be conjugated to a suitable carrier such as keyhole limpet haemocyanin (KLH) or mannan (see W0 95/ 18145 and Longeneckerl993). The peptide may also be tagged, may be a fusion protein, or may be a hybrid le. The peptides whose sequence is given in the present invention are expected to stimulate CD4 or CD8 T cells. However, stimulation of CD8 CTLs is more efficient in the presence of help provided by CD4 T-helper cells. Thus, for MHC Class I epitopes that stimulate CD8 CTL the fusion partner or sections of a hybrid molecule suitably provide epitopes which stimulate CD4-positive T cells. CD4- and CD8-stimulating epitopes are well known in the art and include those identified in the present invention.

In one aspect, the vaccine comprises at least one peptide having the amino acid sequence set forth in SEQ ID NO:l to 33 and at least one additional peptide, preferably two to 50, more ably two to 25, even more preferably two to 15 and most preferably two, three, four, five, six, seven, eight, nine, ten, eleven, twelve or thirteen peptides. The peptide(s) may be derived from one or more specific TAAs and may bind to MHC class I les.

The polynucleotide may be substantially pure, or ned in a suitable vector or delivery system. The nucleic acid may be DNA, cDNA, PNA, CNA, RNA or a combination thereof.

Methods for designing and ucing such a nucleic acid are well known in the art. An overview is provided by e.g. (Pascolo et al. 117-22). Polynucleotide vaccines are easy to prepare, but the mode of action of these vectors in inducing an immune response is not fully understood. Suitable vectors and ry systems include viral DNA and/or RNA, such as systems based on adenovirus, vaccinia virus, retroviruses, herpes virus, adeno- associated virus or hybrids containing elements of more than one virus. Non-viral delivery systems include cationic lipids and cationic rs and are well known in the art ofDNA delivery. Physical delivery, such as via a "gene-gun," may also be used. The peptide or peptides encoded by the nucleic acid may be a fusion protein, for e with an epitope that stimulates T cells for the respective opposite CDR as noted above.

The medicament of the invention may also include one or more nts. Adjuvants are substances that non-specifically enhance or potentiate the immune response (e. g., immune responses mediated by CTLs and helper-T (TH) cells to an antigen, and would thus be considered useful in the ment of the present invention. Suitable adjuvants include, but are not limited to, 1018 ISS, aluminium salts, Amplivax®, ASl5, BCG, CP-870,893, CpG7909, CyaA, dSLIM, flagellin or TLR5 ligands d from flagellin, FLT3 ligand, , IC30, IC31, Imiquimod (ALDARA®), resiquimod, ImuFact IMP321, Interleukins as IL-2, IL-l3, IL-21, Interferon-alpha or -beta, or pegylated derivatives thereof, IS Patch, ISS, ISCOMATRIX, ISCOMs, Juvamune, LipoVac, MALP2, MF59, monophosphoryl lipid A, Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide , in-oil and oil-in-water emulsions, , OM-l74, OM MP-EC, ONTAK, OspA, PepTel® vector system, poly(lactid co-glycolid) [PLG]—based and dextran microparticles, talactoferrin SRL172, Virosomes and other Virus-like particles, YF- 17D, VEGF trap, R848, beta-glucan, s, Aquila's QS21 stimulon, which is d from saponin, mycobacterial extracts and synthetic bacterial cell wall mimics, and other proprietary adjuvants such as Ribi's Detox, Quil, or Superfos. Adjuvants such as Freund's or GM-CSF are preferred. Several immunological adjuvants (e.g., MF59) specific for dendritic cells and their preparation have been described previously (Allison and Krummel 932-33). Also cytokines may be used. Several cytokines have been directly linked to influencing dendritic cell migration to lymphoid s (e. g., TNF-), accelerating the maturation of dendritic cells into efficient antigen-presenting cells for T-lymphocytes (e. g., GM-CSF, IL-1 and IL-4) (US. Pat. No. 5,849,589, specifically incorporated herein by reference in its entirety) and acting as immunoadjuvants (e. g., IL-l2, IL-lS, IL-23, IL-7, IFN-alpha. IFN-beta) [Gabrilovich 1996].

CpG immunostimulatory oligonucleotides have also been reported to enhance the effects of adjuvants in a vaccine setting. Without being bound by theory, CpG oligonucleotides act by activating the innate daptive) immune system via Toll-like receptors (TLR), mainly TLR9. CpG triggered TLR9 activation enhances antigen-specific humoral and ar responses to a wide y of antigens, including peptide or protein antigens, live or killed viruses, dendritic cell vaccines, autologous cellular vaccines and polysaccharide conjugates in both prophylactic and therapeutic es. More importantly it enhances dendritic cell maturation and differentiation, resulting in enhanced activation of TH1 cells and strong cytotoxic T-lymphocyte (CTL) generation, even in the absence of CD4 T cell help. The TH1 bias induced by TLR9 ation is maintained even in the presence of vaccine adjuvants such as alum or incomplete Freund’s adjuvant (IFA) that normally promote a TH2 bias. CpG oligonucleotides show even greater adjuvant activity when formulated or co-administered with other adjuvants or in formulations such as microparticles, nanoparticles, lipid emulsions or similar formulations, which are especially necessary for inducing a strong response when the antigen is relatively weak. They also accelerate the immune response and enable the n doses to be reduced by approximately two orders of magnitude, with able dy responses to the filll—dOSG e without CpG in some experiments (Krieg 471-84). US Pat. No. 6,406,705 Bl describes the combined use of CpG oligonucleotides, non-nucleic acid adjuvants and an antigen to induce an antigen-specific immune response. A CpG TLR9 antagonist is dSLIM (double Stem Loop Immunomodulator) by Mologen (Berlin, y) which is a red ent of the pharmaceutical composition of the present invention. Other TLR binding molecules such as RNA binding TLR 7, TLR 8 and/or TLR 9 may also be used.

Other examples for useful adjuvants include, but are not limited to chemically modified Cst (e.g. CpR, Idera), dsRNA analogues such as Poly(I:C) and derivates thereof (e.g.

AmpliGen®, Hiltonol®, poly-(ICLC), poly(IC-R), poly(I:C12U), non-CpG bacterial DNA or RNA as well as immunoactive small molecules and dies such as cyclophosphamide, sunitinib, zumab, celebrex, NCX-4016, sildenafil, tadalafil, vardenafil, nib, temozolomide, temsirolimus, XL-999, CP-547632, pazopanib, VEGF Trap, ZD217l, l, anti-CTLA4, other antibodies targeting key structures of the immune system (e. g. anti-CD40, GFbeta, anti-TNFalpha receptor) and SC58175, which may act therapeutically and/or as an adjuvant. The amounts and concentrations of adjuvants and additives useful in the context of the present invention can readily be determined by the skilled artisan without undue experimentation.

Preferred adjuvants are imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, CpG oligonucleotides and derivates, poly-(I:C) and derivates, RNA, sildenafil, and particulate formulations with PLG or virosomes.

In a red embodiment, the pharmaceutical ition according to the invention the adjuvant is selected from the group consisting of colony-stimulating factors, such as Granulocyte Macrophage Colony ating Factor (GM-CSF, sargramostim), imiquimod, resiquimod, and interferon-alpha.

In a preferred embodiment, the pharmaceutical composition according to the ion the adjuvant is selected from the group consisting of colony-stimulating factors, such as Granulocyte Macrophage Colony Stimulating Factor (GM-CSF, sargramostim), immiquimod and resimiquimod.

In a preferred embodiment of the pharmaceutical composition according to the invention, the adjuvant is imiquimod or resiquimod.

This composition is used for parenteral administration, such as subcutaneous, intradermal, intramuscular or oral administration. For this, the peptides and optionally other molecules are dissolved or suspended in a pharmaceutically acceptable, ably aqueous carrier. In addition, the composition can contain excipients, such as s, binding agents, blasting agents, diluents, flavours, lubricants, etc.. The peptides can also be administered together with immune stimulating substances, such as cytokines. An ive listing of excipients that can be used in such a composition, can be, for e, taken from A. Kibbe, Handbook of Pharmaceutical Excipients, 3. Ed. 2000, American Pharmaceutical ation and pharmaceutical press. The composition can be used for a prevention, prophylaxis and/or therapy of adenomateous or cancerous diseases. ary formulations can be found in EP2113253.

The present invention provides a medicament that useful in treating , in particular gastric cancer, renal cell carcinoma, colon cancer, non-small cell lung carcinoma, adenocarcinoma, prostate cancer, benign neoplasm and malignant melanoma.

The present invention fiarther includes a kit comprising: (a) a ner that contains a pharmaceutical composition as described above, in solution or in lyophilized form; (b) optionally a second ner containing a diluent or reconstituting solution for the lyophilized formulation; and (c) optionally, instructions for (i) use of the solution or (ii) reconstitution and/or use of the lyophilized formulation.

The kit may further comprise one or more of (iii) a buffer, (iv) a diluent, (v) a filter, (vi) a needle, or (v) a syringe. The container is preferably a bottle, a vial, a syringe or test tube; and it may be a multi-use container. The pharmaceutical composition is preferably lized.

Kits of the present invention preferably comprise a lyophilized formulation of the present invention in a suitable container and ctions for its reconstitution and/or use. Suitable containers include, for example, bottles, vials (e.g. dual chamber vials), syringes (such as dual chamber syringes) and test tubes. The container may be formed from a y of materials such as glass or plastic. ably the kit and/or container contains instructions on or associated with the container that indicates directions for reconstitution and/or use.

For example, the label may indicate that the lyophilized formulation is to reconstituted to e concentrations as described above. The label may fiarther te that the ation is useful or ed for subcutaneous administration.

The container holding the formulation may be a multi-use vial, which allows for repeat administrations (e.g., from 2-6 administrations) of the reconstituted formulation. The kit may fiarther comprise a second ner comprising a suitable diluent (e.g., sodium onate solution).

Upon mixing of the diluent and the lyophilized formulation, the final peptide concentration in the reconstituted formulation is preferably at least 0.15 mg/mL/peptide (=75 ug) and preferably not more than 3 mg/mL/peptide ug). The kit may further include other als desirable from a commercial and user standpoint, including other buffers, ts, filters, needles, syringes, and package s with instructions for use.

Kits of the present invention may have a single container that contains the formulation of the ceutical compositions according to the present invention with or without other components (e.g., other compounds or pharmaceutical compositions ofthese other compounds) or may have distinct container for each component.

Preferably, kits of the invention include a formulation of the ion packaged for use in combination with the co-administration of a second compound (such as adjuvants (e. g.

GM-CSF), a chemotherapeutic agent, a natural product, a hormone or antagonist, a giogenesis agent or inhibitor, a apoptosis-inducing agent or a chelator) or a pharmaceutical composition thereof. The components of the kit may be mplexed or each component may be in a separate distinct container prior to stration to a patient.

The components of the kit may be provided in one or more liquid solutions, preferably, an aqueous solution, more preferably, a sterile aqueous solution. The components of the kit may also be provided as solids, which may be converted into liquids by addition of suitable solvents, which are preferably provided in another distinct ner.

The container of a therapeutic kit may be a vial, test tube, flask, bottle, syringe, or any other means of enclosing a solid or liquid. Usually, when there is more than one component, the kit will contain a second vial or other container, which allows for separate . The kit may also contain another container for a pharmaceutically acceptable liquid. Preferably, a therapeutic kit will contain an apparatus (e.g., one or more s, syringes, eye droppers, pipette, etc.), which enables administration ofthe agents of the invention that are components of the present kit. - llO - The present formulation is one that is suitable for administration of the es by any acceptable route such as oral (enteral), nasal, ophthal, aneous, ermal, intramuscular, intravenous or transdermal. Preferably the stration is s.c., and most preferably, i.d. Administration may be by infilsion pump.

Since the peptides of the invention derived from MSTlR, UCHLS, SMC4, NFYB, PPAP2C, AVL9, UQCRB and MUC6 were isolated from gastric , the medicament of the invention is preferably used to treat gastric cancer.

The t invention will now be described in the following examples that describe preferred embodiments thereof, nevertheless, without being limited thereto. For the purposes of the present invention, all references as cited herein are incorporated by reference in their entireties.

EXAMPLES EXAMPLE 1: Identification oftumor associated peptides presented on cell surface Tissue samples Patients’ tumor tissues were provided by Kyoto Prefectural sity of Medicine (KPUM), Kyoto, Japan, Osaka City University Graduate School of Medicine (OCU), Osaka, Japan, and University Hospital Tubingen, Germany. Written informed consents of all patients had been given before surgery. Tissues were shock-frozen in liquid nitrogen ately after surgery and stored until isolation of TUMAPs at -80°C.

Isolation of HLA peptides from tissue samples HLA peptide pools from shock-frozen tissue samples were obtained by immune precipitation from solid tissues according to a slightly modified protocol (Falk, K.l99l; Seeger, 999} using the HLA-A, -B, -C-specif1c antibody W6/32, the HLA-A*02- ic antibody BB7.2, CNBr-activated sepharose, acid treatment, and ltration.

Methods WO 13819 The HLA peptide pools as obtained were ted according to their hydrophobicity by reversed-phase chromatography (nanoAcquity UPLC system, Waters) and the eluting peptides were analyzed in an LTQ-Orbitrap hybrid mass spectrometer (ThermoFisher Scientific) equipped with an ESI source. Peptide pools were loaded directly onto the analytical fused-silica micro-capillary column (75 um id. x 250 mm) packed with 1.7 um C18 reversed-phase material (Waters) applying a flow rate of 400 nL per minute.

Subsequently, the peptides were separated using a two-step 180 minute-binary gradient from 10% to 33% B at a flow rate of 300 nL per minute. The gradient was composed of Solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile). A gold coated glass capillary (PicoTip, New Objective) was used for introduction into the nanoESI source. The LTQ-Orbitrap mass spectrometer was operated in the data-dependent mode using a TOPS strategy. In brief, a scan cycle was initiated with a full scan of high mass accuracy in the orbitrap (R = 30 000), which was ed by MS/MS scans also in the orbitrap (R = 7500) on the 5 most abundant precursor ions with dynamic exclusion of previously ed ions. Tandem mass spectra were interpreted by T and additional manual control. The identified peptide ce was assured by comparison of the generated natural peptide fragmentation pattern with the fragmentation pattern of a synthetic sequence-identical reference peptide. Fig 1 shows an exemplary spectrum obtained from tumor tissue for the MHC class I associated peptide CDC2-001 and its elution profile on the UPLC system.

Expression profiling of genes encoding the peptides of the invention Not all peptides identified as being presented on the e oftumor cells by MHC molecules are le for immunotherapy, because the majority of these peptides are derived from normal cellular proteins expressed by many cell types. Only few of these peptides are associated and likely able to induce T cells with a high icity of recognition for the tumor from which they were derived. In order to identify such peptides and minimize the risk for autoimmunity induced by vaccination the inventors d on those peptides that are derived from proteins that are over-expressed on tumor cells compared to the majority of normal tissues.

The ideal peptide will be derived from a protein that is unique to the tumor and not present in any other tissue. To identify peptides that are derived from genes with an expression profile r to the ideal one the identified es were assigned to the proteins and genes, respectively, from which they were derived and expression profiles of these genes were generated.

RNA sources and preparation ally removed tissue ens were provided by different clinical sites (see Example 1) after written informed consent had been obtained from each patient. Tumor tissue specimens were snap-frozen in liquid nitrogen immediately after y and later homogenized with mortar and pestle under liquid nitrogen. Total RNA was prepared from these samples using TRI Reagent (Ambion, Darmstadt, Germany) followed by a cleanup with RNeasy N, Hilden, y); both methods were performed according to the manufacturer's ol.

Total RNA from healthy human tissues was obtained cially (Ambion, Huntingdon, UK; Clontech, Heidelberg, Germany; Stratagene, Amsterdam, Netherlands; BioChain, Hayward, CA, USA). The RNA from several individuals en 2 and 123 individuals) was mixed such that RNA from each individual was equally weighted. Leukocytes were isolated from blood samples of 4 healthy volunteers.

Quality and quantity of all RNA samples were ed on an Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) using the RNA 6000 Pico LabChip Kit (Agilent).

Microarray experiments Gene sion analysis of all tumor and normal tissue RNA samples was performed by Affymetrix Human Genome (HG) U133A or HG-Ul33 Plus 2.0 oligonucleotide microarrays (Affymetrix, Santa Clara, CA, USA). All steps were carried out according to the Affymetrix manual. Briefly, double-stranded cDNA was synthesized from 5—8 ug of total RNA, using SuperScript RTII (Invitrogen) and the oligo-dT-T7 primer (MWG Biotech, Ebersberg, Germany) as described in the manual. In vitro transcription was performed with the BioArray High Yield RNA Transcript Labelling Kit (ENZO Diagnostics, Inc., gdale, NY, USA) for the U133A arrays or with the GeneChip IVT 2011/053863 Labelling Kit (Affymetrix) for the U133 Plus 2.0 arrays, followed by cRNA fragmentation, hybridization, and staining with streptavidin-phycoerythrin and biotinylated anti- avidin antibody (Molecular Probes, Leiden, Netherlands). Images were scanned with the Agilent 25 00A ray Scanner (U133A) or the Affymetrix Gene-Chip Scanner 3000 (U133 Plus 2.0), and data were analyzed with the GCOS software (Affymetrix), using default settings for all parameters. For normalisation, 100 housekeeping genes provided by Affymetrix were used. Relative expression values were calculated fiom the signal log ratios given by the e and the normal kidney sample was arbitrarily set to 1.0.

The expression profiles of source genes of the present invention that are highly over- expressed in gastric cancer are shown in Fig. 2.

EXAMPLE 3 In vitro immunogenicity for IMA941 MHC class I presented peptides In order to obtain information ing the immunogenicity of the TUMAPs ofthe present invention, we performed investigations using a well established in vitro stimulation platform already described by r, S, Herrgen, L, Schoor, O, Jung, G, Wernet, D, Buhring, HJ, Rammensee, HG, and Stevanovic, S; 2003, Cutting edge: predetermined avidity of human CD8 T cells expanded on ated MHC/anti—CD28-coated microspheres, J. Immunol., 171, 4974-4978). With this system we could show positive immunogenicity (i. e. ion of specific T cells) s for 47 of 54 tested HLA- A*2402 restricted TUMAPs and for 3 of 3 tested HLA-A*0201 restricted TUMAPs of the invention, demonstrating that these peptides are T-cell epitopes against which CD8+ precursor T cells exist in humans (Table 4).

In vitro priming of CD8+ T cells In order to m in vitro stimulations by artificial antigen presenting cells (aAPC) loaded with peptide-MHC complex (pMHC) and anti-CD28 antibody, we first isolated CD8 T cells fiom fresh HLA-A*24 leukapheresis products or fiom HLA-A*2 buffy coats of y donors obtained fiom the Blood Bank Tuebingen.

CD8 T cells were either directly enriched or PBMCs (peripheral blood mononuclear cells) were isolated first by using standard gradient separation medium (PAA, Colbe, Germany). — 114 — Isolated CD8 lymphocytes or PBMCs were incubated until use in T-cell medium (TCM) ting of RPMI-Glutamax (Invitrogen, Karlsruhe, Germany) supplemented with 10% heat inactivated human AB serum (PAN-Biotech, Aidenbach, Germany), 100 U/ml Penicillin / 100 ug/ml Streptomycin (Cambrex, Cologne, Germany), 1 mM sodium pyruvate (CC Pro, Oberdorla, Germany), 20 ug/ml ycin (Cambrex). 2.5 ng/ml IL-7 (PromoCell, berg, y) and 10 U/ml IL-2 (Novartis , erg, Germany) cytokines were added to the TCM for this culture step. Isolation of CD8+ lymphocytes was performed by positive ion using CD8 MicroBeads (Miltenyi Biotec, Bergisch—Gladbach, Germany).

Generation of pMHC/anti—CD28 coated beads, T-cell stimulations and readout was performed as described before (Walter et al. 4974-78) with minor modifications. , biotinylated peptide-loaded recombinant 2402 and HLA-A*0201 molecules lacking the transmembrane domain and biotinylated at the carboxy terminus of the heavy chain were produced. The ed costimulatory mouse IgG2a anti human CD28 Ab 9.3 (Jung, Ledbetter, and Muller-Eberhard 4611-15) was chemically biotinylated using Sulfo- N—hydroxysuccinimidobiotin as recommended by the manufacturer (Perbio, Bonn, Germany). Beads used were 5.6 um large streptavidin coated polystyrene particles (Bangs Laboratories, is, USA). pMHC used as high and low immunogenic controls were A*0201/MLA-001 (peptide ELAGIGILTV from modified Melan—A/MART-l) and A*0201/DDX5-001 (YLLPAIVHI from DDX5), respectively. 800.000 beads / 200 ul were coated in 96-well plates in the presence of 600 ng biotin-anti- CD28 plus 200 ng relevant biotin-pMHC (high density beads). Stimulations were initiated in l plates by co-nincubating 1x106 CD8+ T cells with 2x105 washed coated beads in 200 ul TCM supplemented with 5 ng/ml IL-12 (PromoCell) for 3-4 days at 37°C, 5% C02 and 95% relative ty. Half of the medium was then exchanged by fresh TCM supplemented with 80 U/ml IL-2 and incubation was continued for 3-4 days at 37°C. This stimulation cycle was performed for a total of three times.

Finally, multimer analyses were performed by staining cells with fluorescent A*0201 or A*2402 HLA multimers (produced as described by {Altman, 1996 ALTMAN1996 /id}) and CD8-FITC antibody clone SKl (BD, Heidelberg, Germany) or additionally with a viability marker (Live/dead-Aqua or —Violet dye (Invitrogen, Karlsruhe, Germany)), and were conducted on a four-color FACSCalibur (BD) or a LSRII SORP cytometer (BD; eighteen color, equipped with a blue (488 nm), violet (405 nm), red (640 nm) and green (532 nm), respectively. Peptide specific cells were calculated as percentage of total CD8+ T cells. Evaluation of multimer is was done using the ress or FlowJo software (Tree Star, Oregon, USA). In vitro priming of specific multimer+ CD8+ lymphocytes was detected by riate gating and by comparing to negative control stimulations. Immunogenicity for a given n was detected if at least one evaluable in vitro stimulated well of one healthy donor was found to contain specific CD8+ T-cells after in vitro stimulation (i.e. the fraction of multimer+ cell population within this well constituted at least 1% of the CD8+ cells, the frequency was at least 10-fold over the median of the respective negative controls (stimulation with irrelevant and staining with relevant multimer) and the cells were not located on the diagonal of the plot).

In vitro immunogenicity for IMA941 es For 47 of 54 tested HLA-A*2402 peptides and for 3 of 3 tested HLA-A*0201 es, in vitro immunogenicity could be demonstrated by generation of peptide c T-cell lines.

Exemplary flow cytometry results after TUMAP-specific multimer staining for two peptides of the invention are shown in figure 3 together with a corresponding negative control. Results for 54 A*2402 and 3 A*0201 peptides of the invention are ized in Table 4.

Table 4: In vitro immunogenicity ofHLA class I peptides ofthe invention Results of in vitro immunogenicity experiments conducted by Immatics are showing the percentage of positive tested donors and wells among evaluable. At least four donors and 48 wells were ble for each peptide.

Donors Wells positive/evaluable positive/evaluable [%] [%] WO 13819 _——22 22 —_ ———— ———_ ———— ———— ———— ———— ———_ ———— ———— ———— ——__ ———— ———— ———— ———— ———— The following peptides were already bed in other applications by immatics and included in the vaccines IMA901 (MET-001 and TOP-001), IMA910 (MET-001 and TOP- 001) and IMA950 (IGF2BP3-001). As for e MET-001 leads to extremely good in Vivo reactions, the data can be seen as an indication for the clinical usefillness of the peptides of the invention, Donors Wells positive/evaluable positive/evaluable [%] [%] Reference List Ahmed, A. U., et al. "Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth." J Natl.Cancer Inst. 100.22 (2008): 1606-29.

Allison, J. P. and M. F. l. "The Yin and Yang ofT cell costimulation." Science 270.5238 (1995): 932-33.

Altmeyer, A., et al. "Tumor-specific cell surface expression ofthe-KDEL containing, endoplasmic reticular heat shock protein gp96." Int J Cancer 69.4 (1996): 340-49.

Appay, V., et al. "Decreased ic CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide." Eur.J l. 36.7 (2006): 1805-14.

Banerjee, S. K., et al. "Expression of cdc2 and cyclin B1 in Helicobacter pylori-associated gastric MALT and MALT lymphoma : relationship to cell death, proliferation, and transformation." Am J Pathol. 156.1 (2000): 217-25.

Bartman, A. E., et al. "Aberrant expression ofMUC5AC and MUC6 gastric mucin genes in colorectal polyps." Int J Cancer 80.2 (1999): 210-18.

Basu, S., et al. "Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a l maturation signal to dendritic cells and activate the NF-kappa B pathway." Int Immunol. 12.11 : 1539-46.

Bauer, B., S. Bartfeld, and T. F. Meyer. "H. pylori ively blocks EGFR endocytosis via the non-receptor kinase c-Abl and CagA." Cell Microbiol. 11.1 (2009): 156-69.

Benatti, P., et al. "A balance between NF-Y and p53 governs the pro- and anti-apoptotic transcriptional response." Nucleic Acids Res 36.5 (2008): 1415-28.

Bertolini, G., et al. "Highly genic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatmen ." Proc cad.Sci.U.S.A 106.38 : 16281-86.

Bierie, B. and H. L. Moses. eta and cancer." Cflokine Growth Factor Rev. 171-2 (2006): 29-40.

Bitoun, E. and K. E. . "The robotic mouse: unravelling the function of AF4 in the cerebellum." Cerebellum. 4.4 (2005): 250-60.

Bolhassani, A. and S. Rafati. "Heat-shock proteins as powerful weapons in e development." Expert.Rev.Vaccines. 7.8 (2008): 1185-99.

Borset, M., et al. "The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies." Leuk.L§@phoma 323-4 (1999): 249-56.

Bradbury, P. A., et al. "Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal arcinoma risk and prognosis." Carcinogenesis 30.5 (2009): 793-98.

Brown, C. E., et al. nition and killing of brain tumor stem-like ting cells by CD8+ cytolytic T cells." Cancer Research 69.23 (2009): 8886-93.

Bruckdorfer, T., O. , and F. Albericio. "From production of es in milligram amounts for research to multi-tons quantities for drugs of the filture." Curr.Pharm.Biotechnol. 5.1 (2004): 29-43.

Brunsvig, P. F., et al. "Telomerase peptide ation: a phase I/II study in patients with non-small cell lung cancer." Cancer Immunol.Immunother. 55.12 (2006): 1553-64. s, D., et a1. "Gp96 is a receptor for a novel Listeria monocytogenes virulence factor, Vip, a e protein." EMBO J 24.15 (2005): 2827-38. o, M. A., et al. "An inducible autoregulatory loop between HIPK2 and Siah2 at the apex of the hypoxic response." Nat.Cell Biol. 11.1 (2009): 85-91.

Castelli, C., et al. "Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer." Cancer Immunol.Immunother. 53.3 (2004): 227- Castriconi, R., et al. "Both CD133+ and C." Eur.J Immunol. 37.11 (2007): 6.

Chanock, S. J., et al. "HLA-A, -B, -Cw, -DQA1 and -DRB1 Alleles in a Caucasian Population from Bethesda, USA." Hum.Immunol. 65 (2004): 1211-23.

Chen, C. H., et al. "Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3." m Natl.Acad.Sci.U.S.A 100.16 (2003): 9226-31.

Chen, Z. and J. J. O'Shea. "Regulation of IL-17 production in human lymphocytes." Cy_tokine 41.2 (2008): 71-78.

Cho, S. 0., et al. "Helicobacter pylori in a Korean Isolate Expressed Proteins Differentially in Human Gastric Epithelial Cells." s.Sci. (2009).

Christianson, J. C., et al. "OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1- SELlL ubiquitin ligase complex for ERAD." Nat.Cell Biol. 10.3 (2008): 272-82.

Cisek, L. J. and J. L. Corden. "Phosphorylation of RNA polymerase by the murine homologue ofthe cell-cycle control protein cdc2." Nature 27 (1989): 679-84.

Colombetti, S., et al. nged TClVCD28 ment drives ILindependent T cell clonal expansion h signaling mediated by the mammalian target of rapamycin." 1 Immunol. 176.5 (2006): 2730-38.

Confalonieri, S., et al. "Alterations of ubiquitin s in human cancer and their association with the natural history of the tumor." Oncogene 28.33 : 2959-68.

Corso, S., et al. "Silencing the MET oncogene leads to regression of experimental tumors and metastases." Oncogene 27.5 (2008): 684-93.

Cox, C. V., et al. "Expression of CD133 on leukemia-initiating cells in childhood ALL." Blood 113.14 (2009): 3287-96.

Cunha-Ferreira, 1., et al. "The SCF/Slimb ubiquitin ligase limits centrosome amplification through degradation of SAK/PLK4." Curr.Biol. 19.1 (2009): 43-49.

DeLuca, J. G., et al. "Hecl and nuf2 are core components of the kinetochore outer plate ial for organizing ubule attachment sites." Mol.Biol.Cell 16.2 (2005): 519-31.

Deng, H., et al. "Matrix oproteinase 11 depletion inhibits cell proliferation in gastric cancer cells." Biochem.Biophys.Res Commun. 326.2 (2005): .

Dengj el, J ., et al. "Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas." Clin Cancer Res. 12.14 (2006): 4163-70.

Deremer, D. L., C. Ustun, and K. Nataraj an. "Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia." Clin Ther. 30.11 (2008): 1956-75.

Di Renzo, M. F., et al. "Overexpression and amplification of the met/HGF or gene during the progression of colorectal cancer." Clin.Cancer Res. 1.2 (1995): 147-54.

Dong, G., et al. "Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma." Cancer @61.15(2001):5911-18.

, M. E., et al. "Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes." Science 298.5594 (2002): 850-54.

Dudley, M. E., et al. "Adoptive cell transfer therapy following non-myeloablative but lymphodepleting herapy for the treatment of patients with refractory metastatic melanoma." J.Clin.Oncol. 23.10 (2005): 2346-57.

Duong, C., et al. "Pretreatment gene expression s can be used to predict se to neoadjuvant chemoradiotherapy in esophageal ." Ann Surg Oncol 14.12 (2007): 3602-09.

Egland, K. A., et al. "High sion of a cytokeratin—associated protein in many cancers." Proc Natl.Acad.Sci.U.S.A 103.15 (2006): 5929-34.

Eramo, A., et al. "Identification and expansion of the tumorigenic lung cancer stem cell population." Cell Death Differ 15.3 (2008): 504-14.

Esashi, F., et al. "CDK—dependent phosphorylation of BRCA2 as a regulatory ism for recombinational repair." Nature 434.7033 (2005): 598-604.

Escobar, M. A., et al. "Profiling of nuclear extract proteins from human neuroblastoma cell lines: the search for fingerprints." Pediatr.Surg 40.2 (2005): 349-58.

Ferracini, R., et al. "The Met/HGF receptor is xpressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit." Oncogene 10.4 (1995): 739-49.

Fischer, J ., et al. "Duplication and overexpression of the mutant allele of the MET proto- ne in multiple hereditary papillary renal cell tumours." Oncogene 17.6 (1998): 733- Flanagan, J. M., et al. "Genomics screen in transformed stem cells reveals RNASEH2A, , and ADARBl as putative anticancer drug targets." ncer Ther. 8.1 (2009): 249-60.

Fong, L., et al. "Altered peptide ligand ation with Flt3 ligand expanded dendritic cells for tumor therapy." Proc.Natl.Acad.Sci.U.S.A 98.15 (2001): 8809-14.

Frasor, J ., et al. "Estrogen down-regulation of the corepressor N—CoR: mechanism and implications for estrogen derepression of N—CoR-regulated genes." m Natl.Acad.Sci.U.S.A 102.37 (2005): 13153-57.

Frew, I. J., et al. ation and is of Siah2 mutant mice." Mol.Cell Biol. 23.24 (2003): 9150-61.

Fu, Y. and A. S. Lee. "Glucose regulated proteins in cancer progression, drug resistance and immunotherapy." Cancer Biol.Ther. 5.7 (2006): 741-44.

Furge, K. A., et al. "Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase." Proc.Natl.Acad.Sci.U.S.A 98.19 (2001): 10722-27.

Furge, K. A., Y. W. Zhang, and G. F. Vande Woude. "Met receptor tyrosine kinase: enhanced signaling through adapter proteins." Oncogene 19.49 (2000): 5582-89. 2011/053863 Gattinoni, L., et al. "Adoptive immunotherapy for cancer: building on success." Nat.Rev.Immunol. 6.5 (2006): 383-93.

Gherardi, E. and M. Stoker. "Hepatocyte growth factor--scatter : mitogen, motogen, and met." Cancer Cells 3.6 : .

Glen, A., et al. "iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with ssion." J me.Res 7.3 (2008): 897-907.

, S., et al. "NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer." Int J Cancer (2009).

Guo, W. C., et al. "Expression and its clinical significance of heat shock n gp96 in human osteosarcoma." Neoplasma 57.1 (2010): 62-67.

Habelhah, H., et al. "Stress-induced decrease in TRAF2 stability is mediated by Siah2." EMBO J 21.21 (2002): 5756-65. to, A., et al. "Aberrant expression ofthe c mucin MUC6 in human ary adenocarcinoma afts." Int J Oncol 26.4 (2005): 891-96.

Harada, T., et al. "Genome-wide analysis of pancreatic cancer using microarray-based techniques." Pancreatology. 9.1-2 (2009): 13-24.

Harper, L. J ., et al. "Stem cell ns in cell lines derived from head and neck squamous cell carcinoma." J Oral Pathol.Med 36.10 (2007): 594-603.

Hayama, S., et al. "Activation of CDCAl-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis." Cancer Research 66.21 (2006): 10339- Hayashi, M., et al. "High expression of HER3 is associated with a decreased survival in gastric cancer." Clinical Cancer Research 14.23 (2008): 7843-49.

Heike, M., et al. "Expression of stress protein gp96, a tumor rejection antigen, in human colorectal cancer." Int J Cancer 86.4 (2000): 489-93.

Hodorova, 1., et al. "Gp96 and its different expression in breast carcinomas." Neoplasma 55.1 (2008): 31-35.

Horton, R. A., et al. "A substrate for deubiquitinating enzymes based on time-resolved fluorescence resonance energy transfer between terbium and yellow fluorescent protein." Anal.Biochem. 360.1 (2007): 138-43.

House, C. M., A. , and D. D. Bowtell. "Siah proteins: novel drug targets in the Ras and hypoxia pathways." Cancer Research 69.23 (2009): 8835-38.

Howard, E. W., et al. "Decreased veness, resistance to anoikis and suppression of GRP94 are integral to the survival of circulating tumor cells in prostate cancer." @ Exp.Metastasis 25.5 (2008): 497-508.

Hu, G. and E. R. Fearon. "Siah-l N—terminal RING domain is required for proteolysis filnction, and C-terminal sequences te oligomerization and binding to target proteins." Mol.Cell Biol. 19.1 (1999): .

Huang, Y., et al. "Characterization of GPR56 protein and its suppressed expression in human pancreatic cancer cells." Mol.Cell Biochem. 3081-2 (2008): 133-39.

Jansen, M. P., et al. "Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer." Breast Cancer Res Treat. 116.2 (2009): 263-71.

Jia, H. L., et al. "Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma." Clinical Cancer Research 13.4 (2007): 1133-39.

Jucker, M., et al. "The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma." Leuk.Res. 18.1 (1994): 7-16.

Jung, G., J. A. Ledbetter, and H. J. Muller-Eberhard. "Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates." Proc Natl Acad SciU S A 84.13 : 4611-15.

Jung, H. M., S. J. Choi, and J. K. Kim. ssion profiles of SV40-immortalization— associated genes upregulated in s human cancers." J Cell m. 106.4 (2009): 703-13.

Kaneko, N., et al. "siRNA-mediated knockdown against CDCAl and KNTC2, both frequently overexpressed in colorectal and gastric cancers, sses cell eration and induces apoptosis." m.Biophys.Res Commun. 390.4 (2009): 1235-40.

Kang, H. M., et al. "Effects of Helicobacter pylori Infection on gastric mucin expression." J Clin Gastroenterol. 42.1 : 29-35.

Ko, M. A., et al. "Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis." net. 37.8 (2005): 883-88.

Kobayashi, M., et al. "Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas." Oncogene 22.9 (2003): 1294-301.

Koochekpour, S., et al. "Met and hepatocyte growth factor/scatter factor expression in human gliomas." Cancer Res. 57.23 (1997): 5391-98. — 124 — Korzeniewski, N., et al. "Cullin 1 functions as a centrosomal suppressor of centriole lication by ting polo-like kinase 4 protein levels." Cancer Research 69.16 (2009): 6668-75.

Krieg, A. M. "Therapeutic potential of Toll-like receptor 9 activation." Nat.Rev.Drug Discov. 5.6 (2006): 471-84.

Kunimoto, K., et al. "Involvement of IQGAP3, a regulator of Ras/ERK—related cascade, in hepatocyte proliferation in mouse liver regeneration and development." J Cell Physiol 220.3 (2009): 621-31.

Kuriyama, R., et al. "Gamma-tubulin-containing abnormal centrioles are induced by insuff1cientPlk4 in human HCT116 ctal cancer cells." J Cell Sci. l22.Pt 12 (2009): 2014-23.

Lee, H. S., et al. "MUCl, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic tors." Cancer 92.6 (2001): 1427-34.

Leivo, 1., et al. "Characterization of gene expression in major types of salivary gland carcinomas with epithelial differentiation." Cancer Genet.Cy_togenet. 156.2 : 104-13.

Lemmel, C., et al. "Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling." Nat.Biotechnol. 22.4 (2004): 450-54.

Li, G., et al. "Downregulation of E-cadherin and lein 1 by autocrine hepatocyte growth factor during melanoma development." Oncogene 20.56 : 8125-35.

Lim, S. O., et al. "Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules." World J Gastroenterol. 11.14 : 2072-79.

Lin, W., et al. ine kinases and gastric cancer." Oncogene 19.49 (2000): 5680-89.

Liu, B. and Z. LI. "Endoplasmic reticulum HSP90b1 (gp96, grp94) optimizes B-cell fianction via chaperoning integrin and TLR but not immunoglobulin." Blood 112.4 (2008): Liu, S. Y., et al. "Requirement of MMP-3 in anchorage-independent growth of oral squamous cell carcinomas." J Oral Pathol.Med 36.7 (2007): 430-35.

Lochter, A., et al. "The icance of matrix oproteinases during early stages of tumor progression." Ann N.Y.Acad.Sci. 857 (1998): 180-93.

Lund, C. V., et al. "Zinc finger ription factors ed for bispecif1c coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology." Mol.Cell Biol. 25.20 (2005): 9082-91.

Ma, S., et al. "Identification and characterization oftumorigenic liver cancer stem/progenitor cells." Gastroenterology 132.7 (2007): 2542-56.

MacLeod, R. J ., M. Hayes, and I. o. "Wnt5a secretion stimulated by the ellular calcium-sensing receptor inhibits defective Wnt ing in colon cancer cells." m Physiol Gastrointest.Liver Physiol 293.1 (2007): G403-G411.

Macmillan, J. C., et al. "Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer." Ann Surg Oncol 8.9 (2001): 729-40.

Maney, T., et al. "The kinetochore of higher eucaryotes: a lar view." Int Rev.Cflol. 194 (2000): 67-131.

Martin, C. M., et al. "Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy." Methods Mol.Biol. 511 : 333-59.

Matsukita, S., et al. "Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in mucinous carcinoma ofthe breast: comparison with invasive ductal carcinoma." Histopathology 42.1 (2003): 26-36.

, G., et al. "Role of the hepatocyte growth factor receptor, c-Met, in nesis and potential for therapeutic inhibition." Cy_tokine Growth Factor Rev. 13.1 (2002): 41-59.

Mizrak, D., M. Brittan, and M. Alison. "CD133: le of the moment." J Pathol. 214.1 (2008): 3-9.

Montesano, R., et al. "Differential effects of cyte growth factor isoforms on epithelial and endothelial tubulogenesis." Cell Growth Differ. 9.5 : 355-65.

Monzani, E., et al. "Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential." Eur.J Cancer 43.5 (2007): 935-46.

Moore, A. and L. an. "The mechanism, function and regulation of depolymerizing kinesins during mitosis." Trends Cell Biol. 14.10 (2004): 537-46.

Morgan, R. A., et al. r Regression in Patients After Transfer of Genetically Engineered Lymphocytes." Science (2006).

Mori, M., et al. "HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry." Transplantation 64.7 (1997): 1017- Murray, G. 1., et al. "Matrix metalloproteinases and their inhibitors in gastric cancer." @ 43.6 (1998): 791-97.

Murshid, A., J. Gong, and S. K. Calderwood. "Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation." Expert.Rev.Vaccines. 7.7 (2008): 1019-30.

Nakaigawa, N., et al. "Inactivation of von -Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma." Cancer Res. 66.7 (2006): 3699-705.

Nakamura, Y., et al. "Clinicopathological and biological significance of mitotic centromere-associated kinesin overexpression in human c cancer." Br.J Cancer 97.4 : 543-49. ma, K., J. Qi, and Z. Ronai. "The ubiquitin ligase Siah2 and the hypoxia response." Mol.Cancer Res 7.4 (2009): 443-51.

Naldini, L., et al. "Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET." Oncogene 6.4 (1991): 501-04.

Nguyen, Q. N., et al. "Light controllable siRNAs regulate gene suppression and phenotypes in cells." Biochim.Biophys.Acta 1758.3 (2006): 3.

Nishio, K., et al. al structure of the de-ubiquitinating enzyme UCH37 (human UCH- L5) catalytic domain." Biochem.Biophys.Res Commun. 390.3 (2009): 855-60.

Nojima, H., et al. "IQGAP3 regulates cell proliferation through the Ras/ERK signalling cascade." Nat.Cell Biol. 10.8 : 971-78.

Nomura, H., et al. "Enhanced production of matrix metalloproteinases and activation of matrix oproteinase 2 inase A) in human gastric carcinomas." Int J Cancer 69.1 (1996): 9-16.

Nomura, H., et al. "Network-based analysis of calcium-binding protein genes identifies Grp94 as a target in human oral carcinogenesis." Br.J Cancer 97.6 (2007): 792-801.

Ohnuma, S., et al. "Cancer-associated splicing variants of the CDCAl and MSMB genes expressed in cancer cell lines and surgically resected gastric cancer s." Egg 145.1 (2009): 57-68.

Park, Y. H., et al. "Capecitabine in combination with Oxaliplatin (XELOX) as a first-line y for advanced gastric cancer." Cancer Chemother.Pharmacol. (2007).

Pascolo, S., et al. "The non-classical HLA class I le HFE does not influence the NK— like activity contained in fresh human PBMCs and does not interact with NK cells." Int.Immunol. 17.2 (2005): .

Peel, N., et al. "Overexpressing centriole-replication proteins in vivo induces centriole overduplication and de novo formation." Curr.Biol. 17.10 (2007): 834-43.

Pereira, M. B., et al. "Immunohistochemical study of the expression of MUC5AC and MUC6 in breast carcinomas and nt breast s." J Clin Pathol. 54.3 (2001): 210- Pietra, G., et al. "Natural killer cells kill human melanoma cells with characteristics of cancer stem cells." Int Immunol. 21.7 (2009): 1.

Poller, D. N., et al. "Production and characterization of a onal antibody to the c-erbB- 3 protein: examination of c-erbB-3 protein expression in adenocarcinomas." J . 168.3 (1992): 275-80.

Pons, E., C. C. Uphoff, and H. G. Drexler. "Expression of hepatocyte growth factor and its receptor c-met in human leukemia-lymphoma cell lines." Leuk.Res. 22.9 (1998): 797-804.

Ponzetto, C., et al. "A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor." ll Biol. 13.8 (1993): 4600-08.

Poppe, M., et al. "Phosphorylation of Helicobacter pylori CagA by c-Abl leads to cell motility." Oncogene 26.24 : 3462-72.

Pytel, D., et al. "Tyrosine kinase blockers: new hope for successful cancer therapy." Anticancer Agents Med Chem. 9.1 : 66-76.

Qi, J ., et al. "The tin ligase Siah2 regulates tumorigenesis and metastasis by HIF- dependent and endent pathways." Proc Natl.Acad.Sci.U.S.A 105.43 (2008): 16713- Qian, C. N., et al. "Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma." Cancer Res. 62.2 (2002): 589-96.

Qian, Z., et al. "Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia." Chem.Biol.Interact. (2009).

Ramirez, R., et al. "Over-expression of hepatocyte growth /scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma." @ Endocrinolngf) 53.5 (2000): 635-44.

Rammensee, H. G., et al. "SYFPEITHI: database for MHC ligands and peptide motifs." Immunogenetics 503-4 (1999): 213-19.

Rammensee, H. G., J. Bachmann, and S. Stevanovic. MHC s and Peptide Motifs.

Springer-Verlag, Heidelberg, Germany, 1997.

Rappa, G., O. Fodstad, and A. . "The stem cell-associated antigen CD133 (Prominin- 1) is a molecular therapeutic target for metastatic melanoma." Stem Cells 26.12 (2008): 3008-17.

Richardson, G. D., et al. "CD133, a novel marker for human prostatic epithelial stem " J Cell Sci. 117.Pt 16 (2004): 3539-45.

Rini, B. 1., et al. "Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus zumab in patients with serologic progression of prostate cancer after definitive local therapy." Cancer 107.1 (2006): 67-74.

Rodrigues-Martins, A., et al. "Revisiting the role of the mother centriole in centriole biogenesis." Science 27 (2007): 1046-50.

Rosenberg, S. A., et al. "A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone." N.Engl.J.Med. 316.15 (1987): 889-97.

Rosenberg, S. A., et al. "Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy ofpatients with metastatic ma. A preliminary ." N.Engl.J Med 319.25 (1988): 1676-80.

Rott, R., et al. "Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells." J Biol.Chem. 283.6 (2008): 3316- Rutella, S., et al. "Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors." Clinical Cancer Research 15.13 (2009): 1 1.

Saiki, R. K., et al. "Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase." Science 239.4839 (1988): .

Samant, G. V. and P. W. Sylvester. "gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells." Cell Prolif. 39.6 (2006): 563-74. s, E. E., et al. ssion ofthe c-erbB-3 gene product in gastric cancer." M Cancer 54.6 (1993): 935-40.

Scott, G. K., et al. inate ssion of ERBB2 and ERBB3 by ed expression ofmicro-RNA miR-125a or miR-125b." J Biol.Chem. 282.2 (2007): 1479-86.

Sergina, N. V., et al. "Escape from HER-family tyrosine kinase inhibitor therapy by the -inactive HER3." Nature 445.7126 (2007): 437-41.

Shah, M., et al. "Inhibition of Siah2 ubiquitin ligase by Vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis." Pigment Cell Melanoma Res 22.6 (2009): 799-808.

Shapiro, G. I. "Cyclin—dependent kinase ys as targets for cancer treatment." J Clin Oncol 24.11 : 1770-83.

Sherman-Baust, C. A., et al. "Remodeling of the extracellular matrix through pression of en VI contributes to tin resistance in n cancer " Cancer Cell 3.4 (2003): 377-86.

Sheu, M. L., S. H. Liu, and K. H. Lan. "Honokiol induces calpain-mediated glucoseregulated n-94 cleavage and apoptosis in human gastric cancer cells and reduces tumor growth." PLoS.ONE. 2.10 (2007): e1096.

Shimo, A., et al. "Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis." Cancer Sci. 99.1 (2008): 62-70.

Singh, S. K., et al. "Identification of a cancer stem cell in human brain tumors." Cancer @63.18 (2003): 5821-28.

Singh, S. K., et al. "Identification of human brain tumour initiating cells." Nature 432.7015 (2004): 396-401.

Sithanandam, G. and L. M. Anderson. "The ERBB3 receptor in cancer and cancer gene therapy." Cancer Gene Ther. 15.7 (2008): 413-48.

Sithanandam, G., et al. "Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and veness of human lung adenocarcinoma cell line A549." Oncogene 24.11 (2005): 1847-59.

Skawran, B., et al. "Gene expression profiling in hepatocellular carcinoma: upregulation of genes in amplified chromosome regions." Mod.Pathol. 21.5 (2008): 505-16.

Slesak, B., et al. "Expression of mal growth factor receptor family proteins (EGFR, c-erbB-2 and -3) in gastric cancer and chronic gastritis." Anticancer Res 18.4A (1998): 2727-32.

Small, E. J., et al. "Placebo-controlled phase III trial ofimmunologic therapy with sipuleucel—T (APC8015) in patients with metastatic, asymptomatic hormone tory prostate cancer." J Clin Oncol. 24.19 (2006): 3089-94.

Smith, L. M., et al. "CD133/prominin-1 is a potential therapeutic target for antibody-drug ates in hepatocellular and gastric cancers." Br.J Cancer 99.1 (2008): 100-09.

Smith, M. J., et al. "Analysis of differential gene expression in colorectal cancer and stroma using fluorescence-activated cell sorting purification." Br.J Cancer 100.9 (2009): 1452-64.

Smogorzewska, A., et al. ification ofthe FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair." Cill 129.2 : 289-301.

Staehler, M., Stenzl, A., Dietrich, P. Y., Eisen, T., Haferkamp, A., Beck, J., Mayer, A., Walter, S., Singh-Jasuja, H., and Stief, C. A phase I study to evaluate safety, immunogenicity and umor activity of the peptide vaccine IMA901 in renal cell carcinoma patients (RCC). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I Vol 25, No. 18S (June 20 Supplement), 2007: 5098. 62007.

Ref Type: Abstract Stemmann, 0., et al. "Dual inhibition of sister chromatid separation at ase." Cill 107.6 (2001): 715-26.

Suetsugu, A., et al. "Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells." Biochem.Biophys.Res.Commun. 351.4 (2006): .

Suva, M. L., et al. "Identification of Cancer Stem Cells in Ewing's a." Cancer Research (2009).

Swallow, C. J ., et al. "Sak/Plk4 and mitotic fidelity." ne 24.2 (2005): 306-12.

Szczepanowski, M., et al. "Regulation of repp86 stability by human Siah2." Biochem.Biophys.Res Commun. 362.2 (2007): 485-90.

Tajima, Y., et al. "Gastric and intestinal phenotypic marker expression in early differentiated-type tumors of the stomach: opathologic significance and genetic background." Clinical Cancer Research 12.21 (2006): 6469-79.

Takaishi, S., et al. ification of gastric cancer stem cells using the cell surface marker CD44." Stem Cells 27.5 (2009): 1006-20.

Takayama, H., et al. se tumorigenesis associated with aberrant development in mice overexpressing cyte growth factor/scatter factor." Proc.Natl.Acad.Sci.U.S.A 94.2 (1997): 701-06.

Teofili, L., et al. "Expression of the c-met proto-oncogene and its , hepatocyte growth factor, in Hodgkin disease." Blood 97.4 (2001): 1063-69.

Thorsen, K., et al. "Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis." Mol.Cell Proteomics. 7.7 (2008): 1214-24.

Tirino, V., et al. "The role of CD133 in the identification and characterisation of tumour- initiating cells in non-small-cell lung cancer." Eur.J Cardiothorac.Surg 36.3 (2009): 446-53.

Todaro, M., et al. "Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4." Cell Stem Cell 1.4 (2007): 389-402.

Topol, L., et al. "Wnt-5a inhibits the canonical Wnt y by promoting GSK—3- independent atenin degradation." J Cell Biol. 162.5 : 899-908.

Toribara, N. W., et al. "Human gastric mucin. Identification of a unique species by expression g." J Biol.Chem. 268.8 (1993): 5879-85.

Tsan, M. F. and B. Gao. "Heat shock protein and innate immunity." Cell Mol.Immunol. 1.4 (2004): 274-79.

Tuck, A. B., et al. "Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma." Am.J.Pathol. 148.1 (1996): 225-32.

Vairaktaris, E., et al. "Association of -1171 promoter polymorphism of matrix metalloproteinase-3 with increased risk for oral cancer." Anticancer Res 27.6B (2007): 4095-100.

Vandenbroeck, K., E. Martens, and I. Alloza. "Multi—chaperone complexes regulate the folding of eron-gamma in the asmic reticulum." Cy_tol , S., et al. "Cutting edge: ermined aVidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres." J.Immunol. 171.10 (2003): 4974-78.

Wang, Q., et al. "Overexpression of endoplasmic reticulum molecular chaperone GRP94 and GRP78 in human lung cancer tissues and its significance." Cancer Detect.PreV. 29.6 (2005): 544-51.

Wang, R., et al. "Activation of the Met receptor by cell attachment s and sustains hepatocellular carcinomas in transgenic mice." J.Cell Biol. 153.5 (2001): 1023-34.

Wang, R. Q. and D. C. Fang. "Effects of Helicobacter pylori ion on mucin expression in gastric carcinoma and ncerous tissues." Gastroenterol.Hepatol. 21.2 (2006): 425- Wang, S., et al. "IQGAP3, a novel effector of Racl and Cdc42, regulates neurite outgrowth." J Cell Sci. 120.Pt 4 (2007): 567-77.

Wang, X., et al. "Immunolocalisation of heat shock protein 72 and glycoprotein 96 in colonic adenocarcinoma." Acta Histochem. 110.2 (2008): 117-23.

Wang, X. P., et al. "Expression and significance of heat shock protein 70 and glucose- ted protein 94 in human esophageal carcinoma." World J Gastroenterol. 11.3 (2005): 429-32.

Wang, X. P., et al. "Correlation between opathology and sion of heat shock protein 70 and glucose-regulated protein 94 in human colonic arcinoma." World J Gastroenterol. 11.7 (2005): 1056-59.

Wang, X. P., Q. X. Wang, and X. P. Ying. "Correlation between clinicopathology and expression of heat shock n 72 and glycoprotein 96 in human gastric adenocarcinoma." Tohoku J Exp.Med 212.1 (2007): 35-41.

Weinschenk, T., et al. "Integrated functional genomics approach for the design of patient- indiVidual antitumor vaccines." Cancer Res. 62.20 (2002): 7.

White, C. D., M. D. Brown, and D. B. Sacks. "IQGAPs in : a family of scaffold proteins underlying tumorigenesis." FEBS Lett. 583.12 (2009): 1817-24.

Wicks, S. J et al. "Reversible ubiquitination regulates the Smad/TGF-beta signalling pathway." Biochem.Soc Trans. 34.Pt 5 (2006): 761-63.

Wicks, S. J., et al. "The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signalling." Oncogene 24.54 (2005): 8080-84.

, S., et al. ssion profiling of fecal colonocytes for RNA-based screening of colorectal cancer." Int J Oncol 31.5 (2007): 1029-37.

Yang, L., et al. "IL-21 and TGF-beta are required for differentiation of human T(H)17 cells." Nature (2008).

Yang, S., et al. "Molecular basis of the differences n normal and tumor tissues of gastric cancer." Biochim.Biophys.Acta 1772.9 (2007): 1033-40.

Yao, D. F., et al. "Abnormal expression of HSP gp96 associated with HBV replication in human hepatocellular carcinoma." HepatobiliaryPancreat.Dis.Int 5.3 (2006): 381-86.

Yasui, W., et al. "Increased expression of 2 and its kinase actiVity in human gastric and colonic carcinomas." Int J Cancer 53.1 (1993): 36-41.

Yee, C., et al. "Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in V1VO persistence, migration, and mor effect of transferred T cells." Proc.Natl.Acad.Sci.U.S.A 99.25 (2002): 16168-73.

Yin, S., et al. "CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity." Int.J Cancer 120.7 (2007): 1444-50.

Yokozaki, H., W. Yasui, and E. Tahara. "Genetic and epigenetic changes in stomach cancer." Int ReV.Cy_tol. 204 (2001): 49-95.

Yuan, W., et al. "Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor ssion and lymphogenous asis." Pathol.Oncol Res 15.3 (2009): 473-78.

WO 13819 Yuan, W. J. et al. "Over-expression of EphA2 and EphrinA-l in human , gastric adenocarcinoma and its prognostic value for postoperative patients." Dig.Dis.Sci. 54.11 (2009): 2410-17.

Zaremba, S., et al. "Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen." Cancer Res. 57.20 (1997): 4570-77.

Zhang, X., R. M. Kedl, and J. Xiang. "CD40 on converts TGF-beta-secreting genic CD4 dendritic cells into ILsecreting immunogenic ones." Biochem.Biophys.Res Commun. 379.4 (2009): 954-58.

Zhang, X. L., et al. "Comparative study on overexpression of HER2/neu and HER3 in c cancer." World J Surg 33.10 (2009): 2112-18.

Zhao, C., et al. hog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia." Nature (2009).

Zheng, H., et al. "Cell surface targeting of heat shock protein gp96 induces dendritic cell maturation and antitumor immunity." J Immunol. 167.12 (2001): 6731-35.

Zheng, H., et al. "MUC6 egulation correlates with gastric carcinoma progression and a poor prognosis: an immunohistochemical study with tissue rrays." J Cancer Res Clin Oncol 132.12 (2006): 817-23.

Zheng, H. C., et al. "Overexpression of GRP78 and GRP94 are markers for sive behavior and poor prognosis in gastric carcinomas." Hum.Pathol. 39.7 (2008): 1042-49.

Zhou, G., et al. "2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers." Mol.Cell Proteomics. 1.2 (2002): 117-24.

Zhou, L. et al. "TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation , by antagonizing RORgammat fianction." Nature 453.7192 (2008): 236-40.

Zhu, K. J., et al. "Imiquimod inhibits the differentiation but enhances the maturation of human te-derived tic cells." nt Immunopharmacol. 9.4 (2009): 412-17.

Claims (2)

Claims 1.

1. Use of a peptide consisting of the amino acid sequence of SEQ ID No. 86 in the manufacture of a medicament for the treatment of cancer, n said cancer is gastric, gastrointestinal, colorectal, pancreatic, lung or renal cancer.

2. Use according to Claim 1, wherein said peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or -II. WO 13819